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Abstract 
 
Chronic obstructive pulmonary disease (COPD) is a progressive chronic inflammatory lung 
disease characterised by insensitivity to the anti-inflammatory actions of corticosteroids. 
Reactive oxygen species deriving from cigarette smoke or other environmental noxious 
particles or gases are a critical etiologic factor in the pathogenesis of COPD and contribute to 
the reduced corticosteroid action. In the lungs of COPD patients the increased levels of 
reactive oxygen species induce activation of the Phosphoinositide 3-kinase (PI3K)/Akt and 
mitogen activated protein kinase (MAPK) pathways which are known to be involved in 
regulating inflammatory responses as well as corticosteroid insensitivity. Members of these 
pathways have been implicated in phosphorylating glycogen synthase kinase (GSK3β) on 
serine 9 leading to inhibition of its activity. GSK3β is a constitutively active serine/threonine 
kinase that regulates a number of cellular processes, including inflammatory responses, cell 
cycle and metabolism. In this thesis I investigated whether GSK3β is modulated in primary 
peripheral macrophages and peripheral blood monocytes from COPD patients and/or under 
exposure to oxidative stress and how this modulation affects corticosteroid function. 
The results obtained showed that the levels of p-GSK3β-Ser9 are increased in peripheral lung 
macrophages and peripheral blood monocytes from COPD patients compared to smokers 
with normal lung function and non-smokers. This is mediated by increased levels of reactive 
oxygen species as in response to H2O2-derived oxidative stress, Akt, p38 MAPK and 
extracellular signal regulated kinase (ERK) 1/2 MAPK phosphorylate and inactivate GSK3β in 
a time- and concentration-dependent manner. Inhibition of GSK3β by treatment with the 
specific inhibitor CT99021, gene silencing using siRNA or overexpression of a kinase dead 
mutant reduced the anti-inflammatory effects of corticosteroids in monocytes and led to 
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increased pro-inflammatory cytokine release upon LPS (Lipopolysaccharide) stimulation. In 
addition, overexpression of a constitutively active mutant GSK3β with a serine 9 to alanine 
mutation reversed H2O2-induced reduction of corticosteroid function. 
GSK3β-regulated corticosteroid function under exposure to oxidative stress does not involve 
impaired glucocorticoid receptor (GR) nuclear translocation, GR binding to (nuclear factor 
kappa B) NF-B/p65 or p65 DNA binding capacity. By contrast, my data showed that GSK3β 
regulates the key co-repressor recruited by GR, histone deacetylase 2 (HDAC2). Inhibition of 
GSK3β led to reduction of HDAC2 activity which correlated with an increased 
phosphorylation on its serine 394 residue. This finding suggests that GSK3β regulates 
corticosteroid function by inhibiting histone deacetylation leading to chromatin 
condensation at the site of NF-B-mediated transactivation of inflammatory gene expression.  
Analysis of the effects of CT99021 on global gene expression using microarrays confirmed 
that GSK3β is a key regulator of corticosteroid-sensitive inflammatory gene expression. 
Among the genes that were differentially expressed in response to CT99021, protein kinase A 
(PKA) was upregulated suggesting that it may play a significant role in mediating GSK3β-
dependent corticosteroid function in monocytes.  
My findings suggest that there are multiple parallel mechanisms that mediate the oxidative 
stress-induced corticosteroid unresponsiveness and GSK3β is a key member of the redox-
sensitive signalling pathways in COPD. Identification of the downstream targets of GSK3β 
that mediate phosphorylation and inhibition of HDAC2 activity will assist identification of 
novel key mediators with potential for therapeutic targeting.  
 
5 | P a g e  
 
Acknowledgments 
I would like to thank my supervisors, Prof. Ian M. Adcock, Dr. Paul Kirkham and Dr. Iain Kilty 
for their tremendous support over the past three years. I would like to thank Ian mostly for 
his invaluable help and guidance during my PhD study and for giving me the great 
opportunity to undertake this project independently and drive it forward.   
I would like to thank Dr. John Marwick from University of Edinburgh for performing the 
immunohistochemistry experiments and Dr. Mark Lindsay and Dr. Eleni Tsitsiou from 
University of Manchester for performing the microarrays. 
 
I would like to thank Dr. Christos Rossios, Dr. Charalambos Michaeloudes, Dr. Maria Sukkar, 
Dr. Sarah Essilfie-Quaye, Dr. Nadia Khorasani and Dr. Andrew Durham for their support and 
great advice. I would like to thank everyone in my group for the support and help at all 
times. 
 
I would like to thank my partner Miguel and my best friends, Anna Buzi, Elli Buzi, Kostas 
Buzis, Catherine Panagopoulou, Shaz Naeem, Patrick Roche and Savina Nikolakaki for 
supporting me throughout this time of my life and always being present at my ups and 
downs during this PhD study…! 
 
I dedicate this thesis to my mum, my dad and my brother Dimitri, for the 
love and understanding….for always being there for me and supporting all 
my steps and decisions… 
 
6 | P a g e  
 
Publications 
 Ngkelo, A., Marwick, J. A., Stevens, L., Kilty, I., Kirkham, P., Barnes, P. J. and Adcock, I. 
M. (2012). Oxidative stress induced inhibition of GSK3β reduces dexamethasone 
function in COPD monocytes and bronchial epithelial cells. (Submitted to Nature 
Medicine). 
 
 Ngkelo, A., Meja, K., Yeadon, M., Adcock, I. & Kirkham, P.A. (2012). LPS induced 
inflammatory responses in human peripheral blood mononuclear cells are mediated 
through NOX4 and Giα dependent PI-3kinase signaling. Journal of Inflammation. 9:1. 
 
 Morello, S., Sorrentino, R., Montinaro, A., Luciano, A., Maiolino, P., Ngkelo, A., Arra, 
C., Adcock, I. M. and Pinto, A. (2011). NK1.1 cells and CD8 T cells mediate the 
antitumor activity of Cl-IB-MECA in a mouse melanoma model. Neoplasia. 13, 365-
373. 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 | P a g e  
 
Table of Contents 
Abstract ....................................................................................................................................... 3 
Publications ................................................................................................................................. 6 
Chapter I .................................................................................................................................. 18 
Introduction .............................................................................................................................. 18 
1.1. Chronic obstructive pulmonary disease (COPD) ................................................................ 19 
1.1.1. Definition .................................................................................................................. 19 
1.1.2. Prevalence ................................................................................................................ 20 
1.1.3. Pathophysiology........................................................................................................ 20 
1.2. Inflammation and immunity............................................................................................. 21 
1.2.1. The normal inflammatory response ........................................................................... 21 
1.2.2. Inflammation in COPD ............................................................................................... 22 
1.2.3. The role of macrophages in driving inflammation in COPD ......................................... 22 
1.3. Reactive oxygen species ................................................................................................... 26 
1.3.1. Reactive oxygen species and their role in COPD pathogenesis .................................... 27 
1.4.1.1. The MAPK family: members and function ................................................................ 29 
1.4.1.2. Redox regulation of the MAPKs’ activity.................................................................. 30 
1.4.2. The phosphatidylinositol 3-kinase (PI3K) signalling pathway ...................................... 33 
1.4.2.1. Activation of the PI3K signalling pathway ............................................................... 33 
1.4.2.2. Classes  and structure of the PI3Ks .......................................................................... 33 
1.4.2.3. Akt: structure and function ..................................................................................... 35 
1.4.2.4. Regulation of Akt activation ................................................................................... 37 
1.4.2.5. Redox regulation of the PI3K/Akt signalling pathway .............................................. 37 
1.4.3. The Glycogen Synthase Kinase 3 (GSK3) ..................................................................... 39 
1.4.3.1. Structure of GSK3 ................................................................................................... 40 
1.4.3.2. Substrate recognition by GSK3 ................................................................................ 41 
1.4.3.3. Regulation of GSK3 activity ..................................................................................... 42 
1.4.3.4. The role of GSK3β in regulating the Wnt/β-catenin signalling pathway .................... 46 
1.4.3.5. GSK3β and its role in regulating inflammation ........................................................ 49 
1.5. Signalling to the nuclear factor kappa B (NF-B) ............................................................... 52 
1.5.1. NF-B: structure and function .................................................................................... 52 
1.6. The role of histone acetylation on driving gene transcription ............................................ 54 
1.6.1. Histone deacetylases (HDACs): role and classes .......................................................... 56 
1.6.2. HDACs regulate NF-B activity in COPD ...................................................................... 57 
8 | P a g e  
 
1.7. The anti-inflammatory role of corticosteroids ................................................................... 59 
1.7.1. The glucocorticoid receptor (GR): structure and isoforms ........................................... 59 
1.7.2. Ligand binding –dependent GR activation .................................................................. 60 
1.7.3. Corticosteroids: mechanism of action ........................................................................ 61 
1.8. Corticosteroid insensitivity in COPD ................................................................................. 62 
1.8.1. Molecular mechanisms of corticosteroid insensitivity in COPD ................................... 63 
1.8.1.1. Regulation of GRβ activity ...................................................................................... 63 
1.8.1.2. Genetic variation .................................................................................................... 64 
1.8.1.3. Oxidative stress and corticosteroid responsiveness .................................................. 64 
1.8.1.3.1. The role of HDAC2 in oxidant-induced corticosteroid insensitivity in COPD ............ 65 
1.8.1.3.2. The role of kinase signalling pathways in regulating corticosteroid insensitivity in 
COPD .................................................................................................................................. 67 
1.9. Rationale for the study .................................................................................................... 70 
1.9.1. Hypothesis ................................................................................................................ 71 
1.9.2. Aims ......................................................................................................................... 71 
Chapter II ................................................................................................................................... 72 
2.1. Materials ......................................................................................................................... 73 
2.1.6. Transient transfections of MonoMac 6 cells ............................................................... 76 
2.2. Methods .......................................................................................................................... 79 
2.2.1. Human studies .......................................................................................................... 79 
2.2.1.1. Peripheral lung sections .......................................................................................... 79 
2.2.2. Peripheral blood monocytes ...................................................................................... 79 
2.2.1.2. Lung tissue processing and immunohistochemistry .................................................. 80 
2.2.1.3. Isolation of peripheral blood mononuclear cells (PBMCs) ......................................... 80 
2.2.1.4. Monocyte isolation from PBMC population using MACS® Cell Separation ................. 80 
2.2.1.5. Cell culture and treatment of monocytes ................................................................. 81 
2.2.2. Culture and treatments of the human monocytic cell line MonoMac6 ........................ 82 
2.2.2.1. Cell culture and treatment of MonoMac6 ................................................................ 82 
2.2.2.2. Transient transfections of MonoMac6 cells ............................................................. 82 
2.2.2.2.1. Transfection with GSK3β siRNA ............................................................................ 82 
2.2.2.2.2. Transfection with plasmid DNA ............................................................................ 83 
2.2.3. Cell viability assay ..................................................................................................... 83 
2.2.4. Measurement of endotoxin levels in plasmid DNA constructs ..................................... 84 
2.2.5. Purification of DNA plasmid constructs using ethanol precipitation ............................ 85 
9 | P a g e  
 
2.2.7. Determination of protein expression by Western blotting .......................................... 88 
Chapter III ................................................................................................................................ 100 
3.1. Introduction .................................................................................................................. 101 
3.2. Results .......................................................................................................................... 104 
3.2.1. Phosphorylation of GSK3β on Ser9 is increased in peripheral lung macrophages and 
monocytes in patients with COPD compared to healthy subjects ....................................... 104 
3.2.2. Inactivation of GSK3β suppresses dexamethasone anti-inflammatory function in human 
primary monocytes ........................................................................................................... 108 
3.2.2.1. Inhibition of GSK3β activity by treatment with CT99021 had no effect on cell viability 
and basal inflammatory cytokine release .......................................................................... 108 
3.2.2.2. Treatment of monocytes with CT99021 had no effect on LPS-induced cytokine release
 ........................................................................................................................................ 109 
3.2.2.3. Treatment of monocytes with CT99021 reduces dexamethasone function in a 
concentration-dependent manner ..................................................................................... 112 
3.2.3. Inactivation of GSK3β suppresses dexamethasone function in the human monocytic cell 
line MonoMac6 ................................................................................................................ 115 
3.2.3.1. The anti-inflammatory function of dexamethasone in MonoMac6 cells .................. 115 
3.2.3.2. Treatment of MonoMac6 with the GSK3β inhibitor CT99021 had no effect on cell 
viability or LPS-induced pro-inflammatory cytokine release ............................................... 116 
3.2.3.3. Treatment of MonoMac6 with the GSK3β inhibitor CT99021 decreased 
dexamethasone function in a concentration-dependent manner ........................................ 116 
3.2.3.4. Treatment of MonoMac6 with on-target GSK3β siRNA inhibited total levels of GSK3β 
in a concentration- and time-dependent manner ............................................................... 119 
3.2.3.5. Effect of transfection with GSK3β siRNA on MonoMac6 cell viability over time ....... 120 
3.2.3.6. GSK3β protein knock down had no effect on LPS-induced pro-inflammatory cytokine 
release in MonoMac6 cells ................................................................................................ 123 
3.2.3.7. GSK3β protein knock down suppressed dexamethasone anti-inflammatory function in 
MonoMac6 cells ............................................................................................................... 126 
3.2.4. Plasmid overexpression in MonoMac6 cells ............................................................. 129 
3.2.4.1. Transient transfection efficiency and effect on cell viability ................................... 129 
3.2.4.2. Efficiency of the overexpression of the mutant GSK3β mRNA in MonoMac6 cells 
following plasmid transfection .......................................................................................... 129 
3.2.4.2. Effect of transient plasmid overexpression on basal and LPS-induced pro-
inflammatory cytokine release .......................................................................................... 133 
3.2.4.3. Measurement of endotoxin levels of the plasmid constructs .................................. 135 
3.2.4.4. Inhibition of LPS did not reverse plasmid DNA induced pro-inflammatory response in 
MonoMac6 cells ............................................................................................................... 136 
10 | P a g e  
 
3.2.4.5. Transfection of MonoMac6 cells with other plasmid DNA construct induces a pro-
inflammatory response ..................................................................................................... 138 
3.2.4.5. Effect of mutant GSK3β overexpression on dexamethasone function in MonoMac6 
cells .................................................................................................................................. 139 
3.2.4.5.1. Inactive K85R mutant GSK3β overexpression suppresses the anti-inflammatory 
effect of dexamethasone .................................................................................................. 140 
3.2.4.5.2. Exposure of MonoMac6 cells to H2O2 inhibits dexamethasone-induced suppression 
of LPS-stimulated GM-CSF release ..................................................................................... 141 
3.2.4.5.3. H2O2-induced inhibition of dexamethasone function is regulated by Ser9 on GSK3β: 
overexpression of the S9A mutant kinase restored dexamethasone function ...................... 143 
3.3.1. The inhibitory Ser9 phosphorylation levels of GSK3β are increased in lung macrophages 
and blood monocytes from patients with COPD and smokers compared to non-smokers ... 145 
3.3.2. Role of GSK3β inactivation on inflammation ............................................................ 146 
3.3.3. Role of GSK3β inactivation on corticosteroid anti-inflammatory function ................. 148 
Chapter IV ............................................................................................................................... 154 
The mechanism of GSK3β-regulated corticosteroid function in response to oxidative stress ....... 154 
4.1. Introduction .................................................................................................................. 155 
4.2. Results .......................................................................................................................... 158 
4.2.1. Mechanism of oxidative stress induced GSK3β inactivation ...................................... 158 
4.2.1.1. Effect of H2O2 exposure on monocyte viability ....................................................... 158 
4.2.1.2. Exposure to H2O2-induced Ser9 phosphorylation on GSK3β in a time-and 
concentration-dependent manner ..................................................................................... 158 
4.2.1.3. Effect of H2O2 treatment on kinase phosphorylation over time ............................... 160 
4.2.1.4. Exposure to H2O2 induced Ser9 phosphorylation on GSK3β in an ERK1/2-, Akt-, and p38 
MAPK- dependent pathway in monocytes derived from PBMCs ......................................... 164 
4.1.5. Exposure to H2O2 induced activation of ERK1/2 is not mediated by Akt or PI3Kδ in 
human monocytes ............................................................................................................ 166 
4.2.2. Investigation of the effects of the CT99021 compound and H2O2 on kinase activity .... 168 
4.2.3. Mechanism of GSK3β induced impairment of glucorticoid function .......................... 170 
4.2.3.1. Effect of GSK3β knock down on GR expression ....................................................... 170 
4.2.3.2. Effect of GSK3β inactivation on GR nuclear translocation ....................................... 170 
4.2.3.3. Effect of GSK3β inactivation on association of GR with NF-B/p65 ......................... 173 
4.2.3.4. NF-B p65 DNA binding capacity is not regulated by GSK3β kinase activity ............ 175 
4.2.3.5. Effect of GSK3β inhibition on HDAC2 mRNA and protein expression ....................... 176 
4.2.3.6. Effect of GSK3β inhibition on HDAC2 activity ......................................................... 177 
4.2.3.7. Inhibition of GSK3β led to post-translational modifications on HDAC2 ................... 177 
11 | P a g e  
 
4.3. Discussion ..................................................................................................................... 181 
4.3.1. Mechanism of H2O2 induced GSK3β inactivation ....................................................... 181 
4.3.1.1. Exposure of monocytes to H2O2 leads to activation of PI3K and ERK1/2 MAPK and 
inactivation of GSK3β in a time-dependent manner ........................................................... 181 
4.3.1.2. H2O2 induced inactivation of GSK3β is mediated by p38 MAPK, ERK1/2 MAPK and Akt 
in primary monocytes ....................................................................................................... 182 
4.3.2. Evaluation of the CT99021 specificity against a range of kinases .............................. 184 
4.3.3. Mechanism of GSK3β regulated corticosteroid insensitivity in monocytes ................. 185 
Chapter V ................................................................................................................................ 190 
5.1. Introduction .................................................................................................................. 191 
5.2. Methods ........................................................................................................................ 192 
5.2.1. Culture treatment of MonoMac6 cells and sample preparation ................................ 192 
5.2.2. Agilent microarrays ................................................................................................. 192 
5.2.3. Data analysis ........................................................................................................... 192 
5.3. Results .......................................................................................................................... 194 
5.3.1. CT99021 regulates the Wnt signalling pathway via up-regulation of FRAT1 and FRAT2 
gene expression ................................................................................................................ 194 
5.3.2. Effect of CT99021 on regulation of inflammatory gene expression and the pathways 
regulated .......................................................................................................................... 194 
5.3.3. Confirmation of the effect of CT99021 on dexamethasone-induced inhibition of IL-8 and 
CSF2 gene expression in LPS-stimulated MonoMac6 cells .................................................. 200 
5.4. Discussion ..................................................................................................................... 203 
5.4.1. Inhibition of GSK3β activity affects the activation of the Wnt signalling pathway via up-
regulation of FRAT expression ........................................................................................... 203 
5.4.2. Effect of CT99021 on regulation of inflammatory pathways ...................................... 204 
Chapter VI ............................................................................................................................... 208 
6.1. Rationale of the study .................................................................................................... 209 
6.2. Summary of the study findings ....................................................................................... 210 
6.3. Discussion ..................................................................................................................... 212 
6.4. Future directions ........................................................................................................... 217 
7. References ........................................................................................................................... 219 
 
 
12 | P a g e  
 
List of Figures 
1.1 
1.2 
Macrophages orchestrate the chronic inflammation in COPD 
The mechanisms of reactive oxygen species-induced activation of the MAPK 
signalling pathway 
25 
 
32 
1.3 Activation of the PI3K/Akt signalling pathway 38 
1.4 Schematic representation of the mammalian GSK3α and GSK3β isoforms 41 
1.5 Regulation of GSK3β activity by serine phosphorylation 44 
1.6 Regulation of GSK3β activity by phosphorylation 45 
1.7 The role of GSK3β in the Wnt/β-catenin signalling pathway 48 
1.8 Chromatin remodelling-controlled gene expression 57 
1.9 Mechanism of corticosteroid insensitivity in COPD 69 
2.1 Diagram of a basic ImmunoPrecipitation procedure 97 
3.1 p-GSK3β-s9/total GSK3β is increased in COPD peripheral lung macrophages 
compared to smokers with normal lung function and non-smokers 
 
106 
3.2 p-GSK3β-s9/total GSK3β is increased in COPD peripheral blood monocytes 
compared to smokers with normal lung function and non-smokers 
 
107 
3.3 The effects of inhibition of GSK3β by treatment with CT99021 on cell viability 
and basal GM-CSF levels in primary human monocytes 
 
110 
3.4 The effect of inhibition of GSK3β by CT99021 on LPS-induced GM-CSF levels 
released in primary human monocytes 
 
111 
3.5 CT99021 reduces dexamethasone (10-8M) anti-inflammatory function in a 
concentration-dependent manner 
 
113 
3.6 CT99021 inhibits dexamethasone (10-6M) anti-inflammatory function in 
human peripheral blood monocytes 
 
114 
3.7 Dexamethasone induced a concentration-dependent inhibition of pro-
inflammatory cytokine release 
 
115 
3.8 Effect of inhibition of GSK3β by CT99021 on cell viability and on LPS-induced 
CXCL8 levels released in the monocytic cell line MonoMac6 
 
117 
3.9 Inhibition of GSK3β by CT99021 suppresses dexamethasone function in 
human MonoMac6 cells 
 
118 
3.10 On-target GSK3β siRNA reduced total GSK3β protein levels in a time- and 
concentration-dependent manner 
 
121 
3.11 Electroporation affected MonoMac6 cell viability but addition of siRNAs had 
no impact on cell death 
 
122 
3.12 Reduction of GSK3β protein levels following 24 hours of siRNA transfection 
had no effect on LPS-induced pro-inflammatory cytokine release 
 
124 
3.13 Reduction of GSK3β protein levels following 48 hours of siRNA transfection 
had no effect on LPS-induced pro-inflammatory cytokine release 
 
125 
3.14 Inactivation of GSK3β by siRNA transfection for 24 hours reduced 
dexamethasone anti-inflammatory function in LPS-stimulated MonoMac6 
cells 
 
 
127 
13 | P a g e  
 
3.15 Inactivation of GSK3β by siRNA transfection for 48 hours had no overall 
significant effect on dexamethasone anti-inflammatory function in LPS-
stimulated MonoMAc6 cells 
 
 
128 
3.16 Transfection efficiency was measured by levels of GFP fluorescence emitted 
under UV light 
 
130 
3.17 Effect of transient transfection with pcDNA3.1 on cell viability 131 
3.18 Overexpression of the mutant GSK3β constructs measured by RT-PCR 134 
3.19 Transfection of MonoMac6 cells with plasmid DNA increases both basal and 
LPS-induced GM-CSF levels of release 
 
134 
3.20 Endotoxin levels of the plasmid constructs 135 
3.21 Effect of plasmid transfection on basal and LPS-induced GM-CSF release 
following plasmid endotoxin removal in MonoMAc6 cells 
 
137 
3.22 Inhibition of LPS by Polymyxin B did not reverse the pro-inflammatory effect 
of plasmid transfection in MonoMac6 cells 
 
138 
3.23 Transfection of MonoMac6 cells with a different plasmid DNA construct 
induced Polymyxin B-independent release of GM-CSF release 
 
138 
3.24 Overexpression of the kinase dead K85R GSK3β mutant suppresses 
dexamethasone function in LPS-stimulated MonoMac6 cells 
 
140 
3.25 
 
3.26 
H2O2-induced suppression of dexamethasone anti-inflammatory function in 
MonoMac6 cells 
H2O2-induced suppression of dexamethasone function is reversed in cells 
expressing the S9A mutant GSK3β kinase 
 
142 
 
144 
4.1 High concentrations of H2O2 induced reduction of cells viability in primary 
monocytes 
 
159 
4.2 H2O2 induced phosphorylation of GSK3β (Ser9) in a concentration-dependent 
manner 
 
159 
4.3 H2O2 exposure leads to Akt phosphorylation in primary monocytes 161 
4.4 H2O2 exposure leads to ERK1/2 activation in primary monocytes 162 
4.5 H2O2 exposure leads to GSK3β inactivation in primary monocytes in a time-
dependent manner 
 
163 
4.6 H2O2 exposure inhibits GSK3β in peripheral blood monocytes via activation of 
the Akt, ERK1/2 and p38 MAPK kinases 
 
165 
4.7 H2O2 -induced activation of ERK1/2 is not mediated by PI3K 167 
4.8 Effect of H2O2 exposure and treatment with the CT99021 compound on kinase 
activation 
 
169 
4.9 GSK3β knock down results in reduction of total GRα protein levels in 
MonoMac6 cells 
 
171 
4.10 GRα nuclear translocation is not affected by GSK3β inhibition 172 
4.11 Levels of GRα bound to NF-/p65 are not affected by GSK3β inhibition  174 
4.12 NF-/p65 DNA binding capacity is not affected by CT99021 in monocytes 
from PBMCs 
 
176 
14 | P a g e  
 
4.13 Inactivation of GSK3β does not affect HDAC2 protein or mRNA expression in 
peripheral blood monocytes 
 
178 
4.14 Inactivation of GSK3β leads to reduction of HDAC2 enzymatic activity in 
primary monocytes 
 
179 
4.15  Inactivation of GSK3β leads to increase p-Ser394-HDAC2 levels in primary 
monocytes 
 
180 
5.1 
5.2 
Principal Component Analysis of microarray data 
Diagrammatic illustration of the effect of CT99021 on regulating expression of 
the genes involved in regulating the Wnt/β-catenin pathway 
193 
 
196 
5.3 Effect of CT99021 on dexamethasone-dependent suppression of LPS-induced 
inflammatory gene expression 
 
197 
5.4 Effect of CT99021 on expression of genes involved in regulating the 
chemokine signalling pathway 
 
198 
5.5 Effect of CT99021 on expression of genes that regulate the JAK/STAT 
signalling pathway 
 
199 
5.6 Effect of CT99021 on dexamethasone function on LPS-induced IL-8 mRNA 
expression 
 
201 
5.7 Effect of CT99021 on dexamethasone function on LPS-induced CSF2 mRNA 
expression 
 
202 
6.1 Mechanism of GSK3β-regulated corticosteroid function in the presence of 
reactive oxygen species in monocytes 
 
211 
List of Tables 
2.1.1 
2.1.2 
Cell culture materials 
Molecular biology reagents 
73 
73 
2.1.3 Buffers and solutions 75 
2.1.4 Kits and assays 76 
2.1.5 Primers’ sequences used for Real-Time qPCR 76 
2.1.6 Antibodies used for Western blotting 77 
2.1.7 Compounds and stimuli 78 
2.1.8 Equipment 78 
2.2.1 Antibodies and conditions used for ELISA 94 
3.1 Characteristics of subjects for peripheral lung sections 105 
3.2 Characteristics of subjects for isolation of peripheral blood monocytes 105 
Abbreviations 
A Alanine 
AC Adenylyl cyclase 
ACD Acid citrate dextrose 
AF-1 Activation function1 
15 | P a g e  
 
AKAP220 A kinase anchoring protein 220 
AP-1 Activator protein 1 
APC Antigen presenting cell 
APC Adenomatous polyposis coli 
AR Androgen 
Arg Arginine 
ASK Apoptosis signal-regulating kinase 
ATF-2 Activating transcription factor 2 
BAD Bcl-2 associated death promoter protein 
BAL Bronchoalveolar lavage 
BAX Bcl-2 associated X protein 
Bcl B cell lymphoma 
cAMP Cyclic adenosine monophosphate 
CBP CREB-binding protein 
CCL CC chemokine ligands 
CDP Cysteine-dependent phosphates 
CK Casein kinase 
c-Myc Avian myelocytomatosis virus oncogene cellular homolog 
COPD Chronic obstructive pulmonary disease 
CREB cAMP response element-binding protein 
CRM1 Chromosome region maintenance 
CXCR C-X-C chemokine receptor 
DBD DNA binding domain 
DLK Dual-leucine-zipper-bearing kinase 
DNA Deoxyribonucleic acid 
Dvl Dishevelled 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
ER Oestrogen 
ERK Extracellular signal-regulated kinase 
FEV1 Forced expiratory volume in one second of expiration 
FRAT Frequently rearranged in advanced T-cell lymphomas 
FVC Forced vital capacity 
Fzl Frizzled 
GBP GSK3β binding protein 
GCPR G coupled protein receptor 
GILZ Glucocorticoid-inducible leucine zipper 
GLUT Glucose transports  
GM-CSF Granulocyte-macrophage colony stimulating factor 
GR Glucocorticoid receptor 
GSH Glutathione 
GSK3 Glycogen synthase kinase 3 
GTP Guanosine triphosphate 
HAT Histone acetyltransferase 
HDAC Histone deacetylase 
HM Hydrophobic motif 
Hop Hsp-organising protein 
16 | P a g e  
 
Hsp Heat shock protein 
IFN Interferon 
IGF Insulin-like growth factor 
IKK Inhibitor of kappa B kinase 
IL Interleukin 
IL1R Interleukin 1 receptor 
IP Immunoprecipitation 
IRS Insulin receptor substrate 
IB Inhibitor of kappa B 
JNK c-Jun N-terminal kinase 
K Lysine 
LBD Ligand binding domain 
LDL Low-density lipoprotein  
LEF Lymphoid enhancer factor 
LPS Lipopolysaccharide 
LRP LDL-related protein 
MAPK Mitogen activated protein kinase 
MCP Monocyte chemotactic protein 
Mdm2 Murine double minute 
MEK MAP/ERK kinase 
MKP MAPK phosphatase 
MLK Mixed-lineage kinase 
MMP Matrix metalloproteinase 
MnSOD Manganese superoxide dismutase 
mTOR Mammalian target of rapamycin 
MyD88 Myeloid differentiation protein 88 
NADPH Nicotinamide adenine dinucleotide phosphate 
NEMO NF-B essential modifier 
NF-B Nuclear factor kappa B 
NL Nuclear localisation site 
NOX NADPH oxidase 
NRS Nuclear retention signal 
P/CAF CBP/p300 associated factor 
P70S6K P70 ribosomal S6 kinase 
P90RSK P90 ribosomal kinase  
PAMP Pathogen associated molecular patterns 
PB Polymyxin B 
PDK 
PCA 
Phospho-inosite-dependent kinase 
Principal Component Analysis 
PH Pleckstrin homology 
PI3K Phosphoinositide 3-kinase 
PKA Protein kinase A 
PKC Protein kinase C  
PP2A Phosphatase 2A 
PR Progesterone 
PRR Pattern recognition receptors 
Ptdln Phosphatidylinositol  
17 | P a g e  
 
PTEN Phosphatase and tensin homologue 
PTM Post-translational modification 
PTPase Protein tyrosine phosphatases 
R Arginine 
RbAp Retinoblastoma protein associated protein  
RBD Ras-binding domain  
RHD Rel homology domain 
ROS  Reactive oxygen species 
RTK Receptor tyrosine kinase 
Ser Serine 
SGIC Serum-glucocorticoids inducible kinase 
SH Src homology  
SHP-2 SH2 domain containing tyrosine phosphatase 2 
siRNA Small interfering RNA 
SIRT Silent information regulator  
SOD Superoxide dismutase 
Src Rous sarcoma oncogene cellular homologue 
TAD Transactivation domain 
TAK Transforming growth factor β-activated kinase  
TAO Thousand and one amino acid  
Tc cells T cytotoxic 
TC45 T-cell protein tyrosine phosphatase 
TFC T cell factor 
TGF Transforming growth factor 
Th cells T helper cells 
Thr Threonine 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TNFR Tumor necrosis factor receptor 
TPL2 Tumor progression loci  
Trcp Beta-transducing-repeat-containing protein 
TROC mTOR complex  
Trx Thioredoxin 
TSA Trichostatin A 
Tyr Tyrosine  
Vps34 Vacuolar protein-sorting defective 34 
WHO World Health Organisation 
Wnt Wingless/Integrated 
ZAK Leucine zipper and sterile-α motif kinase  
 
  
 
 
Chapter I 
Introduction 
 
 
 
 
Introduction 
 
19 | P a g e  
 
1.1. Chronic obstructive pulmonary disease (COPD) 
1.1.1. Definition  
COPD is a lung disease characterised by abnormal chronic inflammatory response of the 
respiratory tract involving the peripheral airways and the lung parenchyma (Barnes 2000; 
Chung and Adcock 2008). The chronic inflammation in COPD is associated with remodelling 
and narrowing of the small airways, which results in airflow limitation and a gradual decline 
of the lung function which is progressive and not fully reversible (Hogg, Chu et al. 2004; 
Rabe, Hurd et al. 2007). COPD is clinically diagnosed by a post-bronchodilator forced 
expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio of <70% and a FEV1 of 
≥80% (Mannino and Buist 2007; Rabe, Hurd et al. 2007). COPD is considered a preventable 
and treatable disease with some extrapulmonary effects that may contribute to its severity 
in individual patients (Rabe, Hurd et al. 2007; GOLD 2011). The inflammatory response in 
the lungs of COPD patients is a result of chronic exposure to noxious particles or gases. The 
main etiologic factor associated with COPD development is cigarette smoking (Mannino and 
Buist 2007; Chung and Adcock 2008) but other risk factors are also involved such as 
exposure to fossil fuels and environmental traffic pollution (Mannino and Buist 2007). The 
chronic inflammatory response in COPD persists even when the main exogenous driving 
factors are removed, contributing to the progression of the disease and lung function 
decline (Barnes 2000; Chung and Adcock 2008). 
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1.1.2. Prevalence  
COPD is a leading cause of morbidity and mortality worldwide. The World Health 
Organisation (WHO) has estimated that 3 million people died from COPD in 2005 and 210 
million people had diagnosed disease in 2007. COPD is the fifth most common cause of 
death and its mortality rates are expected to rise by 30% in the next decade. It has been 
now predicted that it will become the third leading cause of death worldwide by 2030 
(World Health Statistics, W.H.O. 2008). 
 
1.1.3. Pathophysiology 
COPD is a complex disease characterised by three distinct disease processes that contribute 
to the airflow obstruction; chronic bronchitis, emphysema and small airways disease 
(Barnes 2000; Chung and Adcock 2008). The increased mucus production in chronic 
bronchitis and the reduction of mucociliary clearance documented in COPD patients 
contributes to bacterial infections and colonisation during the disease exacerbations (Sethi 
2000; Patel, Seemungal et al. 2002). Emphysema is characterised by destruction of the lung 
parenchyma and enlargement of the alveoli and alveolar ducts distal to the terminal 
bronchioles resulting in loss of the lung elastic recoil thus contributing to airflow limitation 
(Kim, Eidelman et al. 1991). In addition, the degree of small airway narrowing correlates 
with the decline in lung function suggesting that it may be a predominant factor in the 
development of the airflow obstruction documented in COPD (Hogg, Chu et al. 2004). 
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1.2. Inflammation and immunity 
1.2.1. The normal inflammatory response 
Inflammation is the body’s response to infection or injury and plays a key role in both innate 
and adaptive immunity. In response to infection, the resident tissue cells, primarily 
epithelial cells, macrophages, dendritic cells, natural killer cells and mast cells, secrete 
cytokines, chemokines, lipid mediators and bioactive amines. These stimulate capillary 
permeability, local increase of blood flow and recruitment of neutrophils, blood circulating 
monocytes that differentiate into macrophages at the site of inflammation and dendritic 
cells. This acute inflammatory process involves the stimulation of several signalling 
pathways and pro-inflammatory mediators (Steinke and Borish 2006; Commins, Borish et al. 
2010). The most well studied pro-inflammatory responses are initiated by the activation of 
the tumor necrosis factor receptor (TNFR), the interleukin 1 receptor (IL1R), and Toll-like 
receptors (TLRs) (Lawrence and Fong 2010). TLRs are activated by pathogen associated 
molecular patterns (PAMPs) or virulence factors and in response they induce the expression 
of inflammatory mediators that drive pathogen-specific adaptive immune responses 
(Kumar, Kawai et al. 2009). Mononuclear phagocytic cells and other antigen-presenting cells 
(APCs) release cytokines that induce cellular infiltrate and tissue damage.  
Monocytes are activated via pattern recognition receptors (PRRs) and they release pro-
inflammatory cytokines such as tumor necrosis factor (TNF), Interleukins, IL1, IL-6, CXCL8 
and chemokines including IL-12, IL-15, IL-18, IL-23 and IL-27 (Steinke and Borish 2006). In 
addition to the cytokines that stimulate cytotoxic, cellular, humoral and allergic 
inflammation, others such as IL-1Ra (Interleukin 1 receptor a), TGF-β (transformation 
growth factor-β), IL-10 and IL-35 have anti-inflammatory properties (Commins, Borish et al. 
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2010). Under normal circumstances, the immune system employs several mechanisms to 
resolve inflammation and clear the tissues from inflammatory cells leading to normal tissue 
function. Failure of reversing the inflammatory responses leads to the pathogenesis of 
inflammatory diseases (Lawrence and Gilroy 2007).  
 
1.2.2. Inflammation in COPD 
Inflammation is COPD is characterised by an accumulation of neutrophils, macrophages, B 
cells, lymphoid aggregates and CD8+ T cells (Barnes 2008; Cosio, Saetta et al. 2009). The 
degree of inflammation correlates with disease severity and represents both innate and 
adaptive immune responses to toxic gases and particles (Hogg, Chu et al. 2004). The chronic 
inflammation in COPD is orchestrated by pro-inflammatory chemokines (CC-chemokine 
ligands such as CCL2 and C-X-C motif ligands such as CXCL1 and CXCL8); cytokines (TNF-α, IL-
1β, IL-6 and Interferon γ (INFγ) and proteases such as neutrophil elastase and 
metalloproteinases-9 (MMP9) (Barnes 2008). COPD severity correlates with an increase in B 
cell numbers indicating the role of adaptive immunity in the later stages of disease 
progression (Hogg, Chu et al. 2004; Gosman, Willemse et al. 2006). In addition, 
autoimmunity has been also documented in COPD, where autoantibodies, such as anti-
elastin, anti-epithelial, tobacco anti-idiotypic and anti-carbonyl antibodies are present in 
smoking patients with COPD (Koethe, Kuhnmuench et al. 2000; Lee, Goswami et al. 2007). 
 
1.2.3. The role of macrophages in driving inflammation in COPD 
Alveolar macrophages are activated by a number of stimuli, including cigarette smoke, pro-
inflammatory cytokines (such as TNF-α and IL-1β), bacterial endotoxin (such as LPS) and 
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other immune stimuli (Barnes 2004). Once activated, they secrete inflammatory mediators 
such as chemokines, cytokines, growth factors, lipid mediators and reactive oxygen species. 
Chemokine release leads to recruitment of monocytes from the blood circulation, 
neutrophils and T-lymphocytes. CXCL1, CXCL8 chemokines act via CXCR2 to attract 
neutrophils and monocytes; and CCL2 (monocyte chemotactic protein1 or MCP-1) acts via 
CCR2 to attract monocytes. CXCL9, CXCL10, and CXCL11 act via CXCR3 to attract Th1 cells 
and Tc1 cells, both of which release IFN-γ, which induce the release of more CXCR3-binding 
chemokines (Rot and von Andrian 2004; Lazzeri and Romagnani 2005).  
Proteases such as neutrophil elastase and metalloproteinases-9 are also secreted by 
macrophages leading to destruction of the alveolar wall (emphysema) and mucus 
hypersecretion (Hubbard, Fells et al. 1991; Nagase 1997). Mucus hypersecretion is also 
stimulated by EGF (epidermal growth factor) and TGF-α, whereas TGF-β and the connective 
tissue growth factor (CTGF) regulate small airway fibrosis (Figure 1.1) (Fairlie, Moore et al. 
1999; Takizawa, Tanaka et al. 2001). TGF-β is overexpressed in alveolar macrophages from 
COPD patients compared to normal subjects contributing to the fibrosis documented in the 
small airways of COPD patients (de Boer, van Schadewijk et al. 1998).  
Inflammatory cytokines, such as TNF-α and the granulocyte-macrophage colony stimulating 
factor (GM-CSF), IL-1β and IL-6 are also released in response to inflammatory stimuli and 
cigarette smoking and correlate with disease severity (Keatings, Collins et al. 1996; Culpitt, 
Rogers et al. 2003; Churg, Wang et al. 2004; Marwick, Kirkham et al. 2004; Lambert, Li et al. 
2007; Mortaz, Adcock et al. 2010; Mortaz, Henricks et al. 2011; Winkler, Nocka et al. 2012). 
Alveolar macrophages also release the anti-inflammatory cytokine IL-10 upon inflammatory 
stimuli, the secretion of which is markedly decreased in the sputum of patients with COPD 
(Takanashi, Hasegawa et al. 1999).  
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Due to their key modulator role in inflammation and the diversity of the responses they 
drive, macrophages may account for most of the known features of COPD pathophysiology 
(Shapiro 1999; Tetley 2002). There is a 5 to 10-fold increase in macrophage numbers in the 
airways, lung parenchyma, BAL (bronchoalveolar lavage) fluid and sputum of smokers and 
patients with COPD correlating with disease severity (Di Stefano, Capelli et al. 1998; 
Retamales, Elliott et al. 2001). One reason for this is the increased recruitment of monocytes 
from the circulation in response to monocyte-attracting chemokines that are released in the 
lungs (Barnes 2004). MCP-1 (CCL2) is found elevated in sputum and PAL of patients with 
COPD (Capelli, Di Stefano et al. 1999; de Boer, Sont et al. 2000; Traves, Culpitt et al. 2002) 
and is found to be overexpressed in alveolar and small airway macrophages (de Boer, Sont 
et al. 2000). CXC chemokines are also elevated in sputum and BAL of patients with COPD 
(Traves, Culpitt et al. 2002).  
The increased number of macrophages in COPD is also a result of their increased 
proliferation and survival in the lungs. Macrophages in the lungs of smokers have been 
shown to have increased proliferation rate compared to normal macrophages (Tomita, 
Caramori et al. 2002). Oxidative stress leads to increased expression of anti-apoptotic 
proteins (B cell lymphoma (Bcl)-XL and p21) leading to prolonged survival of alveolar 
macrophages in the lungs of both smokers and COPD patients (Tomita, Caramori et al. 2002; 
Marwick, Kirkham et al. 2004). Macrophages in the airways are cleared by the mucociliary 
clearance which is also shown to be impaired in COPD (Lourenco, Klimek et al. 1971; Foster, 
Langenback et al. 1980). The lymphatic drainage which also clears macrophages from the 
airways might be impaired in COPD patients due to emphysema and small airway fibrosis 
leading to increased number of macrophages in the lungs of COPD patients lungs (Barnes 
2004). 
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Figure 1.1. Macrophages orchestrate the chronic inflammation in COPD. Macrophages are 
activated by cigarette smoke extract, bacterial pathogens and inflammatory stimuli and in response 
they secrete inflammatory mediators that orchestrate the chronic inflammation in COPD. They 
secrete pro-inflammatory mediators (such as TNF-α, IL-6 and IL-1β) and reactive oxygen species. 
They also release chemoattractans, such as CXCL1, CXCL8, CCL2 which attract neutrophils and 
monocytes to the site of inflammation respectively. The release of elastolytic enzymes such as 
neutrophil elastase and matrix metalloproteinase 9 (MMP9) drives the destruction of the alveolar 
wall and mucus hypersecretion. In addition, they release CXCL9, CXCL10 and CXCL11 that activate 
Th1 and Tc1 cells to release IFN-γ. Release of TGF-α activates epidermal growth factor receptors 
(EGFR) which stimulate mucus hypersecretion and release of TGF-β and CTGF induces small airway 
fibrosis. Adapted from (Barnes 2004). 
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1.3. Reactive oxygen species  
Reactive oxygen species are small, highly reactive molecules including the superoxide anion 
radical (
.
O2
-), hydroxyl radicals (
.
OH) and hydrogen peroxide (H2O2).  The high reactivity of 
ROS, results from the presence of one or more unpaired electrons in their atomic or 
molecular orbitals. Although H2O2 is not a free radical, it can be oxidised to the highly 
reactive 
.
OH via the Fenton reaction in the presence of transition metals including iron or 
copper (Valko, Leibfritz et al. 2007). ROS are generated as by-products of cellular metabolic 
processes in mitochondria and peroxisomes, but also through the activity of cytosolic 
enzyme systems. The normal release of ROS in the cell is augmented by the activation of 
oxidative enzymes such as the nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidases (Finkel and Holbrook 2000).  
Reactive oxygen species that are generated normally by cellular events, such as aerobic 
respiration, are counteracted in the cells under normal conditions by the ubiquitously 
expressed antioxidant proteins. These include superoxide dismutase (SOD), catalase, 
glutathione (GSH), glutathione peroxidase, glutaredoxin and thioredoxin (Valko, Leibfritz et 
al. 2007). An imbalance between oxidant production and antioxidant capacity of the cell to 
prevent oxidative injury is called ‘oxidative stress’ and can be induced by pro-inflammatory 
processes, ionising radiation and exposure to chemotherapeutic drugs (Thannickal and 
Fanburg 2000; Valko, Leibfritz et al. 2007). Low levels of reactive oxygen species cause 
changes in the intracellular redox state and can alter the enzymatic function of redox-
sensitive proteins (Reth 2002; Forman 2007). High levels of reactive oxygen species can lead 
to impaired physiological functions via cellular damage of DNA and proteins’ lipid 
peroxidation, all implicated to be involved in human pathologies.  
Introduction 
 
27 | P a g e  
 
Oxidative stress has been implicated in many human diseases such as atherosclerosis, 
cancer, neurodegenerative diseases, ageing and COPD (Valko, Leibfritz et al. 2007). Due to 
the lack of our understanding of the exact mechanisms by which reactive oxygen species 
function in both normal and disease states, it remains uncertain whether oxidative stress is 
a cause or a result of these human pathologies. For that reason, there has been extensive 
investigation focused on addressing this question. Most studies use H2O2 as an agent to 
mimic the actions of reactive oxygen species due to its relatively long half-life and good 
membrane permeability (Reth 2002; Forman 2007). 
 
1.3.1. Reactive oxygen species and their role in COPD pathogenesis 
Reactive oxygen species are released from macrophages in response to inflammatory 
stimuli or cigarette smoke contributing to the increased oxidative stress documented in the 
airways of COPD patients (Montuschi, Collins et al. 2000; Rahman, van Schadewijk et al. 
2002; Stoner, Wang et al. 2008). This is mediated by the activation of the NADPH oxidase in 
the cell membrane which produces superoxide anions (O2
-) which are then converted to 
H2O2 by the enzyme superoxide dismutase (SOD) (Iles and Forman 2002). This elevated 
release of reactive oxygen species regulates the macrophage microbial killing function and is 
also critical for activation of signal transduction pathways and transcription factors which 
orchestrate the inflammatory gene expression in COPD (Barnes 2004). 
Reduced gene expression of the antioxidant manganese superoxide dismutase (MnSOD) in 
the epithelium of smokers and COPD patients suggest amplification of the injurious effects 
of cigarette smoke derived reactive oxygen species (Pierrou, Broberg et al. 2007). The direct 
oxidative effect of cigarette smoke (1015 radicals per puff) on the epithelium is shown by the 
increased nitrotyrosine levels detected in the lung epithelial lining fluid from chronic 
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smokers (Ichinose, Sugiura et al. 2000). Apart from its direct effects, cigarette smoke also 
induces the release of endogenous oxidants as suggested by increased NADPH oxidase (Nox) 
activity in macrophages and neutrophils from smokers (Noguera, Batle et al. 2001; Rahman, 
Biswas et al. 2006). Therefore, migration of neutrophils and macrophages into the lungs of 
chronic smokers is accompanied by elevated levels of ROS and subsequently cellular 
damage, which is reflected by increased H2O2 and lipid peroxidation products  in exhaled 
breath condensate (Montuschi, Collins et al. 2000).  
Oxidative stress in COPD could also affect smaller airways since catalase gene expression is 
reduced in peripheral lung tissue from COPD subjects compared to smokers and non-
smoking healthy controls (Tomaki, Sugiura et al. 2007). Increased release of ROS by 
peripheral blood neutrophils in COPD possibly contributes to systemic oxidative stress, 
evident from the increased lipid and protein peroxidation products in plasma and urine of 
COPD patients (Noguera, Batle et al. 2001; Santus, Sola et al. 2005; Hanta, Kocabas et al. 
2006). Systemic oxidative stress is thought to be involved in the development of some of the 
systemic effects of COPD (Langen, Korn et al. 2003). 
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1.4. Oxidative stress induced regulation of kinase signalling pathways 
1.4.1. The mitogen activated protein kinases (MAPKs) 
1.4.1.1. The MAPK family: members and function 
The MAPKs comprise a family of redox-sensitive protein-serine/threonine kinases that play a 
key role in mediating the transduction of biological signals from the cell membrane to the 
nucleus (Boutros, Chevet et al. 2008; Brown and Sacks 2009). They regulate cell growth and 
fate, therefore their sustained activation leads to uncontrolled proliferation and cell death 
(Winter-Vann and Johnson 2007). There are three well studied subgroups of MAPKs: the 
extracellular signal regulated kinases (ERKs), the c-Jun N-terminal kinases (JNKs) and the p38 
MAPKs (including p38α, p38β, p38γ and p38δ isoforms). Activation of MAPKs is mediated by 
activation of the upstream MAPK kinase kinases (MAP3Ks). The latter phosphorylate and 
activate their downstream targets, the dual specificity MAPK kinases (MAP2Ks) which 
subsequently phosphorylate the threonine and tyrosine residues of the MAPKs leading to 
their activation (Boutros, Chevet et al. 2008; Brown and Sacks 2009). Upon ligand binding to 
growth factor receptors, ligand induced dimerisation and oligomerisation leads to 
phosphorylation and activation of receptor tyrosine kinases (RTKs). These activate the Ras- 
GTPase (Guanosine triphosphatase) which leads to activation of Raf and the MAP/ERK 
Kinase (MEK). MEK is responsible for the activation of the ERK pathway via phosphorylation 
(Aslan and Ozben 2003; Winter-Vann and Johnson 2007).  
The p38 MAPK pathway is activated in response to inflammatory cytokines, ligands for G 
protein-coupled receptors (GCPRs), heat shock, oxidative and osmotic stress (Cuadrado and 
Nebreda 2010). The p38 MAPK family members are activated by the two MEK family 
members MEK3 and MEK6. MEK6 can phosphorylate all four p38 isoforms whereas MEK3 
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activates p38α, p38γ and p38 δ. The members of the MAP3K family shown to stimulate p38 
MAPK activation include the apoptosis signal-regulating kinase-1 (AKS1 or MAP3K5), the 
dual-leucine-zipper-bearing kinase 1 (DLK1), the transforming growth factor β-activated 
kinase 1 (TAK1 or MAP3K7), the thousand and one amino acid (TAO), the mixed-lineage 
kinase 3 (MLK3 or MAP3K11), the tumor progression loci 2 (TPL2 or MAP3K8), the MEKK3, 
MEKK4 and the leucine zipper and sterile-α motif kinase 1 (ZAK1) (Son, Cheong et al. 2011). 
Some of the MAP3Ks that stimulate p38 MAPK activation can also activate the JNK pathway. 
MEK4 and MEK7 have been implicated in phosphorylation of JNKs in response to cytokines, 
agents that interfere with DNA and protein synthesis, growth factors and transforming 
agents (Bogoyevitch, Ngoei et al. 2010).  
 
1.4.1.2. Redox regulation of the MAPKs’ activity 
Reactive oxygen species have been shown to activate RTKs (Nakashima, Takeda et al. 2005) 
but studies have also shown that H2O2 is a critical mediator for ligand-independent 
phosphorylation of growth factor receptors in response to oxidative stress (Meves, Stock et 
al. 2001). Although direct exposure to exogenous H2O2 has been shown to lead to activation 
of MAPK pathways, the exact mechanism is still not known. Reactive oxygen species can 
alter protein structure and function by modifying critical amino acid residues of proteins 
(Meves, Stock et al. 2001). Oxidation of the cysteine-rich motifs present in several growth 
factors and cytokine receptors have been implicated in mediating oxidative stress induced 
activation of the MAPKs. In addition, reactive oxygen species can activate MAPKs via 
oxidative modification of intracellular kinases such as the MAP3Ks (Liu, Nishitoh et al. 2000).  
Studies focused on elucidating the mechanisms by which oxidative stress activates p38 and 
JNK MAPKs have revealed the critical role of the redox-sensitive proteins, thioredoxin and 
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glutaredoxin (Ichijo 1999). Reactive oxygen species can oxidise thioredoxin leading to 
dissociation of the latter from ASK-1 leading to the subsequent activation of the JNK and 
p38 pathways (Matsuzawa and Ichijo 2008). Besides ASK-1, there are other MAP3Ks or 
MAP2Ks that are redox sensitive and regulate oxidant stress-induced activation of MAPKs 
(Son, Cheong et al. 2011). In addition to the above mechanisms, H2O2 induced inactivation 
of the MKPs (MAPK phosphatases) by oxidation of their catalytic cysteine can also lead to 
MAPK activation (Kamata, Honda et al. 2005; Hou, Torii et al. 2008). Reactive oxygen species 
can lead to up-regulation of MKP-1 expression which correlates with inactivation of JNK and 
p38 activity and reduction of MKP-1 expression has been shown to lead to sustained 
activation of the JNK pathway (Kuwano and Gorospe 2008) (Figure 1.2). 
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Figure 1.2. The mechanisms of reactive oxygen species-induced activation of the MAPK signalling 
pathway. Production of reactive oxygen species is stimulated by growth factors, cytokines, and 
stresses. Under normal conditions these are counteracted by the ubiquitisously expressed 
endogenous antioxidant proteins. When the antioxidant capacity is exceeded by the levels of 
reactive oxygen species, then oxidative stress leads to activation of the MAPKs via oxidative 
modifications of the MAPK signalling proteins (RTKs and MAP3Ks). Oxidative stress induced 
inhibition of the MKPs is also a mechanism involved in oxidant stress induced MAPKs activation. 
Continous arrows represent activating/increasing effects and dashed arrows represent 
decreasing/inhibiting actions. Aadapted from (Son, Cheong et al. 2011). 
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1.4.2. The phosphatidylinositol 3-kinase (PI3K) signalling pathway 
1.4.2.1. Activation of the PI3K signalling pathway 
The PI3K signal transduction pathway plays an important role in regulating cell growth, 
proliferation, survival and motility (Leslie 2006). The cascade is activated by phosphorylation 
of RTKs leading to its direct binding to PI3K or its indirect binding to adaptor proteins such 
as insulin receptor substrate (IRS) in the case of insulin-like growth factor (IGF-1) signalling. 
Upon activation PI3K converts the membrane phosphatidylinositol 4,5-biphosphate 
[PI(4,5)P2] to the lipid phosphatidylinositol 3,4,5-triphosphate [PI(3,4,5)P3]. PIP3 in turn 
recruits Akt and 3’-phospho-inosite-dependent kinase-1 (PDK1) to the membrane via 
binding to its pleckstrin homology (PH) domains (Vanhaesebroeck and Alessi 2000) and 
PDK1 phosphorylates Akt on Ser473 leading to its activation (Bhaskar and Hay 2007). 
Activation of Akt can also be mediated by the mTOR (mammalian target of rapamycin) 
complex 2 (TROC2) and it is a Ser/Thr kinase that regulates the function of downstream 
kinases (Sarbassov, Guertin et al. 2005). The PI3K/Akt signalling pathways are tightly 
regulated by phosphatases. The phosphatase and tensin homologue (PTEN) is responsible 
for the enzymatic conversion of PIP3 back to PI(4,5)P2. In addition, protein tyrosine 
phosphatases (PTPases) regulate PI3K activation via inactivation of receptor tyrosine kinases 
(Dillon, White et al. 2007) (Figure 1.3).  
 
1.4.2.2. Classes  and structure of the PI3Ks 
There are three different classes of phosphatidylinositol 3-kinases based on their substrate 
preference and sequence homology (Engelman, Luo et al. 2006). Class I PI3Ks primarily 
generate (phosphatidylinositol) PtdIns(3,4,5)P3 from PtdIns(4,5)P2. Class IA and IB PI3Ks 
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differ primarily on their regulatory subunits. Class IA PI3Ks are heterodimers consisting of a 
regulatory subunit (p85α, p85β or p55γ) and a catalytic subunit (p110) (Fruman, Meyers et 
al. 1998). Each of the regulatory subunits of the Class I of PI3Ks is encoded by a distinct gene 
(PIK3R1, PIK3R2 and PIK3R3, respectively). The basic structure of the p85 regulatory units 
contains 2 Src (Rous carcinoma associated cellular homologue)-homology 2 (SH2) domains 
that flank one p110-binding domain (Songyang, Shoelson et al. 1993). Through their SH2 
domains, the p85 regulatory subunits bind to phosphorylated tyrosine residues on activated 
RTKs or adaptor molecules such as IRS1. This binding is fundamental for the obstruction of 
the inhibitory action that p85 exerts on the p110 catalytic subunit of the PI3K molecule (Yu, 
Wjasow et al. 1998). Three different genes encode the p110 catalytic subunit isoforms 
p110α, p110β and p110δ (PIK3CA, PIK3CB and PIK3CD, respectively) (Fruman, Meyers et al. 
1998).  
While p110α and p110β are ubiquitously expressed, the p110δ subunit is predominantly 
expressed in leukocytes (Engelman, Luo et al. 2006). The p110 catalytic subunit contains 5 
distinct domains: an N-terminal p85-binding domain, a GTPase Ras-binding domain (RBD), a 
C2 domain, a PIK homology domain and the catalytic domain located in the C-terminal end 
of the subunit (Fruman, Meyers et al. 1998). Class IA PI3Ks are activated by the growth 
factor RTKs. While the insulin and IGF-1 receptors utilise the IRS family of adaptor molecules 
to recruit Class IA PI3Ks to the plasma membrane and trigger their activity (Myers, Backer et 
al. 1992; Yamamoto, Lapetina et al. 1992; Giorgetti, Ballotti et al. 1993), other RTKs such as 
the EGFR recruit Class IA PI3K directly (Moscatello, Holgado-Madruga et al. 1998).  
The small GTPase Ras can also directly activate Class IA PI3K by interaction with the RBD 
domain of the p110 catalytic subunit. Class IB PI3Ks have a p101 regulatory subunit and a 
p110γ catalytic subunit. Since class IB PI3Ks do not possess a p85 regulatory subunit, they 
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are typically not regulated by RTKs, and rather activated by the G-protein-coupled receptors 
(Stephens, Smrcka et al. 1994; Stoyanov, Volinia et al. 1995).  
Class II PI3Ks consist of a single p110-like catalytic subunit, in three different isoforms (PI3K 
C2α, β and γ). Although it is generally assumed that class II PI3Ks can phosphorylate both 
PtdIns and PtdIns(4)P in vitro, they seem to have a preferential activity for PtdIns, 
transforming it into PtdIns(3)P. In vivo studies also suggest that PtdIns(3)P might be the 
most abundant product generated by this class of PI3K (Falasca and Maffucci 2007). There is 
still a considerable lack of knowledge regarding the function and regulation of this class of 
PI3Ks. 
Class III is represented solely by the mammalian homolog of the vacuolar protein-sorting 
defective 34 (Vps34) molecule, first identified in Saccharomyces cerevisiae. PtdIns is the only 
substrate of this class of PI3K identified and the only product it generates is PtdIns(3)P. In 
both yeast and mammalian cells, Vps34 is required for the induction of autophagy during 
nutrient deprivation (Backer 2008). However, as Vps34 has also been implicated in the 
positive regulation of mTOR/raptor signaling through nutrient sensing (Byfield, Murray et al. 
2005; Nobukuni, Joaquin et al. 2005), its role in autophagy might be context-dependent. 
More recently, Src has been demonstrated to phosphorylate and activate Vps34, in 
mammalian cells, leading to cellular transformation (Hirsch, Shen et al. 2010).  
 
1.4.2.3. Akt: structure and function 
Akt constists of a central kinase domain flanked by an N-terminal pleckstrin homology (PH) 
domain and a caboxyl-terminal regulatory domain which containts the hydrophobic motif 
(HM) which is characteristic of the AGC (protein kinases A, G and C) kinases including also 
the p70 ribosomal S6 kinase and the serum-glucocorticoid-inducible kinase (SGIC) (Hanad et 
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al, 2004). Akt catalytic activity is regulated by phosphorylation on its Thr308 and Ser473 
residues located on its catalytic and HM domains respectively (Liao and Hung 2010).  
Akt regulates a number signalling cascades that control apoptosis, cell cycle, angionegenesis 
and tissue invasion and thus plays a critical role in regulating malignant neoplastic 
transformation (Hanahan and Weinberg 2000). The kinase inhibits apoptosis by inactivating 
pro-apoptotic proteins and/or activating anti-apoptotic ones. One of its many targets is the 
pro-apoptotic member of the Bcl-2 family, BAD (Bcl-2 associated death promoter protein). 
Akt-induced phosphorylation of BAD on Ser136 disrupts the BAD-Bcl-2-mediated cell death 
(Datta, Dudek et al. 1997). Another member of the Bcl family targeted by Akt is BAX (Bcl-2 
asoociated X protein), whose translocation from the cytoplasm to mitochondria is regulated 
by phosphorylation by the kinase (Tsuruta, Masuyama et al. 2002). Akt is also known to 
phosphorylate and inactivate pro-caspase 9 on Ser196 (Cardone, Roy et al. 1998) and induce 
p53 degradation via phosphorylation of Mdm2 (murine double minute) and subsequent 
increase of the latter’s ability to ubiquitinate p53 (Ogawara, Kishishita et al. 2002). The 
kinase has been also shown to activate IKK (Inhibitor of Kappa B kinase) leading to activation 
of the NF-B (Salminen and Kaarniranta 2010).  
One the most critical roles of Akt signalling is regulation of cell cycle progression. Akt 
phosphorylates and inactivates GSK3, thereby rescuing cyclin D1 and c-Myc (avian 
myelocytomatosis virus oncogene cellular homolog) from ubiquitination and degradation by 
the proteasome and positively regulating G1/S cell cycle progression (Liang and Slingerland 
2003). Its role in metabolism derives from its regulatory function on glucose transport, 
protein and glycogen synthesis and gluconeogenesis suppression (Whiteman, Cho et al. 
2002). Active Akt mediates the effects of insulin signaling in enhancing cell growth. Akt 
promotes glucose uptake into adipocytes by inducing the translocation of the glucose 
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transports 4 (GLUT4) to the plasma membrane (Kohn, Summers et al. 1996; Cong, Chen et 
al. 1997).  In addition, it phosphorylates and inhibits glycogen synthase kinase 3 (GSK3) 
leading to promotion of glycogen synthesis. Akt also promotes protein synthesis via GSK3 
mediated regulation of the eukaryotic initiation factor 2B (eIF2B) (Proud 2006). 
1.4.2.4. Regulation of Akt activation 
Akt activity in mammalian cells is controlled by reversible phosphorylation of serine and 
threonine residues in response to serum stimulation or inhibition of phosphatase 2A (PP2A) 
activity (Andjelkovic, Zolnierowicz et al. 1996). PDK1 is responsible for activating Akt in 
response to insulin and growth factors (Alessi, Deak et al. 1997) via phosphorylation on its 
Thr308 residue. By contrast, PDK2 or mTOR targets the Ser473 residue of Akt1 (Figure 1.3). 
Full activation of Akt requires Thr308 and subsequent Ser473 phosphorylation (Liao and 
Hung 2010). 
1.4.2.5. Redox regulation of the PI3K/Akt signalling pathway 
Oxidative stress regulates the activity of PI3K via oxidative modification of Cys (cysteine)-
dependent phosphatases (CDPs) and protein kinases. CDPs are a large family of enzymes 
that share a catalytic domain with a conserved and highly reactive Cys residue, which at 
physiological pH exists as a thiolate anion. Oxidative modification of the Cys residue leads to 
inactivation of CDPs’ enzymatic function (Salmeen and Barford 2005). The CDPs that control 
the PI3K/Akt signalling pahtway include PI3-phosphatase, PTEN and PTPases. S-nitrosylation 
of the active Cys of PTEN is an key mechanism controlling redox regulating PI3K activity (Yu, 
Li et al. 2005). Under normal condition, PTEN is sustained in a reduced state by the 
NADPH/Trx (thioredoxin) system which is redox sensitive. Any decrease in NADPH, as in the 
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case of mitochondrial dysfunction, leads to oxidative modifications of PTEN and subsequent 
activation of the PI3K/Akt signalling pathway (Pelicano, Xu et al. 2006).  
 
Figure 1.3. Activation of the PI3K/Akt signalling pathway. Upon activation and phosphorylation of 
RTKs, their tails become docking sites for the p85 PI3K subunit which dissociates the p110 subunit of 
PI3K. This phosphorylates PIP2 generating PIP3. PIP3 recruits Akt and PDK1 to the plasma membrane 
via its PH domain. PDK1 phosphorylates Akt on Thr308 priming it for phosphorylation of Ser473 via 
PDK2 or mTOR. PP2A and PHLPP phosphatases are responsible for dephosphorylating Akt and 
inactivating it. In addition, PI3K activation is counteracted by PTEN which targets PIP3 and generates 
PIP2. Adapted from (Liao and Hung 2010). 
 
In addition, protein phosphatases are also known to be targets of ROS-species mediated 
oxidation. These inlcude the PTP1B, SHP-2 (SH2 domain containing tyrosine phosphatase 2) 
and TC45 (T-cell protein tyrosine phosphatase 45), which are all negative regulators of RTKs 
causing activation of the receptor regulated activation of the PI3K/Akt pathway (Lee, Kwon 
et al. 1998; Meng, Fukada et al. 2002; Wang, Zeigler et al. 2007). In addition to 
phosphatases, the PI3K and Akt protein kinases can be also modified by redox modification 
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leading to downregulation of the PI3K/Akt pathway. Oxidant stress stimulates the formation 
of a bisulphide bridge between Cys297 and Cys311 in the Akt kinase domain. This event 
assists the binding of Akt to PP2A leading to dephosphorylation of the former and its 
inactivation (Murata, Ihara et al. 2003).  
The p85 subunit of PI3K is also known to be a direct target for tyrosine nitration which also 
leads to inactivation of the Akt pathway (el-Remessy, Bartoli et al. 2005). Receptor-induced 
activation of PI3K can also activate Rac-NAD(P)H oxidase (NOX) leading to intracellular 
generation of reactive oxygen species (Welch, Coadwell et al. 2003). It was recently 
demonstrated that NOX-induced production of ROS regulates monocyte/macrophage 
survival via activation of Akt and inhibition of the p38 MAPK pathway (Wang, Zeigler et al. 
2007). 
 
1.4.3. The Glycogen Synthase Kinase 3 (GSK3) 
 
GSK3 was first discovered as one of the kinases responsible for the phosphorylation and 
inactivation of glycogen synthase (Embi, Rylatt et al. 1980). Apart from its role in glycogen 
metabolism, GSK3 acts as a downstream regulator that determines the output of numerous 
signalling pathways initiated by diverse stimuli (Frame and Cohen 2001; Grimes and Jope 
2001). Dysfunction of the pathways in which GSK-3 acts as a key regulator have been 
implicated in the development of human diseases such as diabetes, Alzheimer's disease, 
bipolar disorder and cancer (Doble and Woodgett 2003). 
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1.4.3.1. Structure of GSK3  
 
There are two mammalian isoforms of GSK3 (GSK3α and GSK3β) which share a 98% 
homology in their kinase domains but differ substantially in their N-terminal and C-terminal 
domains (Force and Woodgett 2009). GSK3α has a glycine rich N-terminal sequence (Frame 
and Cohen 2001), which accounts for its higher molecular weight compared to GSK3β 
(52kDa versus 47kDa) (Figure 1.4). Homologues of GSK3 exist in all eukaryotes examined to 
date and display a high degree of homology; isoforms from species as distant as flies and 
humans display >90% sequence similarity within the kinase domain (Ali, Hoeflich et al. 
2001). Both isoforms are redundant in regulating Wnt (wingless/integrated)/β-catenin 
signalling, where GSK3α regulates glycogen storage in the liver and GSK3β has the same 
function but in the skeletal muscle (Force and Woodgett 2009). GSK3α knockout mice are 
viable, although they show increased insulin sensitivity and reduced fat mass (MacAulay, 
Doble et al. 2007).  
Embryos carrying homozygous deletions of exon 2 of GSK3β die around embryonic day 16 
due to liver degeneration caused by extensive hepatocyte apoptosis. The inability of GSK3α 
to rescue the GSK3β-null mice indicates that the degenerative liver phenotype is specific to 
the beta isoform (Hoeflich, Luo et al. 2000). The differences in the function of the two 
isoforms are probably due to differences in affinity that they have towards interacting 
molecules such as Akt isoforms (Brognard, Sierecki et al. 2007). Another possible 
explanation is the tissue-specific scaffolds that mediate competitive binding of one of the 
two isoforms to specific targets (Force and Woodgett 2009).  
Another splice variant of GSK3β has been recently identified which accounts for ~15% of 
total GSK3. GSK3β2 contains a 13-residue insert located in the kinase domain (Mukai, 
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Ishiguro et al. 2002). This variant has less activity towards the microtubule-associated 
protein tau compared to the unspliced isoform and is localised primarily to neuronal cell 
bodies. Due to the location of the insert, the splice variant has probably different affinity to 
scaffolding proteins and hence exerts its function to different subset of target proteins 
(Mukai, Ishiguro et al. 2002).  
Figure 1.4. Schematic representation of the mammalian GSK3α and GSK3β isoforms. GSK3α and 
GSK3β share a conserved kinase domain (in purple) where the Y279 and Y216 are respectively 
located. The glycine-rich N-terminal domain is unique to GSK3α. The serine residues that regulate 
GSK3α and GSK3β activity are shown by the blue arrowheads accordingly. Taken from Doble and 
Woodgett (2003). 
 
 
1.4.3.2. Substrate recognition by GSK3 
 
GSK3 targets primed phosphorylated molecules, where the ‘priming’ residue is located four 
amino acids C-terminal to the site of GSK3 phosphorylation (Fiol, Mahrenholz et al. 1987). 
The consensus sequence for GSK3 substrates is Ser/Thr-X-X-X-Ser/Thr-P, where the first Ser 
or Thr is their target residue, X is any amino acid (but often Pro) and the phospho-Ser/Thr is 
the primed site. Although priming phosphorylation increases the efficiency of the kinase 
activity of GSK3 (by 100-1000 fold), it is not strictly required for its function (Thomas, Frame 
et al. 1999; Hagen and Vidal-Puig 2002). As shown in Figure 1.5, the phosphorylated residue 
of the primed substrate binds to the positively charged pocket including the R (Arginine) 96, 
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R180 and K (Lysine) 205 residues. This binding optimises the orientation of the kinase 
domains and places the substrate at the correct position at the catalytic groove promoting 
its phosphorylation. The substrates of GSK3 that lack this priming site have negatively 
charged residues on or near this position which act like ‘pseudo’ phospho-residues (Doble 
and Woodgett 2003).  
 
1.4.3.3. Regulation of GSK3 activity 
 
The crystal structure of GSK3 has been recently identified providing important insights into 
its regulation and its preference for primed, pre-phosphorylated substrates (Bax, Carter et 
al. 2001; Dajani, Fraser et al. 2001; ter Haar, Coll et al. 2001). Activation of GSK3 requires 
phosphorylation in its activation loop (T-loop) on Y279 or Y216 for GSK3α and GSK3β 
respectively (Doble and Woodgett 2003). Y216/Y279 phosphorylation enhances GSK3 kinase 
activity by >200 fold by forcing open the substrate site (Hughes, Nikolakaki et al. 1993) but 
there is no disruption to the open conformation in the unphosphorylated protein thus it is 
not essential for its kinase activity (Dajani, Fraser et al. 2001).  
Negative regulation of GSK3 is the key mechanism controlling its signal transduction since 
the kinase is constitutively active in most resting cells. Downregulation of GSK3 activity is 
regulated by inactivating its kinase domain, by disturbing its ability to bind to its substrates 
or by altering its ability to recognise them (Doble and Woodgett 2003). Phosphorylation of 
the Ser21 or Ser9 residue of GSK3α or GSK3β, respectively, transforms the molecule’s amino 
terminus into a ‘pseudosubstrate’. This phosphoserine occupies the same binding site that 
the priming phosphate of the substrate of GSK3 would occupy thereby blocking the 
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substrate’s access to the active site of the kinase (Cohen and Frame 2001) (Figure 1.5). 
There are several kinases that target these serine sites including AKT (Cross, Alessi et al. 
1995), p90 ribosomal kinase (p90RSK), p70 ribosomal S6 kinase (p70S6K) (Sutherland and 
Cohen 1994), PKA (Liu, Zhang et al. 2004) and protein kinase C (PKC) (Fang, Yu et al. 2002).  
PKA regulates GSK3β activity in response to GPCR activation. GPCRs are activated upon 
hormonal stimulation and activate adenylyl cyclase (AC) mainly via the Gsα subunit of G 
proteins (Krupinski, Coussen et al. 1989). This leads to production of cyclic adenosine 
monophosphate (cAMP) which activates PKA (Kuo and Greengard 1969; Walsh, Perkins et al. 
1971). PKA forms a complex with A kinase anchoring protein (AKAP220) which assist PKA-
induced phosphorylation of GSK3β and subsequent inhibition of its activity (Tanji, 
Yamamoto et al. 2002). c-AMP has multiple effects on cellular processes such as gene 
expression, cell cycle control and cell survival/death decision (Dumont, Jauniaux et al. 1989; 
Glass, Lundquist et al. 1989; Meyer-Franke, Kaplan et al. 1995; von Knethen, Lotero et al. 
1998) and regulation of GSK3β may contribute to these effects establishing the role of the 
kinase on controlling cell proliferation and survival (Hughes, Nikolakaki et al. 1993; Cui, 
Meng et al. 1998). GSK3β regulates cell proliferation/survival and glycogen synthase activity 
in response to growth factors (i.e. insulin and IGF-1) via activation of the PI3K/Akt signalling 
pathway (Sutherland, Leighton et al. 1993; Cross, Alessi et al. 1994; Stambolic and Woodgett 
1994; Cross, Alessi et al. 1995; Pap and Cooper 1998).  
As mentioned in the previous section, the insulin receptor or IGF-1 receptor can activate 
PI3K via utilisation of IRS1 and IRS2 mediators. The insulin receptor has intrinsic tyrosine 
kinase activity and upon ligand binding it phosphorylates its own tyrosine residues. This 
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leads to the recruitment and subsequent phosphorylation of IRS which is recognised by the 
p85 subunit of PI3K leading to activation of Akt (Antonetti, Algenstaedt et al. 1996;  
 
Valverde, Lorenzo et al. 1998; Shaw 2001). Akt phosphorylates GSK3β on Ser9 and 
inactivates it, resulting in dephosphorylation of glycogen synthase, suppresion of its activity 
and stimulation of glycogen synthesis (Parker, Caudwell et al. 1983; Welsh and Proud 1993; 
Cohen, Alessi et al. 1997) (Figure 1.6).  
Figure 1.5. Regulation of GSK3β activity by serine phosphorylation. When GSK3β is constitutively 
active in resting cells, substrates that have been either primed by a priming kinase (PK) or unprimed 
substrates can be phosphorylated by the kinase. In the case of primed substrates, the phospho-
residue on N+4 position binds the positively charged pocket comprising of the arginine (R) and lysine 
(K) residues. The serine or threonine on position N then binds to the catalytic site (C.S.). In 
stimulated cells that GSK3β is phosphorylated on Ser9 by an inactivating kinase (IK), the 
phosphorylated N-terminus becomes a pseudosubstrate, occupying the binding pocket and acting as 
a competitive inhibitor for the target substrates. This leads to inhibition of GSK3β kinase activity. 
Adapted from (Doble and Woodgett 2003). 
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Figure 1.6. Regulation of GSK3β activity via phosphorylation. Two major signalling pathways that 
regulate GSK3β activity via Ser9 phosphorylation include the insulin-regulated activation of PI3K/Akt 
pathway and the GCPR-mediated activation of PKA. (a) Upon insulin stimulation, the receptor 
phosphorylates itself on tyrosine residues (pY). These are then recognised by the PTB domains of the 
IRS1 and IRS2, which are recruited and phosphorylated by the insulin receptor. They interact with 
the SH2 domain of p85 of PI3K, recruiting the p110 subunit leading to activation of Akt. Akt 
phosphorylates GSK3β on Ser9 and inactivates it, resulting in dephosphorylation of glycogen 
synthase. (b) Ligand binding to GCPR results in AC activation and increased production of c-AMP 
leading to PKA activation. AKAP220 binds both PKA and GSK3β and allows PKA-induced 
phosphorylation of GSK3β on Ser9 blocking its activity. Adapted from (Cohen and Frame 2001; Jope 
and Johnson 2004; Rayasam, Tulasi et al. 2009).  
 
 
 
 
α b 
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1.4.3.4. The role of GSK3β in regulating the Wnt/β-catenin signalling pathway 
 
The canonical Wnt signalling pathway regulates cell fate and axis specification. Apart from 
regulating the cell’s ‘decision’ to proliferate or differentiate, Wnt signalling controls several 
cellular processes such as apoptosis, survival and cell motility (Sokol and Melton 1992; 
Moon, DeMarais et al. 1993; Gieseler, Mariol et al. 1995; Huguet, Smith et al. 1995; Edwards 
1999; Ellies, Church et al. 2000; Bonner, Lemon et al. 2003; Tepera, McCrea et al. 2003; 
Simon, Grandage et al. 2005). Recent studies have identified that Wnt5a signalling is 
upregulated in response to pathogens and enhances NF-B-driven inflammatory gene 
expression in human monocytes and macrophages (Nau, Richmond et al. 2002; Chaussabel, 
Semnani et al. 2003; Blumenthal, Ehlers et al. 2006). Although, Wnt5a is known to activate 
the non-canonical pathway, recent studies have shown that it can also activate the 
canonical Wnt pathway (Mikels and Nusse 2006), which is regulated by GSK3β. However, 
regulation of GSK3β activity in the Wnt canonical pathway does not utilise the same 
phosphorylation event as in PI3K/Akt signalling (Ding, Chen et al. 2000; Wu and Pan 2010).  
Under normal conditions, β-catenin is anchored to GSK3β by Axin and adenomatous 
polyposis coli (APC) which form the ‘destruction complex’. Casein kinase 1α (CK1α) 
phosphorylates β-catenin on Ser45 priming it for phosphorylation by GSK3β on Ser37 and 
Ser33 and Thr41 which in turn prepares the molecule for ubiquitination by the β-Trcp (beta-
transducing-repeat-containing protein) E3 ubiquitin ligase subunit and degradation by the 
proteasome (Clevers 2006). Phosphorylation of APC is involved in regulating the release of 
ubiquitinated β-catenin from the Axin/APC/GSK3β complex (Ha, Tonozuka et al. 2004). 
Unphosphorylated  β-catenin and APC bind to different sites on Axin and are both targeted 
for phosphorylation by CK1α and GSK3β. CK1α-induced phosphorylation of APC allows it to 
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bind to β-catenin with high affinity, and hence Axin is displaced and free to bind to new 
unphosphorylated β-catenin molecules (Xing, Clements et al. 2003; Xing, Clements et al. 
2004). β-Catenin is thus maintained at a low level and the DNA-bound T cell factor/lymphoid 
enhancer factor (TFC/LEF) protein family suppresses the transcription of Wnt target genes 
(Seidensticker and Behrens 2000).  
Binding of Wnt ligand to its receptor complex, composed of the seven-span transmembrane 
receptor Frizzled (Fzl) and the single-pass transmembrane protein low-density lipoprotein 
(LDL)-related protein 5/6 (LRP5/6) leads to disruption of the APC/Axin/GSK3β complex as 
shown on Figure 1.7. Upon Wnt binding, CK1γ and GSK3β phosphorylate LPR6 which then 
binds with high affinity to Axin (Davidson, Wu et al. 2005; Zeng, Tamai et al. 2005). Axin is 
therefore re-located to the plasma membrane releasing β-catenin from the disrupted 
complex (Lee, Salic et al. 2003). The cytoplasmic Dishevelled (Dvl) protein is also required for 
Wnt signalling. Dvl is recruited to the LRP5/6 receptor and binds Axin and CK1α, thus 
titrating them away from the destruction complex. In addition, upon stimulation with Wnt, 
the Dvl-FRAT1/2 (frequently rearranged in T cells lymphomas or GSK3β binding protein-GBP) 
complex inhibits GSK3β induced β-catenin inhibition as FRAT1/2 competes with Axin for 
binding to GSK3β (Li, Yuan et al. 1999; Thomas, Frame et al. 1999) (Figure 1.7).  
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Figure 1.7. The role of GSK3β in the Wnt/β-catenin signalling pathway. In the absent of the Wnt 
ligand, GSK3β is bound to Axin forming a complex with CKIα and APC called the destruction complex 
which anchors β-catenin (β-cat). CKIα phosphorylates β-catenin on Ser45, priming it for 
phosphorylation by GSK3β on Thr41, Ser37 and Ser33 which target β-catenin for ubiquitination and 
proteosomal degradation. Stimulation of the Frizzled receptor and LRP5/6 receptor by Wnt results in 
recruitment of FRAT1/2 and Dvl in the destruction complex. GSK3β and CKIγ phosphorylate LRP6 and 
enhance its binding to Axin and the latter relocates to the plasma membrane. In addition, FRAT1/2 
competes with Axin for binding to GSK3β leading to disruption of the destruction complex. GSK3β 
fails to phosphorylate β-catenin, which accumulates in the nucleus and transactivates genes 
regulated by LEF/TCF transcription factors. Adapted from (Doble and Woodgett 2003; Jope and 
Johnson 2004; Rayasam, Tulasi et al. 2009). 
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1.4.3.5. GSK3β and its role in regulating inflammation 
 
A number of studies have documented a role for GSK3β on regulating inflammatory 
responses (Cortes-Vieyra, Bravo-Patino et al. 2012). Inhibition of GSK3β enhanced LPS-
induced IL-10 release from monocytes. In contrast, LPS-stimulated production of IL-1β, IL-6, 
TNF-α and IL-12, was attenuated by GSK3β inhibition. This effect was mediated through 
modulation of the interaction of p65/NF-B with CREB (cAMP response element-binding 
protein) and the co-activator CREB-binding protein (CBP) (Martin, Rehani et al. 2005). The 
same group also demonstrated that GSK3β modulated LPS-induced production of IL-1Ra by 
human monocytes via affecting ERK1/2 activity downstream of targeting the inhibitory 
Ser71 residue on Rac (protein kinase Bα) (Rehani, Wang et al. 2009). Moreover, LPS-induced 
TNF-α expression in cultured neonatal mouse cardiomyocytes is associated with GSK3β 
activation. Inhibition of GSK3β led to increased TNF-α production, whereas its activation or 
overexpression attenuated LPS-induced TNF-α production (Shen, Fan et al. 2008).  
Inhibition of GSK3β activity has also been shown to induce inflammatory responses in LPS 
stimulated macrophages. In the study conducted by Wang, Garcia et al. (2008), LPS 
stimulation of macrophages enhanced IFNβ production in a MyD88 (Myeloid differentiation 
protein 88)-dependent manner. Suppression of GSK3β activity in these cells resulted in 
enhanced IFNβ expression via inhibition of c-jun function. INFγ augments TNF-α production 
by TLR ligands in human primary monocytes and macrophages as a result of suppressing IL-
10 production. Both GSK3β activation and suppression of MAPK activation were linked to 
INFγ-mediated suppression of IL-10. This process could be reversed by inactivation of GSK3β 
activity through the downstream effectors, CREB and AP-1 (activator protein 1) (Hu, Paik et 
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al. 2006). Hence, there is increasing evidence that GSK3β plays a key role in regulating the 
inflammatory responses upon pathogen stimulation.  
Interestingly, there is evidence that pre-stimulation of macrophages with TNF-α induced LPS 
tolerance in a GSK3β-dependent pathway. According to Park, Park-Min et al. (2011), GSK3β 
activation upon TNF-α stimulation, suppressed chromatin accessibility and NF-B-mediated 
transactivation of inflammatory genes. Additionally, GSK3β has been shown to regulate 
mTORC1-induced pro- or anti-inflammatory cytokine production. This was mediated by the 
downstream target of mTORC1, S6K1, which in response to LPS phosphorylates GSK3β 
leading to increased production of IL-12 and IL-10 in human monocytes (Wang, Brown et al. 
2011). In addition in a recent study by Baarsma, Meurs et al. (2011), GSK3β mediated 
cigarette smoke- and IL-1β- induced production of CXCL-8 in airway smooth muscle cells by 
enhancing p65 transactivation activity. The different effects that GSK3β exerts depend on 
the type of cell, the nature of the pathogen and the physiological state of the cell and the 
means by which the kinase is inhibited. Most studies have been focused on the role of 
GSK3β in response to bacterial LPS, but not much work has been conducted to evaluate the 
role of GSK3β activity in response to  exogenously derived reactive oxygen species. In 
addition, most of the pro- or anti-inflammatory effects of GSK3β inhibition have been tested 
via inhibition of the kinase with small molecule compounds that are known to have off-
target effects and regulate other kinases with known inflammatory roles such as histone 
deacetylases, CDK2-cyclin A, ERK8 and inositol monophosphate. There is an emerging need 
to evaluate the role of GSK3β on regulating inflammation upon corticosteroid treatment and 
investigate how is that modulated by reactive oxygen species which are known to be 
elevated in inflammatory cells in the lungs of COPD patients. The existence of such different 
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published functions of GSK3β, summarised on Table 1.1, derives from the different means 
(different compounds known to inhibit GSK3β function) that the authors have used to 
regulate GSK3β function in each study. Further investigation is required to elucidate the 
mechanisms that GSK3β employs to control the pathogenesis of infection and the 
expression of pro- or anti-inflammatory genes (Cortes-Vieyra, Bravo-Patino et al. 2012).  
 
Table 1.1. GSK3β modulation of inflammatory responses 
Cell type GSK3β 
Inhibition/ 
activation 
 Pro- or anti- 
inflammatory 
Inflammatory 
mediators 
Signalling 
effectors 
Human 
Monocytes 
Inhibition  Anti LPS induced: 
IL-6, TNF-α, IL1β 
CREB, CBP 
Mouse 
cardiomyocytes 
Inhibition  Pro- LPS induced: 
TNF-α 
Not studied 
Human 
monocytes 
Inhibition  Pro- LPS induced: 
IL1-Ra 
ERK1/2 
Human 
monocytes  
Activation Pro- IFNγ induced: 
IL-10 
CREB, AP-1 
Human 
monocytes 
Inhibition Anti- LPS induced: 
IL10 , IL12 
mTORC1, S6K1 
Airway smooth 
muscle cells 
Inhibition Pro- CSE- and IL-1β 
induced:  
IL8 and eotaxin 
p65-dependent 
gene  
transactivation 
Human 
monocytes 
Inhibition Pro- Decreased GR-
mediated 
transrepression 
Ser404 GR 
phosphorylation 
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1.5. Signalling to the nuclear factor kappa B (NF-B) 
 
1.5.1. NF-B: structure and function 
 
NF-B signalling regulates multiple aspects of innate and adaptive immunity (Silverman and 
Maniatis 2001; Bonizzi and Karin 2004). The mammalian NF-B family consists of five 
members, p65 (RelA), RelB, c-Rel, p50/p105 (NF-B1) and p53/p100 (NF-B2). In 
unstimulated cells these exist as homo- or heterodimers bound to the inhibitor of NF-B 
(IB) which prevents their translocation to the nucleus, thereby maintaining the 
transcription factor inactive (Duckett, Perkins et al. 1993; Campbell and Perkins 2006) NF-B 
proteins contain an N-terminal conserved 300 amino acids Rel homology domain (RHD) 
which is responsible for dimerisation, interactions with IBs and DNA binding (Hayden and 
Ghosh 2004; Perkins 2006). NF-B signalling occurs either through the classical or the 
alternative pathway (Bonizzi and Karin 2004). The alternative (non-canonical) pathway was 
not investigated in this thesis so only the classical pathway is discussed.  
In the classical pathway, in response to cellular stimulation via regulatory inducers, such as 
TNF-α, IL-1β or LPS, IB is phosphorylated, ubiquitinated and degraded by the proteasome. 
Degradation of IB is initiated upon specific phosphorylation by active IKK. IKK activity can 
be purified as a 700-900 kDa complex consisting of two kinase subunits, IKKα (IKK1) and 
IKKβ (IKK2) and the regulatory subunit NF-B essential modifier (NEMO) or IKKγ (Rothwarf 
and Karin 1999; Ghosh and Karin 2002). In the classical NF-B pathway, IKKβ is necessary for 
IBα phosphorylation on Ser32 and Ser34, and IBβ on Ser19 and Ser23. Once 
phosphorylated, the IB proteins are recognised by the Skp1-Culin-Roc1/Rbx1/Hrt-1-F-Box 
(SCRF) family of ubiquitin ligases (Ben-Neriah 2002) which bind to the phosphorylated E3 
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recognition sequence on IB (Yaron, Gonen et al. 1997; Wu and Ghosh 1999). 
Polyubiquitination of IBα takes place on the conserved Lys21 and Lys22 residues (Alkalay, 
Yaron et al. 1995; Scherer, Brockman et al. 1995; DiDonato, Mercurio et al. 1996) and 
targets the molecule for proteasomal degradation.  
Both p65 and c-Rel have a consensus PKA site at Ser276 (Mosialos and Gilmore 1993; 
Neumann, Grieshammer et al. 1995). Degradation of IB activates the catalytic subunit of 
p65 and phosphorylates it on Ser276 (Zhong, SuYang et al. 1997; Zhong, Voll et al. 1998). 
p65 phosphorylation is required for promoting its binding to DNA and it also provides a site 
for interaction with the co-activator (cAMP-response element binding protein/adenoviral 
protein E1A) CBP/p300 (Zhong, Voll et al. 1998; Zhong, May et al. 2002).  
NF-B binds to promoter and enhancer regions containing B sites with the consensus 
sequence GGGRNNYYCC (N=any base, R=purine and Y=pyrimidine). The N-terminal Ig-like 
domain of the RHD is responsible for sequence specificity, whereas the C-terminal domain 
forms the dimerisation interface (Chen, Huang et al. 1998; Chen, Ghosh et al. 1998; Huxford, 
Huang et al. 1998). RelB, c-Rel and p65 contain the transactivation domain (TAD) which is 
located towards the C-terminus. The TADs promote transcription via dissociation of 
repressor molecules recruitment of co-activators such as CBP/p300, CBP, the CBP/p300 
associated factor (P/CAF) and the activating transcription factor-2 (ATF-2). These have 
intrinsic histone acetyltransferase (HAT) activity and lead to acetylation of core histones and 
also recruit other HAT enzymes to the transactivation site. These enzymes acetylate lysine 
(K) residues on histone tails, which facilitates access to other transcription factors and 
initiation of transcription (Grunstein 1997; Li, Carey et al. 2007).  
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1.6. The role of histone acetylation on driving gene transcription  
Nucleosomal DNA is tightly packaged to varying degrees leading to chromatin compaction as 
small as 10nm fibre to high order structures such as the mitotic chromosomes. 
Condensation of DNA in chromatin leads to coiling of DNA on the surface of the nucleosome 
core and the folding of the nucleosome assemblies resulting in decreased accessibility to 
transcription factors and gene silencing (Wu 1997; Rahman, Marwick et al. 2004). The 
chromatin structure consists of DNA (165 base pairs) wrapped around an octamer of core 
histones composed of two molecules of each the histones H2A, H2B, H3 and H4. Post-
translational modifications (PTMs), such phosphorylation, acetylation and methylation on 
histones regulate gene expression (Urnov and Wolffe 2001). The N-terminal region of the 
histone tail is where the highest density of PTM possibilities exists. These dynamic 
modifications regulate the structure and the function of chromatin through two main 
mechanisms (Kouzarides 2007); causing a change in chromatin dynamics (euchromatin vs 
heterochromatin) (Shogren-Knaak, Ishii et al. 2006) or serving as a docking site for non-
histone proteins including chromatin remodelling engines leading to regulation of chromatin 
organisation via recruitment of transcription factors and co-regulator complexes 
(Ruthenburg, Allis et al. 2007; Gardner, Allis et al. 2011).  
The combination of PTMs in the appropriate context gives rise to a histone code or language 
which is interpreted by an array of diverse proteins (Gardner, Allis et al. 2011; Oliver and 
Denu 2011). These can be classified as ‘writers’, ‘erasers’ and ‘readers’. Writers and erases 
are the enzymes such as HATs, HDACs, kinases, phosphatases, methyltransferases and 
demethylases. Readers are proteins that recognise modified histones, such as those 
belonging to the bromodomain family, which identify acetylated lysine residues in histones 
and non-histone proteins (Mujtaba, Zeng et al. 2007; Sanchez and Zhou 2009). Among all 
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different PTMs on histones that regulate gene transcription, here we focus the discussion on 
acetylation since it is the one examined in this thesis. Acetylation of ε-group on the lysine (K) 
residues of histones leads to neutralisation of the positive charge on the histone tails 
leading to weakening of the DNA backbone and facilitates access to transcription factors 
(Grunstein 1997) (Figure 1.8).  
As described in the previous section, transcriptional coactivators, such as CBP/p300, CBP, 
P/CAF and ATF-2 have intrinsic HAT activity enabling initiation of DNA uncoiling and allowing 
binding of transcription factors (Chen, Fischle et al. 2001). There are several acetylation 
targets in each histone as shown on Figure 1.8. NF-B activation results in acetylation of 
specific lysine residues (primarily K8 and K12, and K5 and K16 at a lower rate) on histone H4 
correlating with increased expression of inflammatory genes in human airway epithelial cells 
(Ito, Barnes et al. 2000). In addition, histone acetylation is associated with other 
modifications on histones. H3 Ser10 phosphorylation inhibits H3 K9 methylation which 
blocks the acetylation of this residue (Richards and Elgin 2002; Hirota, Lipp et al. 2005).  
Methylation of H4 Arg3 stimulated CBP/p300 induced acetylation of H4 K5, K8, K12 and K16. 
This event enhances H3 methylation on Arg residues (Arg2, Arg17 and Arg27) (Daujat, Bauer 
et al. 2002; Huang, Litt et al. 2005). It is therefore clearly evident that both positive and 
negative crosstalk regulates histone acetylation patterns and the associated state of the 
chromatin (Gardner, Allis et al. 2011). 
 
 
 
 
 
Introduction 
 
56 | P a g e  
 
1.6.1. Histone deacetylases (HDACs): role and classes 
The transcriptional activity of inflammatory genes is regulated by reversal of histone 
acetylation which is controlled by the enzymes HDACs. These act by removing acetyl groups 
on amino terminal K residues of histones resulting in DNA condensation into chromatin and 
gene silencing (Henikoff, Strahl et al. 2008; Smith and Workman 2012) (Figure 1.8). HDACs 
can also inhibit gene transcription via acetylation of non-histone proteins, such as NF-B by 
disrupting their activity (Sengupta and Seto 2004). HDACs are therefore critical for 
regulation of cellular processes, such as cell cycle progression and differentiation 
(McLaughlin, Finn et al. 2003).   
There are 18 members of the HDAC family identified in humans (HDACs 1-11) and 7 
members of the silent information regulator (SIRT) family (SIRTs 1-7) (de Ruijter, van Gennip 
et al. 2003; Michan, Li et al. 2010). HDACs are classified into four classes; Class I HDACs 
include HDAC1, 2, 3, and 8 and predominantly located in the nucleus. Class II HDACs include 
HDACs 4-7, 9 and 10 which are expressed in a cell-specific pattern. The Class II HDACs 
include SIRT1-7 NAD+ family and control cellular functions such as inflammation, cell 
senescence and target non-histone substrates. Finally, Class IV HDACs include HDAC11 
(Chen, Mu et al. 2002; Sengupta and Seto 2004; Michan and Sinclair 2007). 
HDACs are required to exist within a co-repressor complex in order to attain their full 
deacetylase activity. HDAC2, for example, can associate with three co-repressor complexes; 
Sin3, NuRD/Mi2 and CoREST. Sin3 and Mi2 contain a core of four proteins HDAC1, RbAp46 
and RbAp48 (Retinoblastoma protein associated protein 46/48) and the mSin3A protein in 
the Sin3 complex and Mi2 in the NuRD/Mi2 complex (Sengupta and Seto 2004).  
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Figure 1.8. Chromatin remodelling-controlled gene expression. Acetylation of the lysine residues of 
histone tails is mediated by histone acetyltransferases leading to the opening up of the chromatin 
structure allowing the binding of transcription factors and RNA polymerase II (RNA Pol II). Removal 
of the acetyl groups is mediated by the histone deacetylases (HDACs). Histone deacetylation leads to 
repacking of chromatin and lack of gene expression or gene silencing. Adapted from (Ito, Yamamura 
et al. 2006). 
 
1.6.2. HDACs regulate NF-B activity in COPD 
The activity of NF-B is also regulated by its acetylation status. CBP/p300 acetylates p65 at 
lysines 218, 221 and 310 (Chen, Fischle et al. 2001). Acetylation of K221 within p65 inhibits 
its association with IBα and thus promotes DNA binding of the transcription factor, 
whereas acetylation of the K310 residue is necessary for its function (Chen, Mu et al. 2002; 
Furia, Deng et al. 2002). By contrast, acetylation of K122 and 123 reduces p65 DNA binding 
affinity (Kiernan, Bres et al. 2003). The pattern of p65 acetylation may also play a critical role 
in selective gene transactivation and this may be a plausible mechanism of the selective 
gene induction documented in COPD (Ito 2007). The p50 subunit has been also found to be 
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acetylated on K431, K440 and K441 in vitro by CBP/p300 (Furia, Deng et al. 2002). Although 
the functional role of p50 acetylation is not very clear, it has been suggested to increase 
DNA binding affinity and increase recruitment of p300 on the NF-B transactivation 
promoter sites (Deng and Wu 2003; Deng, Zhu et al. 2004). 
HDAC1, HDAC2 and HDAC3 have been shown to interact with RelA/p65, regulate its activity 
and control inflammatory gene transcription (Ashburner, Westerheide et al. 2001; Chen, 
Fischle et al. 2001; Zhong, May et al. 2002). Deacetylation of p65 on K221 (by HDAC3) and 
K310 (by SIRT1) has been shown to inhibit NF-B transactivation function. Reduction of 
HDAC activity in alveolar macrophages of smokers compared to non-smokers correlates 
with increased expression of NF-B regulated pro-inflammatory genes (Ito, Lim et al. 2001). 
In addition, a reduction in total HDAC activity in the peripheral lung, bronchial biopsies and 
alveolar macrophages from COPD patients, compared to healthy subjects, correlated with 
disease severity and increased pro-inflammatory gene expression of CXCL8 and increased 
histone acetylation at the NF-B binding site (Ito, Ito et al. 2005; Szulakowski, Crowther et 
al. 2006). Cigarette smoke-induced reduction in HDAC2 activity has been linked with 
increased RelA/p65 activity and subsequent increase of pro-inflammatory gene transcription 
(Yang, Chida et al. 2006). Binding of HDAC2 to NF-B does not involve interaction with the 
DNA binding domain of p65, since the HDAC inhibitor trichostatin A (TSA) does not interfere 
with NF-B DNA binding capacity, hence the domains remain to be identified (Yu, Zhang et 
al. 2002). 
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1.7. The anti-inflammatory role of corticosteroids 
1.7.1. The glucocorticoid receptor (GR): structure and isoforms 
The glucocorticoid receptor is part of the nuclear receptor (NR or steroid hormone receptor 
SHR) superfamily comprising also of oestrogen (ER), androgen (AR) and progesterone 
receptors (PR) (Evans 1988). GR consists of an N-terminal domain comprising of a first TAD)  
(activation function 1/AF-1) responsible for association with basal transcription factors 
(Hollenberg, Weinberger et al. 1985; Kumar and Thompson 1999), a DNA-binding domain 
(DBD) which facilitates dimerisation and DNA-binding (Hard, Kellenbach et al. 1990; 
Dahlman-Wright, Wright et al. 1991; Luisi, Xu et al. 1991; van Tilborg, Bonvin et al. 1995; 
Kumar and Thompson 1999) and a C-terminal ligand binding domain (LBD) which comprises 
of a second TAD (AF-2) and protein binding sites (Darimont, Wagner et al. 1998; Hong, 
Darimont et al. 1999; Robinson-Rechavi, Escriva Garcia et al. 2003; Ricketson, Hostick et al. 
2007). Close to the DBD and at the end of the LBD, lie two nuclear localisation sites, the 
ligand-independent NL1 and ligand-dependent NL2 which are responsible for promoting GR 
nuclear translocation (Savory, Hsu et al. 1999).  
GR exists in multiple isoforms as a result of alternative splicing (GRα, GRβ, GRγ, GR-A, GR-P) 
and different sites of initiation of translation (GRα-A, GRα-B, GRα-C1, GRα-C2, GRα-C3, GRα-
D1, GRα-D2 and GRα-D3. GRα is the predominant isoform found in most human cell types 
and it consists of 777 amino acids, whereas the truncated form GRβ (742 amino acids) does 
not bind to corticosteroids and it is not ubiquitously expressed. It can however act as a 
negative regulator of GRα (Duma, Jewell et al. 2006; Lu and Cidlowski 2006). In addition, a 
number of polymorphisms have been identified in the human GR gene, which affect its 
functions (Charmandari, Kino et al. 2008; Gross, Lu et al. 2009). 
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1.7.2. Ligand binding –dependent GR activation  
In resting cells, GR is located in the cytoplasm and it is associated with a molecular 
chaperone complex which disrupts its ligand-binding pocket and inactivates the NL site. The 
chaperone complex consists of heat shock proteins, Hsp90, Hsp70, the Hsp90-binding 
protein p23, the hsp-organizing protein (Hop), the tetratricopeptide repeat proteins that 
bind Hsp90 as well as the C-terminus of Hsp70-interacting protein (CHIP) (Pratt, Galigniana 
et al. 2004; Grad and Picard 2007). 
Corticosteroids are small hydrophobic molecules that diffuse through the membrane or 
enter the cell via the steroid hormone recognition and effector complex (Haller, Mikics et al. 
2008). Upon ligand binding, GR undergoes conformational changes (Bledsoe, Montana et al. 
2002; Bledsoe, Stewart et al. 2004), which allow it to dissociate from the chaperone 
complex and free its NL site. Nuclear import of GR is regulated by importin-α and importin 
13 via interaction with the NL1 and NL2 sites (195, 217, 218). Nuclear export of GR is 
regulated by the calreticulin-bases and chromosome region maintenance 1 (CRM1) 
mechanism, and its location is also determined by the nuclear retention signal (NRS) 
(Savory, Hsu et al. 1999; Holaska, Black et al. 2002; Walther, Lamprecht et al. 2003; Kumar, 
Chaturvedi et al. 2004; Carrigan, Walther et al. 2007).  
GR translocates into the nucleus where it exerts its positive or negative transcriptional 
effects (Savory, Hsu et al. 1999; De Bosscher, Vanden Berghe et al. 2003; De Bosscher, 
Vanden Berghe et al. 2006; Beck, Vanden Berghe et al. 2009). The GR homodimers bind in 
the major groove of DNA via the DBD targeting the consensus GR responsive elements 
(GREs) (5’ GGT ACA nnn TGT TCT 3’) found on the promoter region of GR-responsive genes 
(Schena, Freedman et al. 1989; La Baer and Yamamoto 1994; Rhen and Cidlowski 2005). 
Activation of GR-responsive genes can be also mediated via the interaction of 
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transcriptional coactivator molecules (including CREB) and the DNA-bound GR (Roth, 
Johnson et al. 2002). This is associated with local acetylation of histones induced by the 
intrinsic histone acetyltransferase activity that the coactivators possess. Chromatin 
remodelling engines (such as the SW1/SNF proteins) are then recruited at the site of 
transcription via bromodomains with subsequent recruitment of RNA polymerase II 
resulting in the initiation of transcription (Adcock and Ito 2000). GR-responsive genes 
include the β2-adrenergic receptor gene (Clark and Lasa 2003) and anti-inflammatory genes 
such as the glucocorticoid-inducible leucine zipper (GILZ) (Clark 2003; Barnes 2006; Ayroldi 
and Riccardi 2009). 
 
1.7.3. Corticosteroids: mechanism of action 
The major anti-inflammatory function of corticosteroids is exerted via repression of genes 
that encode for cytokines, chemokines, adhesion molecules, inflammatory mediators and 
receptors (Barnes and Adcock 2003; Beck, Vanden Berghe et al. 2009) whose transcription is 
regulated by NF-B and AP-1 (Adcock, Ito et al. 2004). Upon ligand binding and nuclear 
translocation, GR recruits HDAC2 in the activated inflammatory gene complex leading to 
deacetylation of histones and suppression of inflammatory gene transcription 
(transrepression). Acetylation of GR (on K492-495) upon ligand binding allows it to associate 
with NF-B and be targeted by HDAC2 (Ito, Yamamura et al. 2006). GR function can be also 
regulated by HDAC6 via acetylation of Hsp90 and regulation of GR nuclear translocation 
(Kovacs, Murphy et al. 2005).  
In addition to the mechanisms described above, GR can exert its anti-inflammatory actions 
via induction of MKP1 which in turn inhibits the MAP-kinase signalling pathway and the 
expression of pro-inflammatory genes (Clark and Lasa 2003). Moreover, corticosteroids have 
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been shown to reverse the ribonuclease-induced mRNA degradation of TNF-α upon 
inflammatory stimulation via transactivation of proteins (such as tristetrapolin) that 
destabilise mRNAs of inflammatory proteins (Smoak and Cidlowski 2006). Another 
mechanism employed by corticosteroids and suppress inflammatory gene expression is by 
interfering with the phosphorylation status of the C-terminal domain of RNA polymerase II 
leading to interruption of initiation of transcription of pro-inflammatory genes (Nissen and 
Yamamoto 2000). 
 
1.8. Corticosteroid insensitivity in COPD 
Corticosteroids are the most effective anti-inflammatory treatments available. Inflammatory 
and immune diseases such asthma, rheumatoid arthritis, autoimmune diseases and 
inflammatory bowel disease are treated by corticosteroids. By contrast, other inflammatory 
diseases, including, interstitial pulmonary fibrosis, acute respiratory distress syndrome and 
cystic fibrosis are relatively resistant to the anti-inflammatory actions of corticosteroids 
(Culpitt, Rogers et al. 2003).  
Most COPD patients respond poorly to high doses of inhaled oral corticosteroids leading to 
the concept that COPD is a relatively corticosteroid insensitive disease (Barnes and Adcock 
2009). A number of studies have documented that corticosteroids have no effect on 
inflammatory cell number or the release of pro-inflammatory mediators in sputum or 
airways of COPD patients (Keatings, Jatakanon et al. 1997; Culpitt, Maziak et al. 1999; 
Bourbeau, Christodoulopoulos et al. 2007). This observation is also reflected ex vivo, where 
corticosteroids fail to suppress inflammatory cytokine release in alveolar macrophages 
derived BAL from patients with COPD (Culpitt, Rogers et al. 2003). Interestingly, only 10% of 
COPD patients show clinical response to inhaled corticosteroids and their increased 
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numbers of airway eosinophils suggests that they possibly have concomitant asthma (Papi, 
Romagnoli et al. 2000; Brightling, McKenna et al. 2005). 
 
1.8.1. Molecular mechanisms of corticosteroid insensitivity in COPD 
 
The molecular mechanisms that regulate corticosteroid insensitivity in COPD remain 
unclear. There is still a variation in corticosteroids responsiveness among different cell types 
and tissues (Gross and Cidlowski 2008) and its unlikely that an intrinsic relative 
corticosteroid insensitivity of one particular cell type or of the lung accounts for the overall 
reduction of corticosteroid function documented in COPD (Marwick and Chung 2010).  
 
1.8.1.1. Regulation of GRβ activity  
One mechanism suggested to lead to corticosteroid unresponsiveness in COPD is increased 
expression of the dominant negative GRβ isoform (Strickland, Kisich et al. 2001). However, 
since levels of GRβ are not found to be elevated in COPD, while GRα expression is shown to 
be reduced, the ratio of GRβ to GRα in the lung or inflammatory cells may account for the 
impaired corticosteroid function. Very few studies have assessed this ratio in COPD, 
particularly in cells from the lung or small airways, and there is no functional effect assigned 
to increased GRβ ratio identified to be able to conclude that this mechanism is responsible 
for the developments of corticosteroid insensitivity in COPD (Marwick and Chung 2010).  
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1.8.1.2. Genetic variation 
Genetic susceptibility is likely to play a role in the development of COPD but in contrast with 
corticosteroid insensitive asthma, no direct link between genetic mutation and 
corticosteroid unresponsiveness has been documented in COPD (Hakonarson, Bjornsdottir 
et al. 2005). However, reduced antioxidant capacity due to genetic variations, such as the 
213Gly variant of the antioxidant SOD3 protein, may contribute to oxidant stress mediated 
development of relative corticosteroid insensitivity (Juul, Tybjaerg-Hansen et al. 2006; 
Young, Hopkins et al. 2006; Mak, Ho et al. 2007; Smolonska, Wijmenga et al. 2009). 
 
1.8.1.3. Oxidative stress and corticosteroid responsiveness 
As described earlier, the elevated oxidant burden in the lungs of COPD patients derives from 
both exogenous (cigarette smoking, pollutants) and endogenously (respiratory burst of 
inflammatory cells) and plays a central role in COPD. It also plays a key role in the 
development of corticosteroid insensitive inflammation (Kirkham and Rahman 2006; 
Rahman and Adcock 2006; Ciencewicki, Trivedi et al. 2008). Cigarette smoking induces 
corticosteroid insensitivity in several experimental models and the clinical observation that 
smoking asthmatics respond poorly to corticosteroids compared to non-smoking asthmatics 
strongly supports the role of oxidative stress in regulating corticosteroid function (Ito, Lim et 
al. 2001; Tomlinson, McMahon et al. 2005; Marwick, Caramori et al. 2009). One mechanism 
that has been suggested to mediate this oxidant stress-mediated affect links the redox 
status of the cells with GR nuclear translocation (Okamoto, Tanaka et al. 1999).  
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1.8.1.3.1. The role of HDAC2 in oxidant-induced corticosteroid insensitivity in COPD  
 
The primary mechanism leading to reduced activity of HDAC2 in the alveolar macrophages 
and peripheral lung tissue from smokers and patients with COPD compared to healthy non-
smokers is post-translational modifications, such as phosphorylation, carbonylation and 
nitration (Ito, Lim et al. 2001; Marwick, Kirkham et al. 2004; Yang, Chida et al. 2006). Of all 
HDACs, HDAC2 activity is affected the most, but reductions in HDAC3 and HDAC5 have been 
also documented. Furthermore, the mRNA expression of other HDACs, such as HDAC5 and 
HDAC8 are decreased in lung tissue from COPD patients, correlating with disease severity 
(Ito et al. 2005). Patients with severe COPD have less than 5% of HDAC2 in their lungs of 
what found in the lungs of healthy subjects. The mRNA levels of HDAC2 have been also 
found to be reduced in COPD but the mechanism that regulates transcriptional regulation of 
the HDAC2 gene remain still unclear (Barnes 2009). Decreased HDAC2 activity has been also 
documented in vitro, where cigarette smoke extract resulted into modifications by 
aldehydes and protein nitration (Yang, Chida et al. 2006). These post-translational 
modifications on HDAC2 impair its catalytic activity and can target the enzyme for 
proteasomal degradation (Galasinski, Resing et al. 2002; Ito, Hanazawa et al. 2004; Rahman, 
Marwick et al. 2004; Marwick, Ito et al. 2007; Meja, Rajendrasozhan et al. 2008; Osoata, 
Yamamura et al. 2009).  
The exact mechanisms by which reactive oxygen and nitrogen species regulate post-
translational modifications on HDAC2 have not yet been elucidated (Ito, Hanazawa et al. 
2004). Recent studies have implicated CK2α-mediated HDAC2 phosphorylation as being 
important as it leads to ubiquitination and subsequent degradation of HDAC2 by the 
proteasome (Adenuga, Yao et al. 2009; Adenuga and Rahman 2010). Ser421 and Ser423 on 
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HDAC2 are critical for the interaction with the co-repressor complex Mi2/mSin3A (Sengupta 
and Seto 2004). Phosphorylation on Ser394, Ser422 and Ser424 also regulates HDAC2 
interactions with transcription factors, co-repressor complex formation, CBP recruitment, 
acetylation on lysine residues and consequently increased transrepression activity (Adenuga 
and Rahman 2010). Thus, although basal phosphorylation of HDAC2 is critical for its 
deacetylase activity, hyperphosphorylation may lead to complex dissociation and inhibit 
deacetylase activity (Galasinski, Resing et al. 2002). 
As previously discussed, the acetylation/deacetylation balance is critically important for 
regulation of gene transcription (Li, Carey et al. 2007). Since HDAC2 activity is fundamental 
for GRα transrepression of inflammatory genes, reduction of its activity can impair 
corticosteroid function (Figure 1.9). In agreement with this, restoration of HDAC2 activity 
correlates with restoration of corticosteroid function in experimental models of COPD 
(Cosio, Tsaprouni et al. 2004; Marwick, Caramori et al. 2009; Zijlstra, Ten Hacken et al. 
2012). In addition to HDAC2, HDAC1 and HDAC3 protein levels are reduced in macrophages 
in response to cigarette smoking and this reduction has been associated with tyrosine 
nitration and α-β unsaturated aldehyde adduct formation (Yang, Chida et al. 2006). 
Since HDACs are involved in repressing pro-inflammatory genes, activation of HDAC2 may 
have therapeutic potential, and studies using the bronchodilator theophylline documented 
that its anti-inflammatory properties are associated with reversal of HDAC2 activity (Ito, Lim 
et al. 2002). Similarly, the dietary polyphenol compound, curcumin restored corticosteroid 
efficacy by reversing cigarette smoke induced reduction of HDAC2 in monocytes (Meja, 
Rajendrasozhan et al. 2008). The exact mechanisms that theophylline or curcumin restore 
Introduction 
 
67 | P a g e  
 
HDAC2 function have not been fully elucidated yet. In contrast, there is evidence that HDAC 
inhibitors have anti-inflammatory functions on their own (Grabiec, Tak et al. 2011). 
 
1.8.1.3.2. The role of kinase signalling pathways in regulating corticosteroid insensitivity in 
COPD 
Increased activation of the p38 MAPK in peripheral lungs and alveolar macrophages 
correlated with reduction in FEV1 and FEV1/FVC in COPD patients (Renda, Baraldo et al. 
2008). Increased p38 MAPK activity has been shown to induce phosphorylation of GRα 
resulting in disruption of its ligand binding ability (Irusen, Matthews et al. 2002) (Figure 1.9). 
Corticosteroids inhibit the p38 MAPK induced inhibition of GRα via induction of the p38 
MAPK-negative regulator MKP-1. In support with the hypothesis that MKP-1 signalling is 
linked with corticosteroid insensitivity in COPD, MKP-1 levels were found reduced in 
response to the corticosteroid dexamethasone in patients with severe corticosteroid 
insensitive asthma compared to those with non-severe asthma (Bhavsar, Hew et al. 2008). 
Oxidant mediated activation of the PI3K/Akt pathways has also been implicated in 
regulating corticosteroid function via modulation of HDAC2 activity (Figure 1.9). Inhibition of 
the PI3Kδ isoform restored HDAC2 activity correlating with restoration of corticosteroid 
function in oxidative stress-induced corticosteroid experimental murine models (Marwick, 
Caramori et al. 2009). However, PI3Kγ had no effect on steroid responsiveness. In 
agreement with this, selective inhibition of PI3Kδ restored corticosteroid regulated anti-
inflammatory mediator expression in PBMCs from patients with COPD compared to smokers 
with normal lung function (Marwick, Caramori et al. 2010). HDAC2 activity has been shown 
to be involved in mediating PI3K induced regulation of corticosteroid function in these 
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studies, however the exact mechanism involved is not known yet. Modulation of post-
translational modifications on HDAC2 and other co-repressors such as Mi2 and mSin3a in 
response to activated PI3K have been suggested to play a role in steroid insensitivity 
(Marwick, Caramori et al. 2009; Marwick, Stevenson et al. 2010)). Tyrosine nitration and 
hyperphosphorylation on the enzyme in response to oxidant stress is a plausible explanation 
but the exact signalling mediators downstream the PI3K/Akt pathway that control this event 
have not been identified yet (Marwick, Caramori et al. 2010). Interestingly, recent studies 
have proposed that the downstream effector of the PI3K/Akt pathway, GSK3β mediates 
hormone-dependent phosphorylation of GRα on Ser404. GSK3β regulated phosphorylation 
of GRα disrupts its interaction with its transcriptional co-regulators (such as CBP/p300) and 
p65 and impairs its function on inhibiting the NF-B dependent inflammatory gene 
transactivation (Blind and Garabedian, 2008; Galliher-Beckley et al., 2008; Ismaili and 
Garabedian, 2004; Wang et al., 2002). Several studies have also suggested the involvement 
of ERK1/2 and JNK in regulating GRα phosphorylation and subsequently its transrepression 
properties (Galliher-Beckley and Cidlowski 2009) (summarised in Figure 1.9). 
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Figure 1.9. Mechanism of corticosteroid insensitivity in COPD. Reactive oxygen species derived 
from cigarette smoking, pollution or released from inflammatory cells, lead to post-translational 
modifications on HDAC2 that interrupt the enzyme’s ability to bind to co-repressor and exert its 
deacetylase function on the NF-B site of pro-inflammatory gene transcription. Oxidant stress 
induced activation of MAPKs has been associated with increased phosphorylation on GRα disrupting 
its ligand ability. Activation of the PI3K/Akt pathway has been associated with reduction on HDAC2 
activity leading to increased histone acetylation of pro-inflammatory genes; and inhibition of the 
PI3Kδ isoform restores corticosteroid insensitivity in cigarette smoking experimental models. The 
bronchodilator, theophylline has also been shown to restore corticosteroid function by protecting 
HDAC2 from oxidant stress induced reduction on its activity. 
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1.9. Rationale for the study 
 
The relatively corticosteroid unresponsive inflammation in the airways of COPD patients is a 
central factor in the development and progression of the disease (Barnes 2008; Barnes and 
Adcock 2009). The increased oxidant burden in the lungs of COPD patients has a profound 
impact on inflammation and has been implicated to drive the corticosteroid 
unresponsiveness. Oxidant stress leads to activation of several kinase pathways including 
p38 MAPK, ERK1/2 and Akt and pro-inflammatory transcription factors such as NF-B 
leading to an enhanced inflammatory response in human macrophages (Irusen, Matthews 
et al. 2002; Marwick, Ito et al. 2007). The constitutively active serine/threonine kinase 
GSK3 is also modulated by oxidative stress and has been linked to several inflammatory 
diseases (Henriksen and Dokken 2006; Billadeau 2007; Jope, Yuskaitis et al. 2007). GSK3 
activity is negatively regulated by phosphorylation of Ser9 which can be mediated by 
ERK1/2, Akt and p38 MAPK (Grimes and Jope 2001). Since these kinase pathways have been 
linked to oxidant-mediated induction of corticosteroid insensitivity, GSK3β may represent an 
important downstream effector molecule of oxidant-mediated signalling.  
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1.9.1. Hypothesis 
 
Oxidant stress-induced regulation of GSK3β activity plays a role in corticosteroid 
responsiveness during inflammatory responses of immune cells.  
1.9.2. Aims 
 
In order to determine the above hypothesis, the following aims were set: 
I. Measure levels of p-Ser9-GSK3β in primary macrophages and peripheral blood 
monocytes from COPD patients, smokers with normal lung function and non-
smokers as a marker of GSK3β activity. Determine whether exposure of primary 
healthy peripheral blood monocytes to H2O2-derived oxidant stress affects GSK3β 
activity and identify the kinases involved in mediating this effect. 
II. Investigate how modulation of GSK3β activity regulates corticosteroid-mediated 
suppression of inflammatory cytokine release in human peripheral monocytes. 
III. Identify the mechanism that mediates GSK3β-regulated modulation of corticosteroid 
function, with respect to GR nuclear translocation, GR binding to p65, p65 
transactivation and HDAC2 activity. 
IV. Investigate whether GSK3β inhibition regulates global mRNA expression of 
corticosteroid responsive pro-inflammatory genes. 
 
 
 
  
 
 
 
 
 
 
Chapter II 
 
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
Materials and methods 
 
73 | P a g e  
 
2.1. Materials 
 
Table 2.1.1. Cell culture materials 
MATERIAL SUPPLIER 
Ficoll Paque™ Plus GE Healthcare, Buckinghamshire, 
UK 
Hank’s Buffered Saline Solution (HBSS) Sigma-Aldrich, Dorset, UK 
Heat-inactivated, fetal bovine serum (FBS) PAA Laboratories Ltd, UK 
L-Glutamine Sigma-Aldrich, Dorset, UK 
OPI Media Supplement Sigma-Aldrich, Dorset, UK 
Phosphate-buffered saline (PBS) Sigma-Aldrich, Dorset, UK 
Roswell Park Memorial Institute (RPMI)  1640 
medium 
Sigma-Aldrich, Dorset, UK 
MEM Non-essential Amino Acid Solution (100×) Sigma-Aldrich, Dorset, UK 
Sterile tissue culture grade water Sigma-Aldrich, Dorset, UK 
 
Table 2.1.2. Molecular biology reagents 
REAGENT SUPPLIER 
5x siRNA buffer Dharmacon, Colorado, USA 
AMV reverse transcriptase enzyme Promega, Southampton, UK 
AMV reverse transcriptase reaction buffer Promega, Southampton, UK 
Bovine Serum Albumin (BSA) Sigma-Aldrich, Dorset, UK 
Complete Protease Inhibitor Cocktail 
Tablets 
Roche Diagnostics Ltd, Burgess Hill, UK 
Deoxynucleotide triphosphates (dNTPs) Bioline, London, UK 
Dimethylsulphoxide (DMSO) Sigma-Aldrich, Dorset, UK 
Dithiothreitol  (DTT) Active Motif, Rixensart, Belgium 
Sodium acetate Sigma-Aldrich, Dorset, UK 
Full-Range Rainbow Molecular Weight 
Marker 
GE Healthcare, Buckinghamshire, UK 
Hank’s Buffered Saline Solution (HBSS) Sigma-Aldrich, Dorset, UK 
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Luminata Forte Western HRP substrate Millipore, MA, USA 
Marvel Milk Powder Waitrose, Berkshire, UK 
Methylthiazolydiphenyl-tetrazolium 
bromide (MTT) 
Sigma-Aldrich, Dorset, UK 
NP-40 Sigma-Aldrich, Dorset, UK 
NuPAGE® LDS Sample Buffer (4x) Invitrogen, Paisley, UK 
NuPAGE® MOPS SDS Running Buffer (20x Invitrogen, Paisley, UK 
NuPAGE® Novex® Bis-Tris 4-12% mini gels Invitrogen, Paisley, UK 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich, Dorset, UK 
Phosphatase inhibitor cocktail Active Motif, Rixensart, Belgium 
Phosphate-buffered saline (PBS) solution Sigma-Aldrich, Dorset, UK 
Phosphate-buffered saline (PBS) tablets Sigma-Aldrich, Dorset, UK 
Radioimmunoprecipitation assay (RIPA) 
buffer 
Millipore, MA, USA 
Random primers Promega, Southampton, UK 
ReBlot™ Plus antibody stripping solution Millipore, MA, USA 
Recombinant RNasin ribonuclease inhibitor Promega, Southampton, UK 
RNase-free water Bioline, London, UK 
Sodium Chloride (NaCl) Sigma-Aldrich, Dorset, UK 
Tween® 20 Sigma-Aldrich, Dorset, UK 
β-mercaptoethanol Sigma-Aldrich, Dorset, UK 
PureProteome Protein A agarose beads 
 
Millipore, MA, USA 
 
FUJIFILM medical X-ray film                
               
Genetic Research Instrumentation Ltd, 
Rayne, UK 
HDAC activity substrate 
(Bis-(BOC-(Ac)-Lys)-Rhodamine110) 
Peptides International, Louisville, USA 
Trypsin Sigma-Aldrich, Dorset, UK 
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Table 2.1.3. Buffers and solutions 
BUFFER/SOLUTION/STAIN  
5M NaCl 292g NaCl; up to 1L with deionised H20. 
Acid citrate dextrose solution (ACD-anti-
coagulant) 
4.2g di-sodium hydrogen citrate; 5g glucose; 
up to 100ml with deionised H20; filter-
sterilise before use. 
Kimura Stain 11ml Toluidine Blue; 0.8ml Light Green; 
0.5ml Saponin saturated in 50% (v/v) 
ethanol; 5ml phosphate-buffered saline 
solution; filter-sterilise before use. 
Stop Solution (for ELISA) 11ml Sulphuric Acid; up to 100ml with 
deionised H20. 
TBS-Tween (for Western blotting) 10ml Tris-HCl; 30ml 5M NaCl; up to 1L with 
deionised H20; 500µl Tween® 20. 
Tris-HCl (pH 7.4) 121g Tris base; adjust to pH 7.4 with HCl; up 
to 1L with deionised H20. 
Wash Buffer (for ELISA) 5 phosphate buffer tablets diluted in 1L 
deionised H20; 500µl Tween® 20. 
TE buffer 10 mM Tris-Cl, pH 7.6. 1 mM EDTA pH 8. 
IP Elution buffer 
IP Neutralization buffer 
0.2 M Glycine HCL pH 3 
1M Tris pH 9 
IP Wash buffer 50 mM Tris HCL pH7.4, 150 mM NaCl, 1% 
NP-40, 1% CHAPS, 1mM EDTA 
Lysis Buffer As indicated in the corresponding sections 
HDAC activity buffer 25mM TRIS-HCl pH 8, 137mM NaCl, 2.7mM 
KCl, 1mM MgCl2, 0.1% CHAPS 
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Table 2.1.4. Kits and assays 
KIT/ASSAY SUPPLIER 
Bicinchoninic acid (BCA) protein assay Pierce Biotechnology, Rockford, IL, USA 
Duoset ELISA Kits  R&D Systems, Abingdon, UK 
Human Monocyte Nucleofector® Kit Lonza, Cologne, Germany 
MACS Monocyte Isolation Kit II Miltenyi Biotec Ltd., Surrey, UK 
Nuclear Extraction Kit Active Motif, Rixensart, Belgium 
QIAshredder Spin Columns Qiagen, Crawley, UK 
QuantiTect SYBR Green PCR Kits Qiagen, Crawley, UK 
RNase-Free DNase Set  Qiagen, Crawley, UK 
RNeasy Mini Kit Qiagen, Crawley, UK 
TransAM NF-B/p65 DNA Binding Assay Active Motif, Rixensart, Belgium 
Human Phospho-Kinase Array Kit      R&D Systems, Abingdon, UK 
ToxinSensorTM Chromogenic LAL  Genscript, Piscataway, NJ, USA 
 
Table 2.1.5. Primers’ sequences used for Real-Time qPCR 
GENE   Primer sequence (5’-3’) 
18s forward CTTAGAGGGACAAGTGGCG 
18s reverse AGCCTGAGCCAGTCAGTGTA 
HDAC2 forward TCATTGGAAAATTGACAGCATAGT 
HDAC2 reverse CATGGTGATGGTGTTGAAGAAG 
GSK3β forward CAGGGCGGCCCAGAACCACCT 
GSK3β S9A mutant CAGGGCGGCCCAGAACCACCG 
GSK3β reverse TCAGGATCCAACAAGAGGTTCTGC 
IL-8 forward AACTTCTCCACAACCCTCTG 
IL-8 reverse TTGGCAGCCTTCCTGATTTC 
GM-CSF forward CACTGCTGCTGAGATGAATGAAA 
GM-CSF reverse GTCTGTAGGCAGGTCGGCTC 
 
2.1.6. Transient transfections of MonoMac 6 cells 
ON-TARGETplus SMARTpool GSK3β was from Dharmacon. The GSK3 beta S9A pcDNA3.1 
plasmid (Addgene plasmid 14754), the GSK3 beta K85A pcDNA3.1 plasmid (Addgene 
plasmid 14755) and the negative control pcDNA3.1 plasmid lacking the insert were from 
Addgene (Cambridge MA, USA)(Stambolic and Woodgett 1994). The eGFPpcDNA3.1 plasmid 
DNA was a kind gift of Prof. A. Oosterhout from University of Groningen, Netherlands.   
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Table 2.1.6. Antibodies used for Western blotting 
1° Antibody Dilution Supplier 
Phospho- Akt (Ser473) 
(#4060) 
1/500 Cell Signaling, Danvers, MA, USA 
Total Akt  
(#9272) 
1/500 Cell Signaling, Danvers, MA, USA 
Phospho- GSK3β (Ser9) 
(#9336) 
1/1000 Cell Signaling, Danvers, MA, USA 
Phospho-GSK3β (Tyr216) 
(sc-135653) 
1/400 Santa Cruz, Heidelberg, Germany 
P- GSK3β (Ser9) and total GSK3β for IHC 
(sc-11757, sc-9166) 
1/100 Santa Cruz, Heidelberg, Germany 
Total GSK3β 
(#9832) 
1/1000 Cell Signaling, Danvers, MA, USA 
Phospho ERK1/2 (Thr202/Tyr204) 
 (#9101) 
1/2000 Cell Signaling, Danvers, MA, USA 
Total ERK1/2 
(#9102) 
1/1000 Cell Signaling, Danvers, MA, USA 
Total NF-κB/p65 (C-20) (IP) 
(sc-372) 
2µg Santa Cruz, Heidelberg, Germany 
Total NF-κB/p65 (WB) 
(#6956) 
1/100 Cell Signaling, Danvers, MA, USA 
Total GR (E-20) 
(sc-1003) 
1/1000 Santa Cruz, Heidelberg, Germany 
Phospho-HDAC2 (Ser394) 
(ab75602) 
1/1000 AbCam, Cambridge, UK 
Total HDAC2 
(H2663) 
1/10000 Sigma-Aldrich, Dorset, UK 
Lamin A/C 
(ab49721) 
1/1000 AbCam, Cambridge, UK 
β-actin 
(ab8227) 
1/10000 AbCam, Cambridge, UK 
 
2° Antibody Dilution Supplier 
Polyclonal Goat Anti-Rabbit 
(P0448) 
1/4000 
DAKO, Cambridgeshire, UK 
Polyclonal Goat Anti-Mouse 
(P0447) 
1/2000 
DAKO, Cambridgeshire, UK 
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Table 2.1.7. Compounds and stimuli 
Treatment Stock Solution Supplier 
IC87114/ PI3Kδ inhibitor 10-2M in DMSO GSK, Stevenage, UK 
CT99021/ GSK3β inhibitor 10-2M in DMSO Pfizer, Cambridge, MA, USA 
SB239063/ p38 MAPK inhibitor  10-2M in DMSO GSK, Stevenage, UK 
U0126/ MEK inhibitor 10-2M in DMSO Cell Signaling, Danvers, MA, USA 
Dexamethasone 10-3M in sterile H20 Sigma-Aldrich, Dorset, UK 
Lipopolysaccharide (LPS; from 
Escherichia coli) 
1mg/mL in PBS Sigma-Aldrich, Dorset, UK 
H2O2  3% wt in H2O Sigma-Aldrich, Dorset, UK 
Polymyxin B 50 mg/mL in H2O Sigma-Aldrich, Dorset, UK 
 
Table 2.1.8. Equipment  
Equipment Supplier 
96-well MicroWell™ NUNC plates  Fisher Scientific UK Ltd,  Loughborough, UK 
Gel Doc-It™ imaging system and 
LabWorks software 
Ultra-Violet Products Ltd., Cambridge, UK 
Inverted light microscope Leica Microsystems, Buckinghamshire, UK 
NanoDrop™ 8000 Labtech International, East Sussex, UK 
Nucleofector® II Device  Lonza, Cologne, Germany 
RotorGene RG3000 (for Realtime PCR) Qiagen, (Corbett Research), Crawley, UK 
BioTek Instruments microplate reader Winooski, VT, USA 
Storm 840 phosphoimager Molecular Dynamics Div, Amersham Pharmacia 
Bioteck Inc, New Jersey, USA 
Corning® Clear Bottom 96 well plate Sigma-Aldrich, Dorset, UK 
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2.2. Methods 
2.2.1. Human studies 
2.2.1.1. Peripheral lung sections 
Subjects for the peripheral lung sections were recruited from the Section of Respiratory 
Medicine of the University Hospital of Ferrara, Italy. Peripheral lung tissue was collected 
from 21 patients with COPD, 19 smokers, and 14 non-smokers. Subjects’ characteristics are 
shown on table 3.1 (chapter III). All subjects were undergoing elective surgery for lung 
cancer, and COPD was diagnosed retrospectively; these subjects were not taking 
bronchodilator, theophylline, antibiotic, antioxidant, and/or glucocorticoid therapy in the 
last month before surgery. The study was approved by the local ethics committee of the 
University Hospital of Ferrara, and all patients were provided written informed consent.  
2.2.2. Peripheral blood monocytes 
Peripheral venous blood was collected from 4 patients with COPD, 3 smokers with normal 
lung function and 4 non-smokers for measurement of p-Ser9-GSK3β/total GSK3β ratio. 
COPD was defined according to the international guidelines as the presence of a post 
bronchodilator FEV1/FVC ratio of less than 70%. Subjects’ characteristics are shown on Table 
3.2 (chapter III). For the rest of the experiments, healthy subjects volunteered for peripheral 
venous blood donation (60ml). Pulmonary function tests were performed as previously 
described (Varani, Caramori et al. 2006). All participants gave informed consent to a 
protocol approved by the ethics committee of the Royal Brompton and Harefield NHS 
Trust/National Heart and Lung Institute. 
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2.2.1.2. Lung tissue processing and immunohistochemistry 
Lung tissue processing and immunohistochemistry were performed as previously described 
(Varani, Caramori et al. 2006). The total numbers of macrophages were counted in 20 non-
consecutive fields (magnification×40). Macrophages were identified by means of 
morphologic staining. Normal nonspecific IgG from the animals in which the primary 
antibodies were raised was used for negative controls (Santa Cruz Biotechnology, Santa 
Cruz, CA). All staining and cell counting was performed in a blind manner. The number of 
positively stained cells was expressed as a percentage of the total cells counted.  
2.2.1.3. Isolation of peripheral blood mononuclear cells (PBMCs) 
80ml of venous blood was collected into syringes containing acid citrate dextrose (ACD; an 
anti-coagulant) to give a final concentration of 1mM. The blood was divided into 4x20ml 
aliquots each of which were then diluted 1:1 with Hanks’ Buffered Saline Solution, HBSS. 
20ml of this mixture was then layered onto 15ml of Ficoll-Hypaque® in a 50ml Falcon tube. 
After centrifugation, 400 x g for 30 minutes at 22°C, PBMCs were collected from the 
interface between the Ficoll® and plasma, washed with HBSS and centrifuged again at 400 x 
g for 10 minutes at 22°C. After this spin, the PBMCs were resuspended in RPMI 1640 
GlutaMAX media with 10% FBS and 2mM L-Glutamine at 37°C with 5% CO2 and 90% 
humidity. Cell count was conducted using Kimura staining and a haemocytometer.  
2.2.1.4. Monocyte isolation from PBMC population using MACS® Cell Separation  
Monocytes were isolated from PBMCs using the MACS® Cell Separation Technology by 
depletion of non-monocytes by a process referred to as ‘negative selection’. The principle 
works on the basis of indirect magnetic labelling of non-monocytes to a cocktail of biotin-
conjugated monoclonal antibodies, as a primary labelling reagent and anti-biotin 
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monoclonal antibodies conjugated to microbeads, as secondary labelling reagent. The 
magnetically labelled non-monocytes are depleted by retaining them on a MACS® Column in 
the magnetic field of a MACS Separator, while the unlabelled monocytes pass through the 
column. Cells were re-suspended in 30µl of separation buffer per 1x107 cells in total. 10µl of 
FCR blocking reagent and biotin–antibody cocktail were also added per 1x107 cells and the 
mixture was incubated on ice for 10 minutes. After this time, 30µl of separation buffer and 
20µl of anti-biotin microbeads were added per 107 cells in total. Cells were then incubated 
for 15 minutes on ice followed by washing with the separation buffer and then re-
suspended in 500µl of buffer. An LS-MACS column was attached to a magnet and rinsed 
with 3ml of buffer. The cell suspension was then added to the column and the run-through 
from the column (the negative fraction, representing the enriched monocytes) was 
collected. A further 9ml of buffer was run through the column and collected. The resulting 
effluent was centrifuged and re-suspended in complete medium. Macrophage purity (>95%) 
was determined using FACS by staining the cells with anti-CD14 antibody.  
2.2.1.5. Cell culture and treatment of monocytes 
Isolated monocytes were cultured in RPMI 1640 GlutaMAX phenol red free media with 1% 
FBS and 2 mM L-glutamine at 37°C (5% CO2 and 90% humidity) and plated (0.5×106 cells per 
ml) into 96-well plates for supernatant collection and 6-well plates for protein extraction. 
Cells were pre-treated with the small molecule inhibitors/compounds for 30 minutes and/or 
with dexamethasone for 30 minutes and treated with LPS for 16 hours prior to collection of 
cell supernatants for ELISA or treated with H2O2 prior to protein extraction for Western 
blotting, ImmunoPrecipitation or kinase array assay. 
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2.2.2. Culture and treatments of the human monocytic cell line MonoMac6 
2.2.2.1. Cell culture and treatment of MonoMac6  
Human monocyte-macrophage cells (MonoMac6) were cultured in RPMI 1640 medium 
supplemented with 10% FBS, 2 mM L-glutamine, 1% nonessential amino acids and 1% 
sodium pyruvate (5% CO2 and 90% humidity) at a density of 0.2×10
6 cells/ml. Cells were 
cultured in starvation media containing only 1% FBS for 24 hours prior to being subjected to 
treatments.  
2.2.2.2. Transient transfections of MonoMac6 cells 
MonoMac6 cells were transiently transfected with siRNA and plasmids using Amaxa 
nucleofection. This process, developed by Amaxa AG biosystems, is a combination of 
electroporation and cell specific solutions which allows the introduction of RNA or DNA 
directly into the nucleus of cells (Hamm et al., 2002). 
2.2.2.2.1. Transfection with GSK3β siRNA 
 
For siRNA transfections, the experimental design included three controls: untransfected 
cells, cells subjected to nucleofection in the absence of siRNA (mock transfection control) 
and cells transfected with functional non-targeting siRNA (scramble control). Briefly, 
MonoMac6 cells were centrifuged at 1200 rpm for 3 minutes and resuspended in HBSS to 
remove any serum resides from the cells. 2×106 cells were aliquotted into sterile tubes and 
were then centrifuged again at 1200 rpm for 3 minutes. The cells were then resuspended in 
RPMI with 10% FBS (untransfected control), in nucleofector solution alone (mock 
transfection control), nucleofector solution containing 200nM or 400nM non-targeting 
siRNA (scramble control) and 200nM or 400nM on target GSK3β siRNA at a total 
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concentration of 100µl. All samples, apart from the untransfected control, were transferred 
into electroporation cuvettes and nucleofected with program W-01 on the nucleofector 
device. The transfected cells were transferred into 1ml of pre-warmed RPMI with 10% FBS 
and re-seeded in both 6-well plates and 96 well plates for 24, 48 or 72 hours. The seeding 
density was empirically determined as 500µl of cell suspension in 6-well plates and 50µl in 
96-well plates. The cells from 6-well plates were used for protein extraction and 
determination of GSK3β protein knock down whereas the cells from 96 well plates were 
used for treatment with dexamethasone +/- LPS for the times and concentrations indicated 
in the specific experiments.  
2.2.2.2.2. Transfection with plasmid DNA 
For plasmid transfections, the same protocol was used but included the following controls: 
1) untransfected cells, 2) mock transfected cells and 3) cells transfected with the empty 
vector (pcDNA3.1) 4) cells transfected with the eGFPpcDNA3.1 vector and 5) cell transfected 
with either the S9ApcDNA3.1 or the K85RpcDNA3.1 vectors. MonoMac6 cells were cultured 
as described and transfected for 18 or 24 hours with plasmid DNA at concentrations varying 
from 1-3µg. Plasmid expressions were verified using wild type primers and S9A mutant 
primers that recognise both endogenous wild type and mutant GSK3β. Following 
optimisation, the cells were transfected with 1µg of eGFPpcDNA3.1 and 2µg of the 
S9ApcDNA3.1 or the K85RpcDNA3.1 for 18 hours before subjected to treatments as 
described in the specific experiments.  
2.2.3. Cell viability assay  
Cell viability was determined by MTT assay. The principle of the assay is based on the ability 
of the yellow MTT dye to become reduced in the mitochondria of living cells, producing a 
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purple formazan product. This product is dissolved in DMSO and the absorbance of the 
resulting solution can give an indication of the number of viable cells present. 
For determining cell viability, cells were seeded in 96-well tissue culture plates and 
stimulated according to the specific experimental procedure. At the end of the stimulation 
period, the supernatants were removed and MonoMac 6 cells or primary monocytes were 
incubated with 150 μl of 1 mg/ml MTT solution in serum-free RPMI at 37°C for 30 minutes. 
Staining of the cells was confirmed by observation under a light microscope and 150 μl 
DMSO were then added to each well and mixed thoroughly to ensure the product is 
dissolved. The resulting solution was then transferred in 96-well microtitre plates and the 
absorbance at 550nm was measured using a microplate reader. The effect of a treatment on 
cell viability was determined as fold change in absorbance compared to the unstimulated 
control. 
2.2.4. Measurement of endotoxin levels in plasmid DNA constructs 
The endotoxin levels in the plasmid constructs were measured using the Toxin Sensor™ 
Chromogenic LAL Endotoxin Assay kit (Genscript, Piscataway, NJ, USA), a quantitative end-
point test which utilises a modified Limulus Amebocyte Lysate (LAL) and a synthetic colour 
producing substrate to detect endotoxin chromogenically. Serial endotoxin standard 
solutions were prepared of 1, 0.5, 0.25, 0.1, 0.05, 0.025 and 0.01 EU/ml by diluting the 
1EU/ml provided endotoxin stock solution with LAL Reagent Water. 100µl of each standard 
sample (in duplicate) and the test samples (diluted 1 in 10 in LAL Reagent Water) were 
dispensed into the endotoxin-free vials provided with the kit. The samples were mixed 
thoroughly for 30 seconds with a vortexer. A blank sample vial containing only 100µl of LAL 
Reagent Water was also used as a negative control. LAL stock solution was reconstituted 
Materials and methods 
 
85 | P a g e  
 
with 1.7ml of LAL Reagent Water and 100µl of the working solution was added into the vials. 
The vials were mixed well by swirling gently and incubated for 45 minutes at 37°C. The 
chromogenic substrate stock solution was reconstituted by addition of 1.7ml of LAL Reagent 
Water to give a final concentration of 2mM. 100µl of the reconstituted chromogenic 
solution was added to each vial and the samples were incubated for 5 minutes at 37°C. The 
Color-stabilizer #1 (Stop Solution) was added (500µl) to each vial and the samples were 
swirled gently to mix well. The Color-Stabilizer #2 was then added to the samples (500µl) 
and the samples were mixed well before addition of the Color-Stabilizer #3 (500µl). The 
samples were swirled gently avoiding bubble formation. The absorbance of each reaction 
vial was measured at 545nm using the microplate reader from BioTek Instruments, Inc 
(Winooski, VT, USA). The endotoxin levels in each vial were calculated graphically according 
to the linear relationship of the standard curve.  
2.2.5. Purification of DNA plasmid constructs using ethanol precipitation 
Ethanol precipitation accomplished with sodium acetate (CH3COONa) was used to purify the 
DNA plasmid constructs and remove endotoxin and impurities (Maniatis 1982). 100% ice 
cold ethanol (1ml) and Sodium acetate (40µl) were added to 400µl TE buffer containing the 
plasmid constructs. The solution was left on dry ice for 15 minutes before centrifugation at 
12,000 rpm for 2 minutes. The supernatant was discarded and the tubes containing the 
precipitated DNA were left open on the bench for 10 minutes for any remaining traces of 
ethanol to evaporate. The constructs were re-suspended in 500µl TE buffer and DNA purity 
was analysed using the NanoDrop ™ 8000 spectrophotometer by the ratio of absorbance at 
260nm and 280nm.   
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2.2.6. Determination of mRNA expression by real-time PCR 
For the determination of mRNA expression, total RNA was extracted from the cells and 
complimentary DNA (cDNA) was prepared by reverse transcription polymerase chain 
reaction (RT-PCR). mRNA levels were quantified by real-time quantitative PCR amplification 
of the cDNA using SYBR Green dye. 
2.2.6.1. RNA extraction     
Cells (primary monocytes or MonoMac6 cells) were washed with 1 ml HBSS solution and 
then incubated with 350 μl /well of RLT buffer containing 1% β-mercaptoethanol for 5 
minutes at room temperature, for cell lysis to take place. RNA extraction was immediately 
performed or cell lysates were stored at -80°C. Total RNA was isolated using the RNeasy 
Mini Kit according to the manufacturer’s instructions. Briefly, cell lysates were homogenised 
by centrifugation through QIAshredder spin columns at 12,000 rpm for 2 minutes. An equal 
amount (350μl) of 70% ethanol was then mixed with the lysate and the resulting solution 
was applied to the RNeasy Mini spin column by centrifugation at 10,000 rpm for 15 seconds, 
in order for total RNA to be retained on the silica-based membrane. The membrane bound 
RNA was washed to remove contaminants and incubated with a DNAse enzyme for 15 
minutes at room temperature to remove any DNA contamination. RNA was eluted from the 
column by applying 30μl H2O and centrifuging at 10,000 rpm for 1 minute. RNA purity was 
determined by determining the ratio of absorbance at 260nm over the absorbance at 
280nm (A260/A280) using the NanoDrop ™ 8000 spectrophotometer. Furthermore, RNA 
concentration in μg/μl was calculated using the relationship: RNA concentration (μg/μl) = 
(A260 x 40 μg/ml x dilution factor) ∕ 1000. 
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2.2.6.2. Reverse-transcriptase PCR 
Total RNA (0.5μg) in a final volume of 10μl was incubated for 5 minutes at 70°C on a thermal 
cycler in order to denature the RNA strands. At the end of the denaturation step the 
reverse-trancription reaction was set-up in a total volume of 20μl, which contained 1mM 
dNTPs, 1X AMV reverse transcriptase reaction buffer, 1 μg random primers, 40U 
recombinant RNasin ribonuclease inhibitor, 10U AMV reverse transcriptase enzyme and 
denatured RNA. The reaction mixture was incubated at 42°C for 60 minutes followed by 
incubation at 90°C for 4 minutes to inactivate the reverse transcriptase enzyme using the 
Rotor-Gene 3000 apparatus (Corbett Research). The final cDNA product was then diluted 3-
fold in nuclease-free water. 
2.2.6.3. Real-time quantitative PCR 
mRNA expression was quantified by means of a two-step quantitative real-time PCR, using 
the fluorescent DNA binding dye SYBR Green. Briefly, 2.5 μl of cDNA were added to capillary 
tubes containing 7.5 μl of PCR reaction mixture, which consisted of SYBR Green PCR Master 
Mix Reagent (containing HotStarTaq DNA polymerase, dNTPs and SYBR Green I dye) and 
gene specific primers, and the PCR reaction was carried out on the Rotor-Gene 3000 PCR 
apparatus (Corbett Research). The reaction involved incubation at 95°C for 15 minutes to 
activate the heat-activated DNA polymerase followed by 30-40 cycles consisting of a 
denaturation step (94°C for 20 sec), an annealing step (55-60°C for 20 sec) and an extension 
step (72°C for 20 sec). Fluorescence emitted from DNA-bound SYBR Green was detected at 
510nm after excitation at 470nm during the extension step. Data from the reaction were 
analysed using the computer software Rotor-Gene 6 v.6. CT values were converted into 
copies of the gene per reaction, by using a standard curve created by serial dilution of a 
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suitable sample. Gene expression was normalised to 18S rRNA expression. Specific primers 
for GSK3β and mutant sequences were designed according to their published sequences 
using the GenScript online primer design software and synthesised by Sigma-Genosys 
(Haverhill, Suffolk, UK). Primer specificity was assessed by using the online sequence 
analysis software BLAST (www.ncbi.nlm.nih.gov/BLAST/). Melting curve analysis and 
agarose gel electrophoresis were carried out in order to ensure the presence of one specific 
PCR product. For CXCL-8 and HDAC2 pre-designed and optimised primers (QuantiTect 
primer assays) from Qiagen were used. 
2.2.7. Determination of protein expression by Western blotting 
Human primary monocytes, PBMCs or MonoMac6 cells were plated at a density of 
0.5×106/ml on a 6-well plate, were kept on ice, scraped in media and transferred into pre-
chilled 2ml eppendorfs. The cells were pelleted by centrifugation at 5000 rpm for 5 minutes 
at 4°C and the supernatant was removed. After washing the cells once with ice cold PBS, 
containing 1X phosphatase inhibitor cocktail (to retain the phosphorylation status of the 
proteins of interest), the supernatant was removed and the cell pellet was resuspended in 
100μl of RIPA buffer containing 1mM PMSF and 1X Complete protease inhibitor cocktail. 
After leaving on ice for 30 minutes, the lysates were centrifuged at 13,000 rpm for 15 
minutes at 4°C and the resulting supernatant (the whole cell extract) was transferred in new 
pre-chilled tubes and stored at -80°C. 
2.2.7.1. Cytoplasmic and nuclear protein extraction 
Primary monocytes or MonoMac6 cells were plated at 2 x 106 /well before being subjected 
to treatments and were then lysed with 100µl of ice-cold lysis buffer (10 mM TrisHCl pH 7.4, 
150 mM NaCl, 0.75% (v/v) NP40, 1mM PMSF, 1mM DTT and 1X phosphatase inhibitor 
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cocktail) for 10 minutes on ice and centrifuged at 13,000 rpm for 5 minutes at 4°C. The 
supernatant (the cytoplasmic fraction) was collected into a fresh eppendorf. The pellet was 
re-suspended in 20µl of nuclei extraction buffer (20 mM HEPES, 1.5 mM MgCl
2
, 0.42 M NaCl, 
0.2 mM EDTA, 25% Glycerol, 1mM PMSF, 1mM DTT and 1X phosphatase inhibitor cocktail) 
and the tube was scraped against a tube rack to help break the nuclear membrane. The 
lysate was left on ice for 30 minutes then centrifuged at 13,000 rpm for 5 minutes at 4°C. 
The supernatant (the nuclear fraction) was collected into a fresh eppendorf and mixed with 
40µl of neutralising buffer (20 mM HEPES, 50 mM KCl, 0.2 mM EDTA, 1mM PMSF, 1mM DTT 
and 1X phosphatase inhibitor cocktail). The cytoplasmic and nuclear fractions were stored at 
-80°C until used for Western blotting. 
2.2.7.2. Bicinchoninic acid (BCA) protein assay 
Protein concentration of whole cell extracts, cytoplasmic extracts or nuclear extracts was 
determined by using a BCA protein assay kit, in a 96-well plate according to the 
manufacturer’s instructions. Briefly, protein extracts were diluted 2-fold in a total volume of 
10μl cell-culture grade water in the plate. BSA standards (0.2, 0.4, 0.8, 1.2, 1.6 and 2 mg/ml) 
were also prepared in cell culture grade water to a total volume of 10μl in each well. The 
BCA protein assay reaction mixture was then prepared by mixing reagent A (sodium 
carbonate, sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1 M sodium 
hydroxide) and B (4% cupric sulphate). 200μl of the mixture was added to the protein 
extracts and standards and the reaction was incubated for 30 minutes at 37°C. The 
absorbance of the product was measured at 562nm using a microplate reader and the 
protein concentrations were determined by comparison to the standard curve. 
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2.2.7.3. SDS PAGE and Western blotting 
10-50 μg of protein extracts were transferred into tubes before NuPAGE® LDS Sample Buffer 
(4X) containing 3.8% β-mercaptoethanol was added. The samples were boiled for 5 minutes 
at 95°C to denature the proteins. The proteins were then loaded onto a 4-12% Bis-Tris 
Novex® pre-cast mini-gel. The gels were placed in an electrophoresis cell connected to a 
power supply and were electrophoresed at 200V for 50 minutes in 1X NuPAGE® MOPS SDS 
running buffer. The gel cassette was opened using a gel knife and the gel was placed into 
the iBlot™ device. The iBlot™ Dry Blotting system uses a semi-dry method to blot proteins 
from polyacrylamide gels onto a nitrocellulose membrane in 7 minutes. The gel was placed 
on top of a ‘Bottom’ stack with a copper anode (negative) layer and a nitrocellulose 
membrane. A mini-roller was used to remove any bubbles between the gel and the 
membrane. A piece of filter paper soaked in deionised H2O was placed onto the gel and 
again, bubbles rolled out. A ‘Top’ stack consisting of a copper cathode (positive) layer was 
placed on top of the sandwich in addition to a layer of sponge and the iBlot™ device was 
tightly closed and the transfer commenced. After the transfer had completed, the sandwich 
was disassembled and the nitrocellulose membrane, onto which the proteins had now 
transferred, was cut to size using a scalpel. To check that the transfer of protein was 
successful, the membrane was incubated in Ponceau-S stain for 5 min before rinsing with 
deionised H2O. 
To prevent any non-specific binding the membrane was rinsed in TBS-Tween (0.1% Tween) 
and blocked by incubating in 5% milk for 1 hour at 4°C on a shaker. The membrane was then 
rinsed in TBS-Tween and incubated with a suitable dilution of the primary antibody for 16 
hours at 4°C on a shaker. After the primary antibody incubation, the membrane was washed 
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three times in TBS-Tween for 5 minutes each time then incubated with the suitable 
secondary antibody for 45 minutes at room temperature. At the end of the incubation, the 
membrane was washed 3 times for 10 minutes each time and then covered with 2 ml of 
Luminata™ Western HRP solution for 5 minutes at room temperature. Excess Luminata™ 
solution was then removed and the membrane was wrapped in cling-film and exposed to a 
medical X-ray film in a dark room. Exposed films were then developed and the relevant band 
intensities were quantified using the Gel Doc-It™ imaging system by scanning densitometric 
analysis using LabWorks™ software. For re-probing, the membranes were stripped by 
incubating in mild antibody stripping solution for 15-20 minutes then blocked in 5% milk and 
TBS-tween solution. Densitometric data of phosphorylated proteins were normalised to 
levels of total protein and the levels of the endogenous control, β-actin. 
 
2.2.8. Determination of cytokine release by ELISA 
Measurement of cytokine (CXCL8, TNF-α and GM-CSF) concentration in cell supernatants 
was performed by means of a sandwich ELISA. Primary monocytes or MonoMac6 cells were 
plated in 96-well plates at a density of 0.5×106 cells/ml and subjected to treatments in a 
final volume of 200µl. At the end of the stimulation period supernatants were removed and 
stored at -20°C or assayed directly. The concentration of CXCL8, TNF-α and GM-CSF in the 
supernatants was determined using specific DuoSet ELISA kits according to the 
manufacturer’s instructions. The antibody working concentrations, standard concentrations 
and supernatant dilutions for each assay are summarised in Table 2.2.3. Briefly, 96-well 
microtitre plates were coated by dispensing 100μl of capture antibody solution at the 
working concentration in PBS and incubating for 16 hours at room temperature. The capture 
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antibody solution was aspirated and then the plate washed three times with 300μl wash 
buffer using an ELISA plate washer (Skatron, Norway) and dried by blotting against paper 
towels. The plate was then blocked by dispensing 300μl of Blocking Buffer (1% BSA and 
0.05% NaN3 in PBS) in each well and incubating for 45 minutes at room temperature 
followed by another wash step as described above. Seven recombinant protein standards 
were then prepared by carrying out 2-fold serial dilutions of the stock protein standard in 
Reagent Diluent buffer (0.1% BSA and 0.05% Tween 20 in PBS). 100μl of the standards and 
diluted supernatants were then dispensed in the plate and incubated for 2 hours at room 
temperature. The plate was then washed and 100μl of detection antibody diluted to the 
working concentration in Reagent Diluent buffer were dispensed in each well and incubated 
for 2 hours at room temperature. The plate was then washed and 100μl of streptavidin-
Horseradish Peroxidase (HRP) solution, diluted 1/200 in Reagent Diluent buffer, were 
dispensed in each well and incubated for 20 minutes at room temperature protected from 
light. After the final wash step, 50μl of the substrate solution, prepared by mixing equal 
volumes of Colour Reagents A (H2O2) and B (Tetramethylbenzidine), were dispensed to each 
well and incubated until the product developed. The substrate reaction was then stopped 
by adding 50μl of stop solution (2N H2SO4). The absorbance of each well was then measured 
at 450nm with a 540nm correction using the microplate reader from BioTek Instruments, Inc 
(Winooski, VT, USA) and a four-parameter logistic standard curve was automatically 
generated using the microplate reader software. The chemokine concentration of each 
sample was determined from the standard curve and corrected for the dilution by 
multiplying by the dilution factor.  
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Table 2.2.3. Antibodies and conditions used for ELISA 
 
Ab: Antibody; conc: concentration 
 
2.2.9. NF-B p65 DNA binding assay 
Human primary monocytes were seeded into 6-well plates at 2x106/ml in RPMI-1540 
supplemented and 1% FBS and were subjected to treatments as indicated on the specific 
experiment. The cells were harvested and the nuclear proteins were extracted as discussed 
previously. The activity of p65 in the nuclear extracts was determined using the TransAM™ 
NF-B p65 Transcription Factor Assay Kit (Rixensart, Belgium). The kit uses an ELISA-base 
method to detect and quantify transcription factor activation and includes a 96-well plate 
that is coated with immobilised oligonucleotide containing the NF-κB/p65 consensus 
binding site (Complete Binding Buffer). The activated p65 subunit contained in the nuclear 
extracts binds to the oligonucleotides and is then detected by addition of an antibody that 
recognises the p65 subunit. The secondary antibody conjugated with HRP is the added to 
the wells and provides the colometric readout that is quantified by spectophotometry. The 
reagents used included Complete Lysis Buffer, Complete Binding Buffer, 1X Wash Buffer and 
1X Antibody Binding Buffer and were prepared according to the manufacturer’s 
recommendations.  Following the addition of Complete Binding Buffer (30μl) to each well to 
Cytokine Capture Ab 
(Working conc.) 
Detection Ab 
(Working conc.) 
Standard conc. 
range 
CXCL8 
Mouse anti-human 
(4 µg/ml) 
Biotinylated goat anti-human  
(40 ng/ml) 
0 – 1600 pg/ml 
GM-CSF 
Mouse anti-human 
(2 µg/ml) 
Biotinylated mouse anti-human 
(500 ng/ml) 
0 – 1000 pg/ml 
TNF-α 
Mouse anti-human 
(4 µg/ml) 
Biotinylated goat anti-human 
(500 ng/ml) 
0 – 1000 pg/ml 
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be used, 10μg of the nuclear protein samples (20μl) appropriately diluted in Complete Lysis 
Buffer were added to the wells and were incubated for 1hour at room temperature with 
mild agitation (100rpm on a rocking platform). Each well was then washed 3 times with 
200μl 1X Wash Buffer and 100μl of NF-B/p65 antibody was added (1:1,000 dilution in 1X 
Antibody Binding Buffer). The plate was incubated for 1hour at room temperature and the 
wells were washed again 3 times with 200μl 1X Wash Buffer. The HRP-conjugated antibody 
(100μl of 1:1,000 dilution in 1X Antibody Binding Buffer) was added to the wells and 
incubated for 1hour at RT. The wells were washed 4 times with 200μl 1X Wash Buffer and 
the Developing Solution was added (100μl/ well) for 2 minutes at room temperature 
protected from direct light. The reaction was stopped by addition of the acidic Stop Solution 
(100μl) and within 5 minutes the absorbance was read at 450nm with a reference 
wavelength of 655nm on a SynergyTM HT multi-detection microplate reader from BioTek 
Instruments, Inc (Winooski, VT, USA).  Nuclear extracts from Jurkat cells stimulated with TPA 
and calcium ionophore were used in the assay as a positive control for p65 activation. The 
corresponding absorbances for the different treatments were plotted as a percentage of the 
nuclear extracts corresponding to untreated cells. 
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2.2.10. The Proteome Profiler™ Array using the Human Phospho-Kinase Array 
kit 
For parallel determination of the relative levels of protein phosphorylation, we used the 
human phospho kinase array. This assay uses a nitrocellulose membrane where capture and 
control antibodies of 46 kinases have been spotted in duplicate. The cell lysates are 
incubated with the array and following streptavidin-HRP and chemoluminescence detection 
a signal is produced at each capture spot corresponding to the amount of phosphorylated 
protein bound. 
Monocytes were seeded at a density of 2×106 cells/ml in a 6-well plate and were subjected 
to the indicated treatments. Following stimulation, the cells were rinsed with PBS and 
solubilised with the lysis buffer provided by the manufacturer at 1×107 cells/ml. The lysates 
were resuspended and incubated with agitation on a rocking platform for 30 minutes at 4°C. 
Cell lysates were then centrifuged at 14,000 rpm for 5 minutes and the supernatants 
(protein extracts) were transferred into a new pre-chilled eppendorf. The protein 
concentration of the lysates was determined using the BCA assay and 500µg of total protein 
was resuspended in lysis buffer at a final volume of 334µl.  
The nitrocellulose membranes were blocked with provided Array buffer (1ml) for 1 hour on 
a rocking platform at room temperature. The protein lysates (334µl) were diluted in block 
buffer (Array buffer 1) to give a final volume of 2ml, of which each ml was incubated with 
array membrane A and array membrane B on a rocking platform overnight at 4°C. The 
membranes were washed 3 times, for 10 minutes each, with the provided 1X Wash Buffer. 
The membranes (part A and part B) were then incubated with 20µl of the provided 
lyophilised biotinylated detection antibody cocktail (A and B accordingly) diluted in 1ml of 
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block buffer (Array buffer 2/3) for 2 hours at room temperature. The membranes were then 
washed 3 times for 10 minutes each and were incubated with Streptavidin-HRP diluted in 
Array buffer 2/3 at a final volume of 1ml for 30 minutes at room temperature. The washing 
step was performed again, and the membranes were covered with 2ml of Luminata™ 
Western HRP solution for 5 minutes at room temperature. Excess Luminata™ solution was 
then removed and the membrane was wrapped in cling-film and exposed to a medical X-ray 
film in a dark room. Exposed films were then developed and the relevant spot intensities 
were quantified using the Storm 840 phosphoimager apparatus. The average density of the 
duplicate spots was normalised to the positive control spot of each membrane. The 
normalised density of protein phosphorylation in treated cells was then compared to 
untreated cells and was expressed as % of change in protein phosphorylation.  
 
2.2.11. ImmunoPrecipitation  
Protein A has a high affinity for mouse IgG2b and rabbit IgG and binds to the Fc region of the 
antibody’s heavy chains resulting in orientating the molecule with antigen-binding sites 
facing outwards. The antigen is recognised and binds the antigen-binding region (Fab). The 
antibody that used to ImmunoPrecipitate HDAC2 is mouse IgG2b and the one that 
recognises p65 is rabbit IgG, hence Protein A agarose beads were used for both IP assays. 
The principle of ImmunoPrecipitation that was used is also shown in Figure 2.1.  
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Figure 2.1. Diagram of a basic ImmunoPrecipitation procedure. Antigen-containing sample (the cell 
lysate), antibody and beaded agarose affinity beads (usually Protein A) are allowed to bind. Non-
bound sample components are washed away, and then antibody and antigen are eluted with a 
buffer that disrupts the binding interactions.  
 
Primary monocytes or MonoMac 6 cells were maintained (1×106 cells/ml) in RPMI-1540 
supplemented and 1% FBS for 24 hours before being subjected to the treatments. Following 
stimulation, the whole cell protein was extracted using modified RIPA buffer (50 mM Tris 
HCL pH7.4, 150 mM NaCl, 0.5% NP-40, 0.25% Na-deoxycholate, 1% CHAPS, 1mM EDTA) with 
freshly added complete protease and phosphatase inhibitor cocktail II. Protein 
concentration was determined by the BCA assay and 500µg of total protein was used for 
ImmunoPrecipitation of HDAC2 in primary monocytes and p65 in MonoMac6 cells. The 
lysates were incubated with agitation with the corresponding antibodies (2µg) overnight at 
4°C, at a final volume of 250µl of RIPA buffer. The following day 10µl of the agarose 
beads/protein A was added to the lysate/antibody mixture and was incubated for 2 hours at 
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4°C with agitation. Non-bound proteins and sample components were then washed 3 times 
with IP wash buffer and centrifuged at 1000 rpm for 20 seconds. 30µl of IP elution buffer 
was added to the beads/antibody/antigen mixture and left on bench for 1 minute before 
being neutralised with 3µl of the IP neutralizing buffer. In the case of HDAC2 IP, 20µl of the 
slurry was kept for the activity assay (as detailed in the following section). The rest of the 
mixture and the p65 IP sample were then centrifuged at 1000 rpm for 20 seconds and the 
immunoprecipitated antigen was transferred in a new eppendorf containing NuPAGE® LDS 
Sample Buffer (4X) and 3.8% β-mercaptoethanol and was boiled for 5 minutes at 95°C. A 
small aliquot of Beads/antibody mixture was also boiled for a negative control. Normal 
Western blotting was then carried out for detection of immunoprecipitated p65 and HDAC2. 
 
2.2.12. HDAC activity assay 
Immunorecipitated HDAC2 bound to the agarose beads was added in duplicates of 10µl to a 
Corning® Clear Bottom 96 well plate. For negative control, equal amount of antibody/beads 
mixture was used without any sample. HDAC activity assay buffer (60µl) and substrate 
solution (10µM) were added on the wells and were incubated with the immunoprecipitated 
HDAC2 for 2 hours at 37°C. Trypsin (200µM) was then added to the wells in a final volume of 
100µl and incubated with the samples for 30 minutes at 37°C. Fluorescence (excitation 
496nm, emission 530nm) was then read in the samples on a SynergyTM HT multi-detection 
microplate reader from BioTek Instruments, Inc (Winooski, VT, USA). Arbitrary units of HDAC 
activity were normalised to negative control and were expressed as % of activity in 
untreated samples.  
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2.2.13. Co-ImmunoPrecipitation 
For the Co-Immunoprecipitation of GRα bound to p65, the IP protocol was performed 
exactly as described in section 2.2.11. Following Western blotting, the blots were striped 
and re-probed with the GRα antibody following the protocols described above. Levels of 
GRα as analysed using densitometry were then normalised to levels of p65 and the effect of 
different treatments was expressed as % change of GRα bound to p65 compared to 
untreated cells. 
 
2.2.14. Statistical analysis 
Results (n≥3) are represented as mean ± standard error of the mean (S.E.M.). Results were 
analysed using one-way ANOVA for repeated measures (Friedman test), followed by Dunnet post-
hoc test to determine differences between the control group and each treatment group. The 
Mann-Whitney non-parametric t-test was also used to compare different treatment groups. The 
statistical analysis was performed using GraphPad Prism® (GraphPad Software, San Diego, CA). P 
values of less than 0.05 were considered to be statistically significant. 
 
 
  
 
 
 
 
 
 
           Chapter III 
 
GSK3β regulates 
corticosteroid function under 
conditions of oxidative stress 
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3.1. Introduction 
COPD is characterised by increased number of activated inflammatory cells. These have the 
capacity to secrete several inflammatory mediators including lipids, cytokines (such as GM-
CSF, TNF-), chemokines (CXCL8) and growth factors (Barnes, Shapiro et al. 2003). Unlike in 
asthma and other chronic inflammatory airway diseases, COPD patients respond poorly to 
the anti-inflammatory actions of corticosteroids and this is associated with reduced 
inhibitory effect of corticosteroids on macrophage release of pro-inflammatory cytokines 
(Adcock and Barnes 2008; Barnes 2008). The precise molecular mechanisms that regulate 
corticosteroid unresponsiveness in COPD remain unclear.  
Oxidative stress has a profound impact on inflammation. The increased oxidant burden in 
the lungs of COPD patients, derived from sources including cigarette smoke and the 
respiratory burst from inflammatory cells, is likely to play a significant role in driving the 
corticosteroid insensitive chronic inflammation (Adcock, Marwick et al. 2010; Chung and 
Marwick 2010). Oxidants activate several kinase pathways including (p38 MAPK, ERK1/2 and 
Akt) and pro-inflammatory transcription factors such as NF-B in both in vitro and in vivo 
oxidant models (Chung and Marwick 2010). Many of these pathways are also elevated in the 
cells and tissue of patients with COPD, leading to an enhanced inflammatory response 
including elevated cytokine production and inflammatory cell recruitment (Irusen, 
Matthews et al. 2002; Marwick, Caramori et al. 2010; Chung 2011).  
GSK3β is a constitutively active serine/threonine kinase that plays a key role in the 
regulation of signalling pathways that control metabolism, cell cycle and gene expression 
(Jope, Yuskaitis et al. 2007). The kinase is inactivated by phosphorylation on its Ser9 residue 
in response to stimulation of cells by mitogens or growth factors. This creates a 
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pseudosubstrate that occupies its catalytic groove. Aberrant activity of GSK3β has been 
linked to the progression of several disease states that involve inflammation, including 
Alzheimer’s disease and diabetes (Henriksen and Dokken 2006; Billadeau 2007). 
Recent studies have illustrated that both H2O2 and the cellular lipid peroxidation product 
HNE enhanced basal phosphorylation and activation of the ERK1/2 signalling pathway which 
also results in Ser9 phosphorylation on GSK3β suggesting the kinase plays a key role in 
regulating cellular protection in response to oxidant insults (Dozza, Smith et al. 2004). In 
addition, cigarette smoke exposure induced elevated cytokine release in airway smooth 
muscle cells in a GSK3β-dependent manner (Baarsma, Meurs et al. 2011). Based on these 
findings there is an emerging need to investigate the role of GSK3β in mediating oxidant 
induced activation of the kinase cross-talk and the corticosteroid insensitivity documented 
in COPD inflammation (Cohen and Goedert 2004; Jope and Johnson 2004; Martin, Rehani et 
al. 2005). I therefore hypothesised that GSK3β phosphorylation on Ser9 is differentially 
regulated in peripheral lung macrophages and monocytes from COPD patients and smokers 
with normal lung function compared to non-smokers. Since phosphorylation on Ser9 
suppresses GSK3β activity by disrupting its substrate binding site, I hypothesised that 
inactivation of GSK3β negatively regulates corticosteroid function.  
The aims of this chapter are: 
 Assess the levels of the p-Ser9-GSK3β/total GSK3β ratio in peripheral lung 
macrophages and monocytes from COPD patients, smokers with normal lung 
function and non-smokers 
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 Investigate whether inhibition of GSK3β activity by pre-treatment with the CT99021 
compound, by knocking down GSK3β protein expression using on-target siRNA or by 
overexpression of the kinase dead mutant K85RGSK3β suppresses dexamethasone 
function in LPS-stimulated monocytes. 
 Assess whether H2O2 stimulation suppresses dexamethasone function in LPS-
stimulated monocytes is GSK3β dependent by investigating whether overexpression 
of the constitutively active S9AGSK3β mutant restores dexamethasone function.  
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3.2. Results  
3.2.1. Phosphorylation of GSK3β on Ser9 is increased in peripheral lung 
macrophages and monocytes in patients with COPD compared to healthy 
subjects 
The levels of p-GSK3β-Ser9, a marker of GSK3β inactivation, were measured in peripheral 
lung macrophages and peripheral blood monocytes from patients with COPD, smokers with 
normal lung function and non-smokers. The characteristics of the subjects recruited for the 
study are illustrated on Table 3.1 and Table 3.2. P-GSK3β-Ser9 staining in the peripheral lung 
was increased in COPD patients compared to smokers with normal lung function and non-
smokers, and was also higher in smokers with normal lung function compared to non-
smokers (Figure 3.1). The ratio of phosphorylated to total GSK3β was also increased in 
peripheral blood monocytes isolated from patients with COPD compared to healthy subjects 
with no smoking history (p=0.015) (Figure 3.2). Exposure of monocytes from healthy 
subjects to H2O2 (100µM) for 30 minutes, induced a significant 2-fold increase of the Ser9 
phosphorylation on GSK3β. An obvious trend for H2O2 –induced p-GSK3β-Ser9 was observed 
in all patients groups but it did not reach statistical significance. (Figure 3.2). 
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Table 3.1. Characteristics of subjects for peripheral lung sections 
Group Age 
Sex 
(M/F) 
Smoking 
Status  
 
Pack 
Years 
FEV1 
(L) 
FEV1 
(% pred) 
FEV1/FVC 
ratio (%) 
GOLD 
Stage 
COPD 
69.1 
± 6.6 
18/3  
7Current  
14Former 
40.5 
± 20.1 
2.03 
± 0.5 
75.3 
± 16.6 
56.1 
± 9.1 
8 stage 1, 
11 stage 2, 
2 stage 3 
Smoker 
70.0 
± 6.7 
18/1  
9Current 
10Former 
49.4 
± 32.3 
2.5 
± 0.7 
91.8 
± 14.6 
75.5 
± 4.6 
N/A 
Non-
Smoker 
67.7 
± 8.1 
0/14  N/A N/A 
2.1 
± 0.4 
101.5 
± 22.5 
76.4 
± 3.5 
N/A 
FEV1: Forced expiratory volume in one second; FVC: Force vital capacity; % pred: % predicted; GOLD: Global 
Initiative for Obstructive Lung Disease. M/F: Male to Female ratio. 
 
Table 3.2. Characteristics of subjects for isolation of peripheral blood monocytes 
Group Age 
Sex 
M/F 
Smoking 
Status 
Pack 
Years 
FEV1 (L) 
FEV1 
(% Pred) 
FEV1/FVC 
ratio (%) 
COPD 57.8 
± 3.8 4/1 
 1Current 
4Former 
35.0 
± 4.5 
2.5 
± 0.2 
76.9 
± 3.5 59.7 ± 7.6 
Smoker 54.6 
± 1.9 2/1  
all 
current 
48.3 
± 5.2 
2.9 
± 0.2 
93.2 
± 10.3 78.7 ± 3.2 
Non-
Smoker 
60.3 
± 2.7 1/3  N/A N/A 
2.2 
± 0.3 
100.5 
± 7.1 81.1 ± 5.1 
FEV1: Forced expiratory volume in one second; FVC: Force vital capacity; % pred: % predicted; GOLD: Global 
Initiative for Obstructive Lung Disease. M/F: Male to Female ratio. 
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Figure 3.1. p-GSK3β-Ser9/total GSK3β is increased in COPD peripheral lung macrophages 
compared to smokers with normal lung function and non-smokers. Phosphorylation levels of Ser9-
GSK3β in macrophages in the peripheral lungs of non-smokers, smokers with normal lung function 
and patients with COPD. Representative images (magnification ×40) of p-Ser9-GSK3β staining in 
peripheral lung sections from (a) non-smokers, (b) smokers and (c) COPD patients are shown. 
Percentage of macrophages positively stained for p-Ser9-GSK3β in the peripheral lung sections from 
non-smokers (n = 14), smokers (n = 19), and patients with COPD (n = 21). NS: Non-smoker.  Data 
represent mean±SEM and one-way ANOVA and Dunnet’s post-hoc test were used to test for 
statistical significance. **p<0.01, ***p<0.001. 
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Figure 3.2. p-GSK3β-s9/total GSK3β is increased in COPD peripheral blood monocytes compared to 
smokers with normal lung function and non-smokers. Ratio of p-Ser9-GSK3β normalised to total 
GSK3β protein levels in non-stimulated cells and cells exposed to H2O2 (100µM) for 30 minutes. 
Monocytes were isolated from non-smokers with normal lung function (n=4), smokers (n=3) and 
COPD patients (n=5). Phosphorylation levels of GSK3β were increased in monocytes derived from 
COPD patients compared to non-smokers. Data represent median with range of p-GSK3β-ser9/total 
GSK3β. *p<0.05 versus healthy subjects. 
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3.2.2. Inactivation of GSK3β suppresses dexamethasone anti-inflammatory 
function in human primary monocytes 
3.2.2.1. Inhibition of GSK3β activity by treatment with CT99021 had no effect on cell 
viability and basal inflammatory cytokine release 
Levels of the inactive phosphorylated form of GSK3β were increased in both lung 
macrophages and blood monocytes from COPD patients and smokers with normal lung 
function compared to non-smokers. To investigate whether GSK3β inactivation has any 
effect on the inflammatory responses driven by these immune cells, I used monocytes as a 
cell model to study the effect of treatment with the GSK3β inhibitor CT99021 on cell viability 
and inflammatory cytokine release. Monocytes were treated with concentrations of 
CT99021 ranging from 10-8M to 10-5M for 16 hours. Cell viability was not affected by 
treatment with the compound at the highest concentrations lower than 10-5M (Figure 3.3a). 
Similarly, basal levels of GM-CSF release were unaffected by exposure to CT99021 at 
concentrations ranging from 10-8M to 10-6M, but at 10-5M CT99021 reduced levels of basal 
GM-CSF release (Figure 3.3b). This effect of the compound at high concentration appears to 
be due to effects on cell viability rather than on inflammatory responses.  
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3.2.2.2. Treatment of monocytes with CT99021 had no effect on LPS-induced cytokine 
release 
Primary human monocytes were pre-treated with the CT99021 inhibitor (10-8M to 10-5M) 
and then stimulated with LPS (10ng/ml) to study the effect of GSK3β inhibition on pro-
inflammatory GM-CSF release. CT99021 had no significant effect on LPS induced GM-CSF 
release at concentrations up to 10-6M. However, 10M of the drug had an inhibitory effect 
on cytokine release (Figure 3.4). These results are in line with the data showing that high 
concentrations of CT99021 interfere with cell viability (Figure 3.3a) and basal levels of GM-
CSF release (Figure 3.3b). 
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Figure 3.3. The effects of inhibition of GSK3β by treatment with CT99021 on cell viability and basal 
GM-CSF levels in primary human monocytes. Peripheral blood monocytes were isolated from 
PBMCs and treated with CT99021 at concentrations ranging from 10-8M to 10-5M and were 
incubated overnight. (a) Cell viability was not affected by CT99021 when used at concentrations up 
to 10-6M. (b) Similarly, those concentrations of the compound did not affect levels of GM-CSF 
release. However, at 10-5M, the inhibitor reduced (a) cell viability and (b) the levels of basal GM-CSF 
release. The data were expressed as % of untreated cells and histograms represent mean±S.E.M. for 
four independent experiments. *p<0.05 vs untreated cells. 
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Figure 3.4. The effect of inhibition of GSK3β by CT99021 on LPS-induced GM-CSF levels released in 
primary human monocytes. Monocytes were isolated from PBMCs and pre-treated with CT90021 
(10-8M-10-5M) for 30 minutes and were then stimulated with LPS (10ng/ml) for 16 hours. The 
inhibitor had no effect on LPS induced pro-inflammatory cytokine release at concentrations up to 10-
6M. At 10-5M, CT99021 inhibited LPS-induced GM-CSF release to 56.4±5.7% of levels induced by LPS 
alone. The data represent mean±S.E.M. of four independent experiments and are expressed as % of 
LPS induced GM-CSF release. *p<0.05, **p<0.01 vs levels of LPS induced GM-CSF release.  
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3.2.2.3. Treatment of monocytes with CT99021 reduces dexamethasone function in a 
concentration-dependent manner 
Monocytes isolated from healthy subjects were pre-treated with CT99021 at concentrations 
that had no effect on cell viability (10-8M to 10-6M) for 30 minutes. The cells were then 
treated with 10-8M of dexamethasone 30 minutes before being stimulated with LPS 
(10ng/ml) for 16 hours. Dexamethasone (10-8M) inhibited LPS-induced GM-CSF release by 
69.2±6.6% (Figure 3.5a). Similarly, dexamethasone inhibited LPS-induced TNF-α release to 
33.9±7.9% (Figure 3.5b). When cells were pre-treated with CT99021 at 10-6M, a 
concentration that had no effect on LPS-induced GM-CSF or TNF-α cytokine release, (Figure 
3.4 and 3.5b, respectively) it suppressed dexamethasone’s anti-inflammatory function in a 
concentration-dependent manner (Figure 3.5). At 10-6M, CT99021 reversed the anti-
inflammatory effects of 10-8M of dexamethasone by ~50% (69.2±6.6% versus 31.1±7.2%) 
(Figure 3.5a) and ablated the dexamethasone effect on LPS-induced TNF-α (101.5±3.0% of 
LPS-induced TNF-α release) (Figure 3.5b). Next I investigated whether GSK3β inhibition 
exerts similar inhibitory effects in the presence of a higher concentration of 
dexamethasone. At 10-6M, dexamethasone suppressed LPS-induced GM-CSF release (Figure 
3.6a) and LPS-induced TNF-α (Figure 3.6b) by 74.3±5.9% and by 55.2±9.2%, respectively. The 
anti-inflammatory effect of dexamethasone was reduced by GSK3β inactivation resulting in 
50.8±7.6% and 20.4±5.5% inhibition of LPS-induced GM-CSF (Figure 3.6a) and TNF-α (Figure 
3.6b) release, respectively.  
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Figure 3.5. CT99021 reduces dexamethasone (10-8M) anti-inflammatory function in a 
concentration-dependent manner. (a) Human monocytes were pre-treated with CT90021 (10-8M-
10-6M) for 30 minutes followed by treatment with dexamethasone (10-8M) for 30 minutes. The cells 
were then stimulated with LPS (10ng/ml) for 16 hours and GM-CSF levels were measured in the cell-
free supernatants. LPS induced GM-CSF release was significantly inhibited by dexamethasone by 
69.2±6.6%. Pre-treatment with CT99021 resulted in a concentration-dependent reduction of 
dexamethasone-induced suppression of LPS-induced GM-CSF release. However, at 10-6M, the 
inhibitor suppressed the anti-inflammatory effects of dexamethasone and the levels of GM-CSF were 
only inhibited by 31.1±7.2%. (b) Similarly, dexamethasone (10-8M)-induced suppression of LPS-
induced TNF-α release (33.9±7.9% inhibition) was reversed by CT99021 (10-6M) back to 101.5±3.0% 
of LPS-induced levels. Data are expressed as % of LPS induced cytokine levels and the bars represent 
mean±S.E.M of four independent experiments. *p<0.05 vs. LPS-induced GM-CSF, #p<0.05 vs. LPS 
plus dexamethasone-induced GM-CSF levels. 
 -       -        +       +        +       +       +       +  
 
CT99021 (-log[M]) 
- + + + +
0
25
50
75
100
*
*
#
-              -              +             -              +
   -      -              -             +             +
T
N
F
- 
 r
e
le
a
s
e
 (
%
 o
f 
c
o
n
tr
o
l)
 
 
 
 
a. 
a. 
b. 
 -       +       +       +        +       +       +       +  
 
LPS (10ng/ml) 
CT99021 (10-6M) 
Dex (10-8M) 
LPS (10ng/ml) 
Dex (10-8M) 
 -       -        -         8          7.5      7       6.5      6 
 
GSK3β regulates corticosteroid function under conditions of OS 
  
114 | P a g e  
 
- + + + +
0
50
100
    -              -              -             +             +
    -              -              + -           +
LPS (10ng/ml)
Dex (10-6M)
CT99021 (10-6M)
*
*
#
G
M
-C
S
F
 r
e
le
a
s
e
 (
%
 o
f 
c
o
n
tr
o
l)
 
- + + + +
0
25
50
75
100
125
150
    -              -              -             +             +
    -              -              + -           +
LPS (10ng/ml)
Dex (10-6M)
CT99021 (10-6M)
*
*
#
T
N
F
- 
 r
e
le
a
s
e
 (
%
 o
f 
c
o
n
tr
o
l)
 
 
Figure 3.6. CT99021 inhibits dexamethasone (10-6M) anti-inflammatory function in human 
peripheral blood monocytes. Inhibition of GSK3β by treatment with the CT99021 (10-6M) reduced 
the inhibitory function of dexamethasone (10-6M) on LPS stimulated (a) GM-CSF release (74.3±5.9% 
versus 50.8±7.6% inhibition) and (b) TNF-α release (55.2±9.2% versus 20.4±5.5% inhibition). 
Histograms represent mean±S.E.M. (n=3). The data are expressed as % of LPS induced cytokine 
release. *p<0.05 vs LPS-induced cytokine release, #p<0.05 vs LPS plus dexamethasone-induced 
cytokine release. 
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3.2.3. Inactivation of GSK3β suppresses dexamethasone function in the 
human monocytic cell line MonoMac6 
3.2.3.1. The anti-inflammatory function of dexamethasone in MonoMac6 cells 
The MonoMac6 cells were pre-treated with dexamethasone (10-8M-10-6M) for 30 minutes 
before being stimulated with LPS (10ng/ml). The inflammatory response to LPS was 
measured by levels of the pro-inflammatory mediators CXCL8 and TNF-α. Dexamethasone 
significantly inhibited both LPS-induced CXCL8 (Figure 3.7a) and TNF-α (Figure 3.7b) release 
in a concentration-dependent manner. The IC50 for dexamethasone induced inhibition was 
29nM for LPS-induced CXCL8 release (Figure 3.7a) and 8.7nM for LPS-induced TNF-α release 
(Figure 3.7b).  
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Figure 3.7. Dexamethasone induced a concentration-dependent inhibition of pro-inflammatory 
cytokine release. The cells were pre-treated with dexamethasone for 30 minutes at the 
concentrations shown and were then stimulated with LPS (10ng/ml) for 16 hours. (a) CXCL8 and (b) 
TNF-α levels of release were measured in cell-free supernatants. Dexamethasone inhibited both 
CXCL8 and TNF-α release in a concentration-dependent manner and had its maximum suppressive 
effect at 10-6 M. Levels of release are expressed as % of LPS induced levels and represent the 
mean±S.E.M. of four independent experiments. *p<0.05, **p<0.01 vs LPS induced cytokine release, 
Kruskal Wallis Anova, Dunn’s post t-test. 
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3.2.3.2. Treatment of MonoMac6 with the GSK3β inhibitor CT99021 had no effect on cell 
viability or LPS-induced pro-inflammatory cytokine release 
MonoMac6 cells were treated with the CT99021 at concentrations ranging from 10-8M to 
10-5M for 16 hours and cell viability was measured by MTT assay (Figure 3.8a). In line with 
its effects on primary monocytes, the compound reduced cell viability only at high 
concentrations of 10-5M.  Next I investigated the effect of CT99021 on LPS-induced CXCL8 at 
concentrations at which it had no effect on cell viability. CT99021 had no significant effect 
on LPS-induced CXCL8 release at concentrations ranging from 10-8M to 10-6M (Figure 3.8b). 
 
3.2.3.3. Treatment of MonoMac6 with the GSK3β inhibitor CT99021 decreased 
dexamethasone function in a concentration-dependent manner 
MonoMac6 were pre-treated with a concentration range of CT99021 (10-8M-10-5M) for 30 
minutes following treatment with dexamethasone (10-8M and 10-6M) before cells were 
stimulated with LPS (10ng/ml) for 16 hours. Dexamethasone inhibited LPS-induced CXL8 
release by 71.1±3.5% at 10-6M (Figure 3.9a). This inhibitory effect of dexamethasone was 
reversed by treatment with CT99021 (10-6M) (71.1±3.5% versus 37.8±7.5% inhibition) 
(Figure 3.9a). Similarly, when dexamethasone was added at 10-8M it inhibited LPS-induced 
cytokine release by 30.6±6.6% (Figure 3.9b). CT99021 (10-6M) completely ablated the ability 
of dexamethasone to suppress LPS-induced CXCL8 release and levels were restored to 
104.1±5.0% of LPS-induced levels (Figure 3.9b).  
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Figure 3.8. Effect of inhibition of GSK3β by CT99021 on cell viability and on LPS-induced CXCL8 
levels released in the monocytic cell line MonoMac6. Cells were pre-treated with CT90021 (10-8M-
10-5M) for 30 minutes and were then stimulated with LPS (10ng/ml) for 16 hours. (a) CT99021 had 
no effect on cell viability at concentrations up to 10-6M but induced death of 56.5±5.7% of cells at 10-
5M. (b) Stimulation of cells with LPS induced a significant increase in CXCL8 release which was 
unaffected by pre-treatment with the CT99021 (10-8M-10-6M).The data represent mean±S.E.M. of 
four independent experiments and are expressed as % of LPS induced CXCL8 release. *p<0.05 vs 
untreated cells. 
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Figure 3.9. Inhibition of GSK3β by CT99021 suppresses dexamethasone function in human 
MonoMac6 cells. MonoMac6 cells were treated with the CT99021 compound for 30 minutes (10-8M-
10-5M) following treatment with dexamethasone at (a) 10-6M and (b) 10-8M. Cells were then 
stimulated with LPS for 16 hours and levels of CXCL8 release were measured in the cell free 
supernatants. Dexamethasone significantly inhibited LPS-induced CXCL8 release at both 
concentrations used. Pre-treatment with CT99021 had a concentration-dependent effect on 
attenuating dexamethasone function that reached significance at 10-6.5M and 10-6M. Data are 
expressed as % of LPS-induced CXCL8 release. Histograms represent mean±S.E.M. values of four 
independent experiments. *p<0.05 vs. LPS-induced CXCL8 release, #p<0.05 vs. LPS and 
dexamethasone-induced CXCL8 release. 
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3.2.3.4. Treatment of MonoMac6 with on-target GSK3β siRNA inhibited total levels of 
GSK3β in a concentration- and time-dependent manner 
Inhibition of GSK3β by pre-treatment with the CT99021 compound showed a clear 
suppression of dexamethasone’s function in LPS-stimulated primary monocytes and 
MonoMac6 cells. To further confirm that this effect is GSK3β-dependent and is not an off-
target effect of the compound, I next assessed whether suppression of GSK3β protein 
expression by siRNA-induced gene silencing leads to similar levels of suppression of 
dexamethasone’s anti-inflammatory function. MonoMac6 cells were transfected via 
electroporation with scramble siRNA and on-target GSK3β siRNA at 200nM and 400nM for 
24, 48 and 72 hours. Total levels of GSK3β in cells transfected with on-target siRNA were 
normalised to levels of the kinase when cells were transfected with scramble siRNA. GSK3β 
siRNA (200nM and 400nM) decreased total protein levels 24 hours post transfection by 
34.3±14.1% and 44.1±8.5% accordingly (Figure 3.10a and 3.10d). 48 hours post transfection 
total levels of GSK3β were inhibited further by 55.3±8.5% with 200nM siRNA and 87.4±4.1% 
with 400nM siRNA (Figure 3.10b and 3.10d). At 72 hours following transfection, GSK3β 
protein levels were inhibited only by 33.9±18.24% (200nM siRNA) and 49.4±13.2% (400nM 
siRNA) compared to control levels, due to de novo protein expression (Figure 3.10c and 
3.10d).  
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3.2.3.5. Effect of transfection with GSK3β siRNA on MonoMac6 cell viability over time 
MonoMac6 cells were transfected via electroporation with siRNA (scramble and on-target) 
for 24, 48 and 72 hours. Cell viability was tested before the cells were subjected to further 
treatments. Subjection of cells to electroporation without addition of siRNAs for 24 (Figure 
3.11a), 48 (Figure 3.11b) and 72 (Figure 3.11c) hours affected cell viability and caused death 
of 50-60% of the total cell number. Transfection of the cells with the scramble siRNA at 
200nM and 400nM and on-target GSK3β siRNA at 200nM and 400nM had no additional 
effect on cell viability (Figure 3.11a, b and c). 
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Figure 3.10. On-target GSK3β siRNA reduced total GSK3β protein levels in a time- and 
concentration- dependent manner. MonoMac6 cells were transfected with scramble siRNA (blue 
bars) and on-target GSK3β siRNA (red bars) at 200nM and 400nM for 24, 48 and 72 hours. Levels of 
total GSK3β protein started decreasing after 24 hours (a, d) of transfection with GSK3β siRNA 
(200nM and 400nM), were further reduced after 48 hours (b, d) but started returning towards 
control levels  after 72 hours (c, d) of transfection. Figures a, b and c show representative Western 
blot images that were used for band densitometry. Total GSK3β levels were normalised to levels of 
β-actin and were plotted as % of total GSK3β protein levels in cells transfected with the control 
scramble siRNA at the according concentration (d). Histograms represent the mean±S.E.M. of four 
independent experiments. *p<0.05, vs. Levels of GSK3β in cells transfected with scramble siRNA for 
24 hours, #p<0.05, ###p<0.001 vs. Levels of GSK3β in cells transfected with scramble siRNA for 48 
hours, &p<0.05 vs. Levels of GSK3β in cells transfected with scramble siRNA for 72 hours. 
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Figure 3.11. Electroporation affected MonoMac6 cell viability but addition of siRNAs had no 
impact on cell death. Mock electroporation of MonoMac6 cells inhibited cell viability up to 50-60% 
after (a) 24, (b) 48 and (c) 72 hours. Transfection of cells with scramble or GSK3β siRNA had no 
additional effect on cell viability. The data are expressed as % of viability of naïve untransfected cells. 
Histograms represent mean±S.E.M. of three independent experiments.  
 
 
3.2.3.6. GSK3β protein knock down had no effect on LPS-induced pro-inflammatory 
cytokine release in MonoMac6 cells 
MonoMac6 cells were transfected with scramble and on-target GSK3β siRNA (200nM and 
400nM) for 24 and 48 hours. At each time point the transfected cells were stimulated with 
LPS for an additional 16 hours and release of the both TNF-α and CXCL8 was measured in 
the supernatants. As previously shown, inhibition of GSK3β by transfection with 200nM and 
400nM siRNA for 24 hours resulted in a 34.3±14.1% and 44.1±8.5% loss in total GSK3β levels 
compared to cells transfected with scramble siRNA (Figure 3.10d). This significant reduction 
in total GSK3β protein levels had no effect on LPS-induced TNF-α (Figure 3.12a) or CXCL8 
release (Figure 3.12b). Following 48 hours of transfection, the total protein levels of GSK3β 
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were reduced by 55.3±8.5% (200nM siRNA) and by 87.4±4.1% (400nM siRNA) without any 
effect on LPS-induced TNF-α (Figure 3.13a) or CXL8 release (Figure 3.13b).  
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Figure 3.12. Reduction of GSK3β protein levels following 24 hours of siRNA transfection had no 
effect on LPS-induced pro-inflammatory mediators’ release. MonoMac6 cells were transfected with 
scramble and on-target GSK3β siRNA for 24 hours. Transfected cells were subjected to LPS 
simulation for 16 hours and the levels of (a) TNF-α and (b) CXCL8 release was measured in the 
supernatants. Inhibition of GSK3β had no effect on LPS-induced either cytokine release compared to 
cells transfected with scramble siRNA. Data are expressed as % release of LPS induced cytokine 
release in cells transfected with scramble siRNA. Histograms represent mean±S.E.M. of three (a) and 
five (b) independent experiments.  
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Figure 3.13. Reduction of GSK3β protein levels following 48 hours of siRNA transfection had no 
effect on LPS-induced pro-inflammatory mediators’ release. MonoMac6 cells were transfected with 
scramble and on-target GSK3β siRNA for 48 hours and were stimulated with LPS for 16 hours. 
Inhibition of GSK3β had no effect on LPS-induced (a) TNF-α or (b) CXCL8 release compared to cells 
transfected with scramble siRNA. Data are expressed as % release of LPS induced cytokine release in 
cells transfected with scramble siRNA. Histograms represent mean±S.E.M. of four (a) and three (b) 
independent experiments.  
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3.2.3.7. GSK3β protein knock down suppressed dexamethasone anti-inflammatory 
function in MonoMac6 cells 
MonoMac6 cells were transfected with 200nM and 400nM of scramble and on-target GSK3β 
siRNA for 24 (Figure 3.14) and 48 hours (Figure 3.15). The cells were pre-treated with 
dexamethasone (10-8M to 10-6M) before being stimulated with LPS (10ng/ml) for 16 hours. 
Dexamethasone had a significant inhibitory effect on LPS-induced CXCL8 (Figure 3.14a, b) 
and TNF-α (Figure 3.14c, d) release in cells transfected with scramble siRNA at 200nM 
(Figure 3.14a, c) and 400nM (Figure 3.14b, d). As previously shown, transfection of cells with 
200nM and 400nM on-target siRNA for 24 hours inhibited total protein GSK3β levels (Figure 
3.10c). GSK3β knock down for 24 hours had a significant effect on dexamethasone-
dependent inhibition of CXCL8 at 200nM of siRNA (p=0.014, Figure 14a) and 400nM siRNA 
(p=0.0012, Figure 3.14b). Similarly, dexamethasone-induced inhibition of TNF-α release was 
suppressed by 24 hour transfection with 200nM GSK3β siRNA (p=0.039, Figure 3.14c) and 
400nM GSK3β siRNA (p=0.013, Figure 3.14d).   
When MonoMac6 cells were transfected with siRNA for 48 hours and then stimulated with 
dexamethasone and LPS for further 16 hours, the effect of GSK3β knock down on 
dexamethasone action was reduced. The concentration-dependent inhibitory effect of 
dexamethasone on LPS-induced CXCL8 release was not significantly affected by 48 hours 
transfection with 200nM (p=0.383, Figure 3.15a) or 400nM (p=0.0814, Figure 3.15b) of 
siRNA. The dexamethasone effect on LPS-induced TNF-α release was more sensitive to 
GSK3β knock down using 200nM of siRNA and its function was significantly suppressed 
(p=0.035, Figure 3.15b). This effect was blunted when the cells were transfected with 
400nM of siRNA (p=0.09, Figure 3.15d). 
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Figure 3.14. Inactivation of GSK3β by siRNA transfection for 24 hours reduced dexamethasone 
anti-inflammatory function in LPS-stimulated MonoMac6 cells. The concentration-dependent 
inhibitory function of dexamethasone on LPS-induced CXCL8 (a, b) and TNF-α (c, d) release was 
significantly suppressed in cells transfected with on-target GSK3β siRNA, 200nM (a, c) and 400nM) 
(b, d) compared to cells transfected with the scramble siRNA for 24 hours (a) p=0.014, (b) p=0.0012, 
(c) p=0.039 and (d) p=0.013). The IC50 for dexamethasone was increased as shown on individual 
graphs. Levels of cytokine release are expressed as % of LPS-induced release in cells transfected with 
scramble siRNA at 200nM and 400nM accordingly. Data represent mean±S.E.M. (n=5 (a), n=6 (b) and 
n=4 (c, d). The statistical significance of the effect of GSK3β knock down on dexamethasone function 
was assessed using a two-way ANOVA. 
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Figure 3.15. Inactivation of GSK3β by siRNA transfection for 48 hours had no overall significant 
effect on dexamethasone anti-inflammatory function in LPS-stimulated MonoMac6 cells. 
Dexamethasone-mediated inhibition of LPS-induced CXCL8 (a, b) and TNF-α (d) release was not 
significantly reduced in cells with on-target GSK3β siRNA, 200nM (a, c) and 400nM (d) compared to 
cells transfected with the scramble siRNA. However, dexamethasone’s effect on TNF-α release in 
response to LPS was significantly affected by transfection with 200nM siRNA. The IC50 for 
dexamethasone was changed as shown on individual graphs. Levels of cytokine release are 
expressed as % of LPS-induced release in cells transfected with scramble siRNA at 200nM and 
400nM accordingly. Data represent mean±S.E.M. (n=5 (a), n=6 (b) and n=4 (c, d). The statistical 
significance of the effect of GSK3β knock down on dexamethasone function was assessed using a 
two-way ANOVA. (a) p=0.383; (b) p=0.0814; (c) p=0.035; (d) p=0.09. 
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3.2.4. Plasmid overexpression in MonoMac6 cells 
3.2.4.1. Transient transfection efficiency and effect on cell viability 
MonoMac6 cells were transfected via electroporation with 3 different constructs of plasmid 
DNA for 18 hours; eGFPpcDNA3.1, the negative control construct pcDNA3.1, the 
constitutively active S9ApcDNA3.1 and the constitutively inactive K85RpcDNA3.1. The cells 
were transfected with the plasmid eGFPpcDNA3.1 at concentrations varying from 1µg to 
3µg and GFP fluorescence was used as a marker for measuring the transfection efficiency. 
Figure 3.16 shows the relative EGFP fluorescence in cells transfected with 1µg of 
eGFPpcDNA3.1 which was significantly higher 18 hours post transfection compared to non-
transfected or electroporated cells without the plasmid. Cell viability was decreased by 
37.6±13.2% compared to non-transfected cells due to electroporation. Addition of the 
plasmids had no effect on cell viability 18 hours post transfection (Figure 3.17). 
 
3.2.4.2. Efficiency of the overexpression of the mutant GSK3β mRNA in MonoMac6 cells 
following plasmid transfection 
MonoMac6 cells were transfected with the S9ApcDNA3.1 and K85RpcDNA3.1 constructs 
and the levels of WT and mutant GSK3β were measured by RT-PCR. The WT GSK3β set of 
primers recognise the wild type endogenous GSK3β protein as well as the mutant forms. 
Transfection of the cells for 18 hours with both S9ApcDNA3.1 and K85RpcDNA3.1 
significantly increased levels of GSK3β mRNA (Figure 3.18a). To validate that our 
S9ApcDNA3.1 construct is being overexpressed in the cells, specific set of primers that 
recognise the mutant sequence were used to amplify the cDNA sequence. As shown in 
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Figure 3.18b, the S9A mutant isoform is significantly overexpressed in the cells following 
transfection.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16. Transfection efficiency was measured by levels of GFP fluorescence emitted under UV 
light. Using an excitation wavelength of 490nm and an emission wavelength of 509nm, fluorescence 
was measured in cells following 18 hours of transfection with the eGFPpcDNA3.1 plasmid (1µg) in 
the presence or absence of the plasmids of interest, S9ApcDNA3.1 and K85RpcDNA at the 
concentrations used in the experiments (2µg). GFP emitted fluorescence levels detected are 
expressed as fold increase compared to non-transfected cells. Data represent mean±S.E.M. of four 
independent experiments. *p<0.05 vs non-transfected cells. Mock electroporation: cells 
electroporated without insertion of plasmid DNA. 
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Figure 3.17. Effect of transient transfection with pcDNA3.1 on cell viability. Cell viability was 
decreased by 62.4±13.2% 18 hours following mock electroporation of MonoMac6 cells. When cells 
were transfected with the plasmid constructs, there was no significant additional effect on cell 
viability. Data are expressed as % of non-transfected cells and represent mean±S.E.M. of four 
independent experiments. *p<0.05 vs non-transfected cells. Mock electroporation: cells 
electroporated without insertion of plasmid DNA. 
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Figure 3.18. Overexpression of the mutant GSK3β constructs measured by RT-PCR. Cells 
transfected with the S9ApcDNA3.1 and K85pcDNA3.1 constructs expressed significantly higher levels 
of GSK3β as recognised by set of primers that bind and amplify both the wild type and mutant GSK3β 
sequence (a). S9A GSK3β specific primers were used to measure overexpression of the S9ApcDNA3.1 
(b). 
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3.2.4.2. Effect of transient plasmid overexpression on basal and LPS-induced pro-
inflammatory cytokine release 
The cells were subjected to transfection with the control pcDNA3.1 construct, the 
S9ApcDNA3.1 and the K85RpcDNA3.1 construct in the presence of the eGFPpcDNA3.1 
plasmid for 18 hours. Transfected cells were then incubated for further 16 hours in the 
presence or absence of LPS (10ng/ml) and the levels of GM-CSF release were measured in 
the cell-free supernatants. All three plasmid constructs induced significant increases in GM-
CSF release that reached levels of 100pg/ml to 150pg/ml (Figure 3.19a). These levels are 
higher than that of LPS-stimulated levels of GM-CSF release in non-transfected but 
electroporated cells (19.5±2.1pg/ml). Plasmid transfection also increased LPS-induced GM-
CSF levels leading to similar amounts of the cytokine released in the supernatants (100pg/ml 
versus 150pg/ml) (Figure 3.19b). LPS stimulation of the cells following transfection is 
independent of electroporation and is driven by all three constructs used (Figure 3.19).  
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Figure 3.19. Transfection of MonoMac6 cells with plasmid DNA increases both basal and LPS-
induced GM-CSF levels of release. The (a) basal and (b) LPS-induced levels of GM-CSF release in 
MonoMac6 cells electroporated with no plasmid DNA (mock) (2.4±0.8pg/ml and 19.5±2.1pg/ml 
accordingly) were both significantly increased by addition of either of the three plasmid constructs 
to levels reaching 100pg/ml to 150pg/ml. The histograms represent the mean±S.E.M. of GM-CSF 
concentration (pg/ml) of GM-CSF of four independent experiments. *p<0.05 vs basal and LPS-
induced GM-CSF levels in cells subjected to mock electroporation. Mock: cells subjected to 
electroporation in the absence of plasmid DNA. 
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3.2.4.3. Measurement of endotoxin levels of the plasmid constructs 
Due to the high inflammatory response that the plasmid transfection induced in the 
MonoMac6 cells, we measured the endotoxin levels in the constructs. The endotoxin assay 
showed that the constructs have 0.1 to 0.3 EU per µg (Figure 3.20). Next, I washed the 
endotoxin from the constructs to levels of <0.05EU/µg and repeated the transfection with 
the purified plasmids. The purified plasmid had a similar effect on both basal and LPS-
induced GM-CSF levels, inducing significantly higher levels of cytokine release than that 
induced by treatment with LPS alone (Figure 3.21). In both unstimulated (Figure 3.21a) and 
LPS stimulated cells (Figure 3.21b), plasmid transfection resulted in an 8- to 9-fold increase 
in GM-CSF release compared to LPS which induced a 6-fold increase in cytokine levels 
(19.8±3.5pg/ml and 127.1±18.8pg/ml accordingly) (Figure 3.21).  
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Figure 3.20. Endotoxin levels of the plasmid constructs. All three plasmid constructs had endotoxin 
levels varying from 0.1 EU/µg to 0.4 EU/µg as measured by the endotoxin assay according to the 
assay standards. The histograms represent mean±S.E.M. endotoxin units for 3 independent 
experiments. –ve: pcDNA3.1 empty plasmid used as a negative control. 
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Figure 3.21. Effect of plasmid transfection on basal and LPS-induced GM-CSF release following 
plasmid endotoxin removal in MonoMac6 cells. The plasmids were subjected to endotoxin wash 
and levels were brought down to <0.05 EU/µg. The cells were transiently transfected with the three 
constructs for 18 hours and were incubated for further 16 hours in the absence or presence of LPS 
(10ng/ml). LPS increased GM-CSF levels from 19.8±3.5pg/ml (a) to 129.1±18.8pg/ml (b) in cells that 
were electroporated without the addition of plasmid DNA.  Transient transfection with the any of 
the three constructs induced an 8- to 9 fold increase of GM-CSF levels in both unstimulated (a) and 
LPS-stimulated cells (b). Histograms represent mean±S.E.M. of GM-CSF levels (pg/ml) of four 
independent experiments. *p<0.05, **p<0.001 vs. LPS-induced GM-CSF levels in cells subjected to 
mock transfection. –ve: pcDNA3.1 empty plasmid used as a negative control. 
 
3.2.4.4. Inhibition of LPS did not reverse plasmid DNA induced pro-inflammatory response 
in MonoMac6 cells 
Non-transfected and transiently transfected MonoMac6 cells were pre-treated with the LPS 
inhibitor, polymyxin B (50µg/ml) for 45 minutes before being stimulated with LPS (10ng/ml) 
for 16 hours. The levels of GM-CSF release induced by LPS were significantly suppressed by 
addition of the inhibitor (Figure 3.22a) in cells subjected to electroporation without addition 
of plasmid DNA. In cells transfected with the pcDNA3.1 induction of GM-CSF release was 
unaffected by addition of polymyxin B (Figure 3.21b). As previously shown, LPS had no 
additional effect on GM-CSF release nor did pre-treatment with Polymyxin (Figure 3.22b).  
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Figure 3.22. Inhibition of LPS by Polymyxin B did not reverse the pro-inflammatory effect of 
plasmid transfection in MonoMac6 cells. Pre-treatment of MonoMac6 cells with Polymyxin B for 45 
minutes suppressed LPS-induced GM-CSF release in cells that were subjected to electroporation 
without addition of plasmid DNA construct (a). GM-CSF release was not affected by the LPS inhibitor 
when cells were transfected with the pcDNA3.1 construct (b). LPS stimulation had no additional 
effect on the high levels of GM-CSF release and similarly, Polymyxin B (PB) did not inhibit the pro-
inflammatory response (b). Data are expressed as % of GM-CSF release in unstimulated non-
transfected cells (a) and cells transfected with the pcDNA3.1 plasmid (b). Histograms represent 
mean±S.E.M. of GM-CSF levels of four independent experiments. *p<0.05, **p<0.001. 
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Mock 
3.2.4.5. Transfection of MonoMac6 cells with other plasmid DNA construct induces a pro-
inflammatory response 
MonoMac6 cells were transfected with a basic pGL3 construct to ensure that the effect is 
not plasmid specific. The cells were transfected with the DNA for 18 hours and the subjected 
to treatment with Polymyxin B (50µg/ml for 45 minutes) and LPS (10ng/ml) for 16 hours 
before GM-CSF release levels were measured in the supernatants. Similar to my previous 
data with the pcDNA3.1 constructs, transient transfection significantly increased levels of 
GM-CSF release which were unaffected by addition of the LPS inhibitor. Stimulation of LPS 
had no additional effect on levels of cytokine release which remained the same even in the 
presence of Polymyxin B (Figure 3.23).  
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Figure 3.23. Transfection of MonoMac6 cells with a different plasmid DNA construct induced 
Polymyxin B-independent release of GM-CSF release. Cells transfected with the basic pGL3 plasmid 
construct produced significantly higher levels of GM-CSF release compared to cells subjected to 
mock transfection via electroporation. This induction was not suppressed by pre-treatment with the 
LPS inhibitor Polymyxin B (PB) (50µg/ml). LPS stimulation of the transfected cells had no additional 
effect on GM-CSG release and cytokine levels were also unaffected by the presence of the LPS 
inhibitor. Data are expressed as % of GM-CSF release in unstimulated non-transfected cells. 
Histograms represent mean±S.E.M. of GM-CSF levels of three independent experiments. Mock: cells 
electroporated in the absence of plasmid DNA; NT: non-treated cells transfected with plasmid DNA.   
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3.2.4.5. Effect of mutant GSK3β overexpression on dexamethasone function in MonoMac6 
cells 
In the previous section it was shown that transfection of MonoMac6 cells with the plasmid 
constructs stimulates an LPS-independent inflammatory response. Since LPS had no 
additional effect on the release of pro-inflammatory cytokines in transfected cells, I wanted 
to investigate whether this response is dexamethasone sensitive and whether it is 
modulated by overexpression of the kinase dead K85R GSK3β mutant. In addition, since 
H2O2 suppresses GSK3β function via Ser9 phosphorylation, I wanted to evaluate its effect on 
dexamethasone function in cells overexpressing the S9A GSK3β mutant. In order to achieve 
this, MonoMac6 cells were transfected with the pcDNA3.1 construct, which was used as the 
negative control, the K85RpcDNA3.1 and the S9ApcDNA3.1 construct. Following 18 hours of 
transfection, the cells were treated with H2O2 (100 µM) for 2 hours before being subjected 
to dexamethasone stimulation (10-8M) and were then stimulated with LPS (10ng/ml) for 16 
hours. The effect of plasmid DNA addition on both basal and LPS-induced GM-CSF release 
compared to cells electroporated without addition of any plasmid construct (mock) was 
shown previously in Figure 3.21. Levels of GM-CSF release in response to LPS in cells 
overexpressing the two mutant GSK3β plasmid constructs were normalised to levels 
induced in the cells transfected with the negative control pcDNA3.1 plasmid.  
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3.2.4.5.1. Inactive K85R mutant GSK3β overexpression suppresses the anti-inflammatory 
effect of dexamethasone 
Treatment with dexamethasone significantly inhibited LPS-induced GM-CSF release by 
26.5±2.5% in the cells transfected with the control pcDNA3.1 plasmid. However, in cells 
overexpressing the kinase dead K85R GSK3β mutant, dexamethasone did not elicit any 
suppressive effect on LPS-induced GM-CSF release (122.9±21.1% versus 129.2±27.7% of LPS-
induced GM-CSF release in cells transfected with the control pcDNA3.1 vector) (Figure 3.24).  
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Figure 3.24. Overexpression of the kinase dead K85R GSK3β mutant suppresses dexamethasone 
function in LPS stimulated MonoMac6 cells. Dexamethasone (10-8M) significantly reduced LPS-
induced GM-CSF release in cells transfected with the control pcDNA3.1. When the inactive K85A 
GSK3β mutant was expressed in the cells, dexamethasone had no significant inhibitory effect on LPS 
induced GM-CSF release (122.9±21.1% versus 129.2±27.7%). Data are expressed as % of LPS induced 
GM-CSF release in the presence of the pcDNA3.1 control plasmid. Histograms represent 
mean±S.E.M. of four independent experiments. *p<0.05. 
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3.2.4.5.2. Exposure of MonoMac6 cells to H2O2 inhibits dexamethasone-induced 
suppression of LPS-stimulated GM-CSF release 
MonoMac6 cells were pre-treated with H2O2 (100µM) for 2 hours before being subjected to 
a concentration range of dexamethasone (30 minutes) and LPS (10ng/ml) stimulation for 16 
hours. As shown in figure 3.25, pre-treatment of cells with H2O2 suppressed the 
concentration-dependent anti-inflammatory function of dexamethasone (p=0.0093). At the 
highest concentration used (10-6M), dexamethasone-induced inhibition of GM-CSF release 
was significantly suppressed and GM-CSF release levels were reversed from 32.8±11.1% to 
88.2±12.8% of LPS-induced GM-CSF levels of release.  
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Figure 3.25. H2O2-induced suppression of dexamethasone anti-inflammatory function in 
MonoMac6 cells. Dexamethasone (10-9 -10-6M) significantly reduced LPS-induced GM-CSF release in 
a concentration dependent manner. By contrast, in cells pre-treated with H2O2, dexamethasone 
failed to suppress GM-CSF release to similar levels (p=0.0093). The maximum response to 
dexamethasone was inhibited by H2O2 and levels of GM-CSF release in response to LPS stimulation 
were significantly higher (88.2±12.8% vs 32.8±11.1%). Data represent mean±SEM of eight 
independent experiments. Data were normally distributed as confirmed by the Shapiro-Wilk 
normality test. Two-way ANOVA was used to test whether H2O2 had a statistically significant effect 
on dexamethasone’s concentration response curve. % of control: % of LPS induced GM-CSF release. 
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3.2.4.5.3. H2O2-induced inhibition of dexamethasone function is regulated by Ser9 on 
GSK3β: overexpression of the S9A mutant kinase restored dexamethasone function 
In cells transfected with the control pcDNA3.1, the anti-inflammatory function of 
dexamethasone was suppressed by pre-treatment with H2O2 (100 µM) for 2 hours and the 
steroid inhibited GM-CSF levels to 89.7±6.1% of LPS induced levels (Figure 3.26a). However, 
in cells overexpressing the S9A GSK3β mutant, the inhibitory effect of H2O2 on 
dexamethasone function was reversed and the steroid significantly suppressed LPS induced 
GM-CSF levels to 64±5.7% (Figure 3.26b). H2O2 showed no significant additional effect on 
LPS-induced GM-CSF in the presence or absence of dexamethasone in cells transfected with 
either the control pcDNA3.1 or the S9ApcDNA3.1 plasmid (Figure 3.26).  
 
 
 
 
 
 
 
 
 
 
 
 
 
GSK3β regulates corticosteroid function under conditions of OS 
  
144 | P a g e  
 
 
40
60
80
100
120
*
ns
G
M
-C
S
F
 (
%
 o
f 
c
o
n
tr
o
l)
 
40
60
80
100
120
**
 
 
Figure 3.26. H2O2-induced suppression of dexamethasone function is reversed in cells expressing 
the S9A mutant GSK3β kinase. (a) Transfection of monocytes with the control pcDNA3.1 plasmid 
had no effect on the ability of dexamethasone (10-8M) to suppress LPS-induced GM-CSF release by 
26.5 ±2.5 %. The anti-inflammatory effect of dexamethasone was attenuated by pre-treatment with 
H2O2 (100 µM) for 2 hours (p=0.31). (b) In the presence of the active S9A mutant, the inhibitory 
effect of H2O2 on dexamethasone function was reversed (10.3±6.1% versus 35±5.7%). Data are 
expressed as % of LPS-induced GM-CSF release in the presence of the pcDNA3.1 control plasmid. 
Histograms represent mean±S.E.M. of four independent experiments. *p<0.05, **p<0.01. 
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3.3. Discussion 
3.3.1. The inhibitory Ser9 phosphorylation levels of GSK3β are increased in 
lung macrophages and blood monocytes from patients with COPD and 
smokers compared to non-smokers 
The results demonstrated that the levels of the inactive p-GSK3-s9 are increased in the 
peripheral lung macrophages and blood monocytes of COPD patients compared to non-
smokers and smokers with normal lung function. Levels of p-GSK3β-s9 were also increased 
in the lung macrophages and monocytes of smokers compared to age-matched non-
smokers. It is evident that lung macrophages and blood monocytes from COPD patients are 
exposed to reactive oxygen species that derive either exogenously from cigarette smoking 
and other environmental pollutants or are secreted by inflammatory cells (Marwick and 
Chung 2010). I therefore investigated whether inactivation of GSK3β is a result of the 
increased levels of oxidant stress. I exposed healthy monocytes to H2O2 –derived oxidant 
stress and measured levels of Ser9 phosphorylation on GSK3β. Treatment of peripheral 
blood monocytes isolated from non-smokers with H2O2 for 30 minutes resulted in a 
significant increase of p-GSK3β-Ser9 levels, whereas exposure to reactive oxygen species 
had no additional significant effect on the levels of the inactive GSK3β form in monocytes 
isolated from COPD patients. However, in all patients groups a trend of increased 
phosphorylation of GSK3β on Ser9 was observed in the presence of H2O2 and increasing n 
numbers should assist confirming statistical significance. These results suggest that 
inactivation of GSK3β in lung macrophages and peripheral blood monocytes, is induced by 
exposure of the cells to increased levels of reactive oxygen species. My findings are in line 
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with studies showing that oxidative stress-related lipid peroxidation product HNE induces 
inactivation of GSK3β by increased phosphorylation on its Ser9 residue (Dozza, Smith et al. 
2004).  
3.3.2. Role of GSK3β inactivation on inflammation  
Recently, a number of reports have documented that GSK3β activity is crucial to regulate 
inflammatory responses either by promoting or inhibiting the expression of pro- or anti-
inflammatory cytokines. Inactivation of GSK3β has been shown to have anti-inflammatory 
effects in LPS-stimulated human monocytes, suggesting the kinase acts as a positive 
regulator of inflammation (Martin, Rehani et al. 2005). Increasing activity of GSK3β has been 
also documented to promote inflammatory response in several inflammatory models. A 
study by Hu, Paik et al. (2006) demonstrated that IFN-γ induces TLR2-dependent production 
of TNF-α in macrophages via increasing GSK3α/β activity. A second study investigating the 
mechanisms by which GSK3β positively regulates inflammation showed that inhibition of 
GSKβ activity suppressed LPS-induced TNF-α production in microglia (Wang, Huang et al. 
2010). In addition in a model of colonic inflammation, increased activation of GSK3β led to 
increased bacterial-induced production of the pro-inflammatory IL-6 and CXCL8 cytokines 
(Duan, Liao et al. 2007). In addition to the inflammatory models described above suggesting 
the kinase plays a pro-inflammatory role, other studies have implied that GSK3β has also a 
role as a negative regulator of inflammation. A study in neonatal mouse cardiomyocytes 
showed that GSK3β suppresses TNF-α expression in cardiomyocytes following LPS 
stimulation (Shen, Fan et al. 2008). Similarly, inhibition of the kinase by Ser9 
phosphorylation in macrophages augmented the levels of IFNβ in LPS-stimulated 
macrophages by a MyD88-independent mechanism (Wang, Garcia et al. 2008). The 
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experimental evidence accumulated so far indicate that GSK3β has anti- or pro-
inflammatory properties on inflammation depending on the cell type and the stimulus used. 
The broad array of immune actions affected by GSK3β is attributed partly to the remarkable 
number of crucial transcription factors and signal transducers that it regulates. It is 
therefore essential to investigate the role of GSK3β in the inflammatory processes in COPD 
and evaluate whether its inactivation in COPD immune cells has a direct effect on regulating 
inflammation. In order to test the above hypothesis, I used monocytes as my cell model 
since the predominant staining in COPD lung was localised in macrophages, and studied 
how inactivation of GSK3β affects inflammatory responses and glucorticoid sensitivity. In 
vitro inactivation of the kinase was performed by pharmacological inhibition using the 
selective compound CT99021, by gene silencing using small interfering RNA and by transient 
overexpression of the constitutively active and inactive mutants, S9AGSK3β and 
K85AGSK3β. 
Primary monocytes isolated from healthy volunteers were first subjected to treatment with 
the small molecule GSK3β inhibitor, CT99021. At concentrations at which the compound 
had no effect on cell viability (10-8M to 10-6M) it also had no effect on basal or LPS-induced 
pro-inflammatory GM-CSF release. These results do not agree with the ones obtained by 
Martin et al., 2005. Their work showed that pharmacological inhibition of GSK3β with 10µM 
of the SB216763 compound, 10mM of LiCl or 200nM of azakenpaullone inhibited LPS-
induced pro-inflammatory TNF-α and IL-6 release (Martin, Rehani et al. 2005). The anti-
inflammatory effects of these drugs may be due to off-target effects of the compounds 
used. The SB216763 compound has been shown to inhibit other protein kinases including 
CDK2-cyclin A, ERK8, DYRK1A, PIM3, SRPK1 and HIPK2 (Polychronopoulos, Magiatis et al. 
2004; Bain, Plater et al. 2007). In addition, the second inhibitor they used was LiCl which is 
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also known to inhibit some non-kinase targets such as inositol monophosphatase and 
histone deacetylases (Phiel and Klein 2001) which may affect pro-inflammatory gene 
transcription. The effect on HDACs may be particularly important as these have an evident 
role in regulating NF-B induced pro-inflammatory gene transactivation (Adcock, Ito et al. 
2005). The third compound they used, azakenpaullone, has been shown to have greater 
selectivity for GSK over CDK1 and CDK5 but there is lack of investigation of its selectivity 
against a large panel of protein kinases (Kunick, Lauenroth et al. 2004). In contrast with the 
compounds mentioned above, CT99021 is the most potent and specific inhibitor of GSK3 up 
to date (IC50=40nM) (Cline, Johnson et al. 2002; Ring, Johnson et al. 2003). Specifically, at 
concentrations up to 10-6M, CT99021 does not inhibit any other protein kinase in the panel 
used by the study conducted by Cohen and Goedert (2004) and it inhibits CDK2-cyclinA 
nearly 50-fold less strongly (IC50 = 1.4µM). Since CT99021 was used at 10
-6M in my study it is 
unlikely to have off-target effects, which was also confirmed when its effects on the activity 
of a range of kinases were tested as discussed on the following chapter. Similar to the 
results obtained from primary monocytes, when I repeated these experiments in the 
monocytic cell line MonoMac6 cells I confirmed that inactivation of GSK3β does not affect 
pro-inflammatory CXCL8 release. 
3.3.3. Role of GSK3β inactivation on corticosteroid anti-inflammatory 
function  
Corticosteroids elicit their actions through binding and activation of GRα (Newton and 
Holden 2007). Recent studies have implicated that GSK3β directly regulates GRα functional 
effect through phosphorylation of serines 134 and 404 which regulate its nuclear export, 
promote its association with co-factors and modulate its trans-repressive actions (Chen, 
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Dang et al. 2008; Galliher-Beckley, Williams et al. 2008). However the direct functional 
impact of GSK3 on the anti-inflammatory actions of corticosteroids has not been assessed. 
My results showed that pre-treatment of primary monocytes with CT99021 at 10-6M had no 
effect on inflammatory cytokine release by itself but significantly suppressed the 
concentration-dependent anti-inflammatory function of dexamethasone. The levels of LPS-
induced TNF-α and GM-CSF cytokine release were not significantly inhibited by 
dexamethasone in the presence of CT99021. I repeated these experiments in the monocytic 
cell line MonoMac6 and obtained similar results. LPS-induced CXCL8 release was 
significantly inhibited by dexamethasone but dexamethasone’s function was attenuated 
when the cells were pre-treated with CT99021.  
In order to validate that GSK3β activity is important for corticosteroid anti-inflammatory 
function, I knocked down total GSK3β levels by gene silencing using on target siRNA and 
studied dexamethasone sensitivity upon LPS stimulation. Due to limiting availability of 
primary monocytes, and since the effect of CT99021 on dexamethasone function was the 
same in the cell line, these experiments were carried out in the monocytic cell line 
MonoMac6. Transfection of cells with on-target GSK3β siRNA for 24 hours led to significant 
inhibition of total kinase levels (50-60%) which were further inhibited following 48 hours of 
transfection (20-40%) but began to return to control levels due to de novo expression of 
GSK3β at 72 hours following transfection (60%). I therefore studied the functional effect of 
GSK3β knock down in cells transfected with siRNA for 24 and 48 hours since this was when 
levels of the kinase were inhibited the most. Cell viability was significantly affected by 
electroporation but this method resulted in the highest transfection efficiency compared to 
other methods that were less toxic to the cells. Although electroporation alone reduced cell 
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viability, addition of the scramble and on-target siRNAs had no additional effect on cell 
death. In addition, transfection of the cells with on-target GSK3β siRNA had no effect on 
LPS-induced CXCL8 and TNF-α release, independent of the concentration of siRNA used 
(200nM and 400nM) or the time of transfection (24 and 48 hours). Importantly, and in 
agreement with the data obtained from pharmacological inhibition of GSK3β, knock down of 
the protein following 24 hours of transfection with the on-target siRNA, significantly 
suppressed the concentration dependent anti-inflammatory function of dexamethasone. 
Interestingly, when cells were transfected with siRNA for 48 hours before being subjected to 
treatment with dexamethasone and LPS for a further 16 hours, GSK3β knock down did not 
significantly affect dexamethasone function (CXCL8 and TNF-α release). This result may be 
due to the fact that the measurements were conducted 64 hours post transfection and 
initiation of de novo expression of GSK3β may be restoring the kinase’s activity in the cells. 
Further experiments using stable transfections in MonoMac6 cells would help to resolve this 
observation. 
Having shown that both pharmacological and molecular inhibition of GSK3β activity 
suppresses dexamethasone anti-inflammatory function, I next confirmed my observations 
by overexpressing the dominant negative K85R GSK3β mutant. When Lys85 on GSK3β is 
mutated to Arg, conformational changes of the substrate binding groove of kinase occur 
that inhibit its activity (Jope and Johnson 2004). Cells overexpressing the kinase dead K85R 
mutant GSK3β did not respond to dexamethasone and LPS-induced GM-CSF release levels 
were not inhibited by dexamethasone in contrast to cells transfected with the negative 
control pcDNA3.1 plasmid.  
GSK3β regulates corticosteroid function under conditions of OS 
  
151 | P a g e  
 
My data so far have shown that GSK3β phosphorylation on Ser9, a marker of its inactivation, 
is increased in COPD and in vitro inactivation of the kinase leads to relative corticosteroid 
insensitivity. It is evident that the increased levels of reactive oxygen species in the lungs of 
COPD patients play a significant role on the effectiveness of corticosteroids (Chung and 
Marwick 2010). Since H2O2 induces Ser9 phosphorylation on GSK3β, I next wanted to 
validate whether this event is involved in driving oxidant stress-induced impaired 
corticosteroid function. In order to investigate this, I transfected MonoMac6 cells with the 
S9ApcDNA3.1 plasmid construct and evaluated whether substitution of Ser9 with Ala will 
affect dexamethasone’ anti-inflammatory function following exposure to H2O2. In cells 
expressing the negative control pcDNA3.1, exposure to H2O2 suppressed the anti-
inflammatory effects of dexamethasone on LPS-induced GM-CSF release. Interestingly, in 
cells overexpressing the S9AGSK3β mutant, exposure to H2O2 no longer affected 
dexamethasone function. This validates my hypothesis that Ser9 phosphorylation is a key 
mechanism regulating corticosteroid function, particularly during oxidant-driven 
inflammation in human monocytes.  
Transfection of MonoMac6 cells with the pcDNA3.1 constructs induced an inflammatory 
response leading to increased levels of GM-CSF release. I first hypothesised that this might 
be due to endotoxin contamination of the plasmid DNA constructs and I reduced endotoxin 
levels down to <0.05 EU/µg before repeating the experiments. Interestingly, this did not 
reverse the pro-inflammatory effect of the DNA constructs plasmids on GM-CSF release. 
This set of data was conducted on cells that were in a higher passage number which 
resulted in both higher basal and plasmid DNA-induced GM-CSF levels compared to those 
measured before the endotoxin removal. I assessed whether the inflammatory effect was 
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LPS-dependent by adding the LPS inhibitor Polymyxin B in combination with the plasmid 
DNA constructs. Although the drug inhibited LPS-induced GM-CSF release in cells that were 
electroporated without addition of any DNA construct, it had no effect on GM-CSF release in 
cells transfected with the control pcDNA3.1 construct. This observation suggests that 
transfection of MonoMac6 cells with plasmid DNA induces an LPS-independent pro-
inflammatory response. The response was induced by both the control pcDNA3.1 plasmid 
and the S9A GSK3β and K85R GSK3β plasmid constructs suggesting that it is not related to 
the GSK3β sequence insertion. In addition, when cells were transfected with another 
plasmid construct, the NF-B reporter pGL3 construct, a similar inflammatory response was 
induced, suggesting that MonoMac6 cells are sensitive to both types of plasmid DNA. Both 
types of vectors contain the amp resistance gene (ampR) which contains two copies of the 
immunostimulatory sequences (ISS) (palindromic CpG hexamer 5' AACGTT 3') (Klinman, 
Conover et al. 1998). These CpG sequences have been shown to stimulate an immune 
response in human monocytes (Sato, Roman et al. 1996) and may be responsible for 
inducing the inflammatory response observed in MonoMac6 cells. Further investigation is 
required to confirm whether this is the mechanism driving the plasmid DNA-induced 
inflammatory response in my cell system. In addition, evaluation of mutant GSK3β 
overexpression was performed by measuring levels of mRNA expression. Due to the 
possibility of the primers detecting the according plasmid DNA sequences inserted, Western 
blotting would be required to further validate the efficiency of my overexpression 
experiments. 
The results obtained in this chapter showed that GSK3β inhibition due to increased 
phosphorylation of its Ser9 residue is increased in COPD patients and smokers with normal 
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lung function. As I hypothesised, inhibition of GSK3β negatively regulates corticosteroid 
function in monocytes. As a result I accept that my hypothesis is true in both primary 
monocytes and MonoMac6 cells. The mechanism(s) by which extracellular reactive oxygen 
species affect GSK3β function and corticosteroid responsiveness in COPD is unknown. The 
next chapter describes a series of experiments designed to investigate the pathways 
involved in oxidant stress-induced GSK3β phosphorylation and the subsequent down-stream 
effects on GR function. 
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4.1. Introduction 
An increasing number of studies have implicated that exposure of immune cells to reactive 
oxygen species is a prominent feature of the corticosteroid insensitivity documented in 
patients with COPD. Oxidative stress leads to activation of the MAPK family, including the 
p38 MAPK, the ERK1/2 MAPK and the PI3K (Birrell, Wong et al. 2008). 
The ERK MAPK pathway is activated by MEK, which is activated by the Raf member of 
MAP3Ks, in response to activated RTKs (Ramos 2008). The p38 MAPKs (including all p38-α, -
β, -γ and -δ isoforms) are activated by MAP2Ks which are similarly activated by MAP3Ks in 
response to RTKs activation (Cuadrado and Nebreda 2010). Reactive oxygen species can 
alter protein structure and function by modifying critical amino acid residues of signalling 
proteins leading to activation of RTKs and the downstream MAPK pathways (Thannickal and 
Fanburg 2000).  
The PI3K cascade is stimulated by phosphorylation of tyrosine kinase receptors, which 
promotes its direct binding with PI3K or indirect binding through adapter proteins. Activated 
PI3K phosphorylates (Ser473) and activates Akt (Vanhaesebroeck and Alessi 2000). The 
PI3K/Akt signalling pathway is redox sensitive. Activation or inhibition of this pathway by the 
redox system is mainly through oxidative modification of Cys-dependent phosphatases 
(CDPs) and protein kinases (Lee, Kwon et al. 1998; Yu, Li et al. 2005).  
Phosphorylation of the p38 MAPK has been found elevated in COPD macrophages (Renda, 
Baraldo et al. 2008) and has been associated with corticosteroid insensitivity (Bhavsar, Hew 
et al. 2008). Recent studies have also identified elevated activation of the PI3K and the 
downstream target Akt in alveolar macrophages from COPD patients, and have shown that 
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activation of the PI3K-δ isoform is a key event mediating in cigarette smoking-induced 
corticosteroid insensitive emphysema in mice. GSK3 activity is negatively regulated by 
phosphorylation of its Ser9 residue which can be mediated by ERK1/2, Akt and p38 MAPK 
(Grimes and Jope 2001). Thus, GSK3 may represent the missing link between oxidant-
mediated activation of ERK1/2, Akt and p38 MAPK and the resulting corticosteroid 
insensitivity documented in COPD.  
Both direct and indirect oxidant-mediated disruption of GR-induced functional repression of 
genes and its ability to bind to its ligand and co-repressors have been implicated to drive 
corticosteroid insensitivity in COPD (Marwick and Chung 2010). Central to this mechanism is 
the reduction in activity and expression of co-repressors, HDAC2 which is critical for GR 
transrepression of several pro-inflammatory genes (Ito, Barnes et al. 2000). HDAC2 is 
recruited by GR to the site of NF-B-regulated gene transcription deacetylates the amino 
terminal tails of the core histone proteins leading to chromatin remodelling and 
inflammatory gene (Ito, Barnes et al. 2000; Barnes, Ito et al. 2004). Alternatively, HDAC2 can 
target acetylated p65 and thereby regulate inflammatory gene expression. Reactive oxygen 
species mediate post-translational modifications (such as phosphorylation and nitration) on 
HDAC2 that impair the enzyme’s catalytic activity, target it for ubiquitination and 
degradation by the proteasome (Osoata, Yamamura et al. 2009) and result in increased 
expression of proinflammatory genes (Ito, Hanazawa et al. 2004). In addition, decreased 
HDAC2 activity has been shown to impair GR deacetylation, prevent its ability to bind to the 
NF-B complex and exert its anti-inflammatory effects. HDAC2 overexpression in BAL 
macrophages from smokers and COPD patients has been also shown to restore 
corticosteroid function (Ito, Ito et al. 2005).  Interestingly, selective inhibition of the PI3K-δ 
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isoform reversed corticosteroid insensitivity in cigarette smoke exposed mice via protection 
against serine hyper-phosphorylation and enzymatic activity suppression of HDAC2 
(Marwick, Ito et al. 2007; Marwick, Caramori et al. 2009). I therefore hypothesised that 
regulation of GSK3β phosphorylation is mediated by members of the PI3K and MAPK 
signalling pathway in response to exogenous reactive oxygen species. Since both these 
redox sensitive pathways are known to regulate GR and HDAC2 activity, I hypothesised that 
differential regulation of either GR or HDAC2 is involved in mediating the GSK3β-dependent 
corticosteroid unresponsiveness. To investigate the above hypothesis I set the following 
aims: 
 Investigate which members of the PI3K and MAPK signalling pathways are activated 
in response to H2O2. 
 Evaluate whether inhibition of the key members of these pathways can restore 
GSK3β phosphorylation on Ser9 in the presence of H2O2. 
 Investigate whether the CT99021 compound has any off-target effects on other 
kinases. 
 Investigate how inhibition of GSK3β by CT99021 affects GR nuclear translocation, its 
binding to p65, p65 DNA binding and HDAC2 activity. 
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4.2. Results 
4.2.1. Mechanism of oxidative stress induced GSK3β inactivation 
4.2.1.1. Effect of H2O2 exposure on monocyte viability 
Monocytes isolated from PBMCs were exposed to H2O2 at concentrations ranging from 
50µM to 800µM for 30 minutes. ROS exposure had no effect on cell viability at 
concentrations up to 100µM. However, cell death was observed when concentrations were 
increased from 200µM to 800µM of H2O2 (Figure 4.1).  
 
4.2.1.2. Exposure to H2O2-induced Ser9 phosphorylation on GSK3β in a time-and 
concentration-dependent manner 
Treatment of monocytes isolated from PBMCs from normal subjects with H2O2 (50 µM-800 
µM) for 30 minutes induced a concentration-dependent increase in GSK3β Ser9 
phosphorylation levels (Figure 4.2). The concentration of H2O2 that induced optimal 
phosphorylation of GSK3β and had no effect of cell viability was 100µM (Figure 4.2), and this 
concentration was used to study the effects of H2O2 exposure over time in the following 
section.  
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Figure 4.1. High concentrations of H2O2 induced reduction of cell viability in primary monocytes.  
H2O2 had no effect on cell viability at 50µM and 100µM, but resulted in 40-50% cell death at higher 
concentrations ranging from 200µM to 800µM, *p<0.05 versus untreated cells. 
 
 
 
 
 
Figure 4.2. H2O2 induced induces phosphorylation of GSK3β (Ser9) in a concentration-dependent 
manner in primary monocytes. Total levels of GSK3β were unaffected by treatment of monocytes 
with H2O2.  Ser9 phosphorylation of GSK3β was induced at 100µM of H2O2 stimulation and was 
further increased at higher concentrations. The Western blot is representative of four individual 
experiments.  
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4.2.1.3. Effect of H2O2 treatment on kinase phosphorylation over time 
Monocytes isolated from PBMCs from healthy subjects were treated with H2O2 (100 µM) for 
a time period ranging from 5 minutes to 60 minutes. Following 5-10 minutes of exposure, 
Akt was phosphorylated on Ser473. P-Ser473-Akt is a marker of activation of the upstream 
PI3K as Akt is its direct substrate (Figure 4.3). Phosphorylation of ERK1/2 (p44/42) on 
Thr202/Tyr204, a marker of its activation, was also induced by H2O2 (100 µM) time-
dependently and was highest after 15 minutes of exposure (Figure 4.4). The 
phosphorylation status of Ser9 on GSK3β, a marker of its inactivation, was significantly 
increased following 30 minutes of H2O2 exposure (Figure 4.5a). The levels of 
phosphorylation on its Tyr216 residue which activates the kinase were also measured 
following H2O2 treatment. P-Tyr216 levels were increased after 5 minutes of exposure to 
H2O2 and remained high after 15 minutes. However, at 30 and 60 minutes following 
treatment with H2O2, the levels decreased back to basal levels (Figure 4.5b).   
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Figure 4.3. H2O2 leads to Akt phosphorylation in primary monocytes. Monocytes from healthy 
subjects were treated with H2O2 (100µM) for a time course ranging from 5 to 60 minutes. Activation 
of PI3K as measured by the phosphorylation status of its downstream direct target Akt on Ser473 
was significantly increased following 5 and 10 minutes of exposure to H2O2 (a, b). (a) Western blot is 
a representative of 4 independent experiments that were used for band densitometry. Phospho-
Ser473-Akt levels were normalised to total Akt. (b) Histograms represent the mean±S.E.M. of 4 
independent experiments, *p<0.05, **p<0.01. 
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Figure 4.4. H2O2 leads to ERK1/2 activation in primary monocytes. Monocytes from healthy 
subjects were treated with H2O2 (100µM) and levels of phospho-p44/42 (ERK1/2) were measured by 
Western blot analysis following 5 to 60 minutes of treatment. Activation of ERK1/2 isoforms was 
evident after 5 minutes of treatment and was highest after 15 minutes of H2O2 exposure (a, b). (a) 
Western blot is a representative of 4 independent experiments that were used for band 
densitometry. (b) Histograms represent the mean±S.E.M. of 4 independent experiments, *p<0.05, 
**p<0.01.  
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Figure 4.5. H2O2 exposure leads to GSK3β inactivation in primary monocytes. Monocytes from 
healthy subjects were treated with H2O2 (100µM) and levels of phospho-Tyr216 and phospho-Ser9 
on GSK3β were measured by Western blot analysis following 5 to 60 minutes of treatment. 
Inactivation of GSK3β was evident at 30 to 60 minutes of exposure to H2O2 as shown by increased 
levels of Ser9 phosphorylation (a and b). The phosphorylation status of Tyr216 was increased in the 
first 5 to 10 minutes of H2O2 treatment but returned to basal levels at 30 and 60 minutes following 
the treatment (a and c). (a) Western blot is a representative of 4 independent experiments that were 
used for band densitometry. (b, c) Histograms represent the mean±S.E.M. of 4 independent 
experiments, *p<0.05, **p<0.01 vs untreated cells.  
 
4.2.1.4. Exposure to H2O2 induced Ser9 phosphorylation on GSK3β in an ERK1/2-, Akt-, and 
p38 MAPK- dependent pathway in monocytes derived from PBMCs 
Oxidant-dependent phosphorylation of GSK3β on Ser9 was significantly inhibited by pre-
treatment (30 minutes) with the selective MEK inhibitor (U0126) and the selective Akt 
inhibitor (MK-2206). Inhibition of the p38MAPK (SB239063) prior to H2O2 stimulation also 
reduced the phosphorylation status of GSK3β but levels were not restored to basal levels. 
The selective PI3K-δ inhibitor (IC87114) had no significant effect on H2O2 induced p-GSK3β 
(Figure 4.6). 
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Figure 4.6. H2O2 exposure inhibits GSK3β in peripheral blood monocytes via activation of the AKT, 
ERK1/2 and p38 MAPK kinases. Monocytes were pre-treated with Akt (MK-2206-Pfizer), MEK 
(U0126), p38 MAPK (SB239063) and PI3Kδ (IC87114) inhibitors for 30 minutes. The cells were then 
subjected to treatment with H2O2 (100µM) for 30 minutes. Exposure to H2O2 leads to a significant 
increase of p-Ser9-GSK3β levels. This H2O2 induced effect was inhibited by selective inhibition of Akt, 
MEK and p38 MAPK. However, oxidant stress induced phosphorylation of GSK3β is independent of 
the PI3Kδ isoform activity. (a) Blots are representative of 6 individual experiments. Histograms 
represent mean±S.E.M. of six independent experiments*p<0.05, **p<0.01.  
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4.1.5. Exposure to H2O2 induced activation of ERK1/2 is not mediated by Akt or PI3Kδ in 
human monocytes 
Exposure of primary monocytes to H2O2 for 30 minutes induced a 3-fold increase in the 
phosphorylation status of Thr202/Tyr204 on p44/42 (ERK1/2) MAPK, which is a marker of 
kinase activation. Inhibition of MEK by 30 minutes pre-treatment with the compound U0126 
(1µM) inhibited ERK1/2 activation and the levels of P-Thr202/Tyr204 on p44/42 MAPK were 
restored to basal levels. By contrast, inhibition of Akt and PI3Kδ by pre-treatment with the 
small molecule inhibitors MK-2206 and IC87114 respectively (both at 1µM) for 30 minutes 
had no effect on H2O2-induced activation of ERK1/2 MAPK suggesting that these kinases are 
not involved in mediating ERK1/2 activation in response to exogenous H2O2 (Figure 4.7). 
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Figure 4.7. H2O2 induced activation of ERK1/2 is not mediated by PI3K. Monocytes were pre-
treated with Akt (MK-2206-Pfizer), MEK (U0126) and PI3Kδ (IC87114) inhibitors for 30 minutes. The 
cells were then subjected to treatment with H2O2 (100µM) for 15 minutes. Exposure to H2O2 led to 
significant increase of phospho-p44/42 MAPK (Erk1/2) on Thr202/Tyr204. This activation of ERK1/2 
was only inhibited by pre-treatment with the MEK inhibitor and is not mediated by the PI3K/Akt 
pathway. (a) Western blots are representative of 4 independent repeated experiments. (b) 
Histograms represent mean±S.E.M. of 4 independent experiments*p<0.05. 
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4.2.2. Investigation of the effects of the CT99021 compound and H2O2 on kinase activity  
In order to confirm that the CT99021 compound does not exert any off-target effects on 
other kinases known to be involved in regulating inflammation, I investigated its effect on 
the activity of a range of kinases. I used H2O2-stimulated monocytes as a control experiment 
to confirm the liability of the kinase array as it is known to lead to rapid 
phosphorylation/activation of a wide range of kinases. Monocytes from healthy subjects 
were treated with 1µM of CT99021 for 30 minutes, which is the time and concentration 
with which the compound induced corticosteroid insensitivity as discussed in chapter 3. 
Whole cell lysates were incubated with a kinase array containing antibodies for a range of 
phosphorylated kinases as a marker of their activation. The duplicate spots on the 
membrane, as shown in Figure 4.8a, represent each phosphorylated kinase protein and 
were used for pixel densitometry. The phosphorylation status of each kinase in the lysates, 
obtained from cells treated with CT99021, was normalised to the phosphorylation status in 
the lysates obtained from untreated cells and the values were expressed as fold increase as 
shown in the histograms in Figure 4.8b. Treatment of monocytes with CT99021 had no off 
target effects on the kinases tested. However, there was a significant increase in total levels 
of beta-catenin, which is the direct downstream effector of GSK3β regulating beta catenin 
degradation. In addition, as a control experiment, monocytes were treated with H2O2 
(100µM) for 30 minutes and the results showed a number of kinases being activated by 
phosphorylation as shown in Figure 4.8c. Activation of ERK1/2 and Stat3 was significantly 
increased in response to exogenous H2O2. Additionally, total beta-catenin protein levels 
were also increased following treatment with H2O2.  
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Figure 4.8. Effect of H2O2 exposure and treatment with the CT99021 compound on kinase 
activation. Monocytes from healthy subjects were treated with the CT99021 (1µM) compound (a 
and b) or with H2O2 (100µM) for 30 minutes (a and c). The whole cell lysates were used to measure 
kinase activation by measuring the levels of their phosphorylation as represented by the (a) dark 
spots (in duplicate) on the kinase array. The spots were used for pixel densitometry and the levels of 
phosphorylation were expressed as fold increase in phosphorylation of unstimulated cells. (b) H2O2 
led to activation of a number of kinases, from which ERK1/2, Stat3 were significantly activated. Total 
beta-catenin levels were also significantly increased. (c) By contrast, CT99021 did not have any off-
target effects and only led to significant increase of levels of beta-catenin. Histograms represent the 
average signal (pixel density) of the pair of duplicate spots normalized to the equivalent one derived 
from untreated cells. The average signal is expressed as fold increase compared to the positive 
control (dark blue bar), represented as a horizontal straight line. The data represent the 
mean±S.E.M. of 3 independent experiments and *p<0.05, **p<0.01 vs untreated cells.  
 
4.2.3. Mechanism of GSK3β induced impairment of glucorticoid function 
4.2.3.1. Effect of GSK3β knock down on GR expression 
I investigated the mechanism by which GSK3 modulates dexamethasone function in 
monocytes. Knock down of GSK3β protein by siRNA (200nM and 400nM) in MonoMac6 cells 
led to significant decrease of total GSK3β protein levels as also shown in more details in the 
previous chapter (Chapter 3). Inhibition of total GSK3β protein levels correlated with a 50% 
decrease of total GRα levels in cells transfected with either 200nM or 400nM of the on-
target GSK3β siRNA (Figure 4.9a, b).  
 
4.2.3.2. Effect of GSK3β inactivation on GR nuclear translocation 
Next I investigated whether inhibition of GSK3β affects GRα nuclear translocation upon 
treatment with dexamethasone. MonoMac6 cells were pre-treated with CT99021 (30 
minutes) at the concentration that it has a functional effect (10-6M) and were treated with 
dexamethasone for 2 hours prior to being stimulated with LPS (10ng/ml). LPS did not affect 
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GR localisation, whereas treatment with dexamethasone induced nuclear translocation of 
the receptor. Treatment with the CT99021 compound did not affect GR nuclear 
translocation in response to dexamethasone either in the presence or the absence of LPS 
(Figure 4.10a, b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. GSK3β knock down resulted in reduction of total GRα protein levels in MonoMac6 cells. 
GSK3β protein knock down reduced total protein levels of GSK3β and GRα in MonoMac6 cells. GRα 
protein levels normalised to β-actin were significantly suppressed in cells transfected with on-target 
GSK3β siRNA, 200nM (a, b) and 400nM (a, c) for 24 hours. Histograms represent mean±S.E.M. of 3 
(b) and 4 (c) independent experiments. KD: knock down of GSK3β protein using on-target GSK3β 
siRNA. 
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Figure 4.10. GRα nuclear translocation is not affected by GSK3β inactivation. GRα nuclear 
translocation upon treatment with dexamethasone was not affected by GSK3β inhibition. Levels of 
cytoplasmic GRα protein levels were decreased upon stimulation with dexamethasone (1µM for 2 
hours) (a) which correlated with increased levels of the protein found translocated in the nucleus 
(b). Pre-treatment with CT99021 for 30 minutes had no effect on GR nuclear localisation (a, b). The 
Western blot bands were used for densitometry and the values were normalised to β-actin for 
cytoplasmic levels of GR and Lamin A/C for nuclear levels of GR. Histograms represent mean±S.E.M. 
(n=3 (a) and 4 (b)). **p<0.01 vs unstimulated cells.  
 
 
4.2.3.3. Effect of GSK3β inactivation on association of GR with NF-B/p65 
As shown in the previous section GR nuclear translocation was not affected by inhibition of 
GSK3β activity. Therefore, I next investigated whether binding of GR to NF-B/p65 in 
response to dexamethasone is affected by GSK3β inactivation. Monocytes from healthy 
volunteers were pre-treated with the CT99021 compound for 30 minutes and subsequently 
stimulated with LPS (10ng/ml) and dexamethasone (1µM) for 2 hours. NF-B/p65 was 
ImmunoPrecipitated in the whole cell lysates and the Western blots were re-probed with 
the GR antibody to detect levels of the receptor that have formed a complex with p65 
(Figure 4.11a). In response to LPS and dexamethasone, GR was bound to p65 in the 
monocytes. In the cells where GSK3β was inhibited by pre-treatment with CT99021 the 
levels of GR bound to p65 were not affected (Figure 4.11).  
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Figure 4.11. Levels of GR bound to NF-B/p65 are not affected by GSK3β inhibition. GR did not 
form a complex with p65 under resting conditions and this was unaffected by LPS (2 hours) alone. In 
the presence of dexamethasone (1µM for 2 hours) a much greater GR/p65 association was seen. In 
the presence of the GSK3β inhibitor alone, with LPS or with dexamethasone alone, GR did not form a 
complex with p65. When monocytes were treated with both LPS and dexamethasone, the presence 
of CT99021 had no effect on the levels of GR bound to p65. The Western blot bands (a) were used 
for densitometry and the values of GR protein levels were normalised to the levels of 
ImmunoPrecipitated p65. Histograms represent mean±S.E.M. of three independent experiments 
with *p<0.05 vs unstimulated cells.  
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4.2.3.4. NF-B p65 DNA binding capacity is not regulated by GSK3β kinase activity 
I next investigated whether the DNA binding capacity is influenced by GSK3β inactivation in 
the absence or presence of dexamethasone under LPS stimulation. Monocytes from healthy 
subjects were pre-treated with the CT99021 (10-6M) inhibitor for 30 minutes before being 
subjected to treatment with dexamethasone (10-6M) followed by stimulation with LPS 
(10ng/ml) for 2 hours. Nuclear proteins were extracted and NF-B/p65 DNA binding 
capacity was measured. Stimulation of the cells with LPS induced a significant increase in 
NF-B DNA binding activity but the ability of the transcription factor to bind to its consensus 
DNA sequence was not affected by 30 minutes pre-treatment with dexamethasone (10-6M). 
Inhibition of GSK3β by CT99021 had no effect on NF-B p65 binding under any stimuli tested 
(Figure 4.12).  
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Figure 4.12. NF-B/p65 DNA binding capacity is not affected by CT99021 in monocytes from 
PBMC’s. The capacity of the NF-B p65 transcription factor to bind to its consensus DNA sequences 
was not affected by inhibition of GSK3β in primary monocytes. LPS stimulation (2 hours) increased 
nuclear p65 DNA binding capacity. Neither dexamethasone nor CT99021 pre-treatment (30 minutes) 
had any effect on p65 binding to DNA. Histograms represent mean±S.E.M. of the OD values of four 
independent experiments, *p<0.05 vs unstimulated cells. 
 
 
4.2.3.5. Effect of GSK3β inhibition on HDAC2 mRNA and protein expression 
Monocytes from healthy subjects were treated with CT99021 for a time course of 16, 24 and 
48 hours. The whole cell lysates were analysed by Western blotting for total protein levels 
of HDAC2. CT99021 treatment did not affect HDAC2 protein expression after 16 and 24 
hours of treatment (1M) (Figure 4.13a). Monocytes were also treated with CT99021 for a 
time course of 4, 6, 8 and 16 hours before RNA was collected for gene expression analysis by 
RT-PCR. HDAC2 mRNA expression was also not affected by treatment with CT99021 (100nM, 
500nM and 1M) for up to 16 hours. 
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4.2.3.6. Effect of GSK3β inhibition on HDAC2 activity  
Inhibition of GSK3β with CT99021 in peripheral blood monocytes for 30 minutes had no 
significant effect on ImmunoPrecipitated HDAC2 activity at 100nM (10.2±9.2%) but reduced 
ImmunoPrecipitated HDAC2 activity by 31.3±5.6% (p<0.05) when added at 1µM. Similar 
levels of reduction in HDAC2 activity (23.3±6.1%) were observed when primary blood 
monocytes were treated with H2O2 (100µM) for 1 hour (Figure 4.14). 
 
4.2.3.7. Inhibition of GSK3β led to post-translational modifications on HDAC2  
Inhibition of GSK3β by CT99021 (1µM) for a time course (15, 30, 60 and 120 minutes) led to 
a two-fold induction of phosphorylation on the Ser-394 residue of HDAC2. This 
phosphorylation event was only evident following 30 minutes of exposure to CT99021 and 
p-Ser394-HDAC2 levels were restored to basal levels after 60 minutes (Figure 4.15).  
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Figure 4.13. Inactivation of GSK3β does not affect HDAC2 protein or mRNA expression in 
peripheral blood monocytes. Inhibition of GSK3β by CT99021 had no effect on HDAC2 mRNA or 
protein expression. Total protein levels of HDAC2 were unaffected after (a) 16 hours and 24 hours 
treatment with CT99021 (1µM). (b) HDAC2 mRNA expression levels normalised to 18S were not 
regulated by CT99021 (100nM, 500nM and 1µM) following 4, 6, 8 and 16 hours of treatment. Blot is 
representative of n=5. Histograms represent mean±S.E.M. (n=3 and n=4) and data are plotted as 
fold-increase gene expressions versus non-stimulated cells. 
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Figure 4.14. Inactivation of GSK3β leads to reduction of HDAC2 enzymatic activity in primary 
monocytes. Exposure of primary monocytes to CT99021 inhibitor (100nM) for 30 minutes had no 
effect on the enzymatic activity of ImmunoPrecipitated HDAC2. By contrast, treatment of monocytes 
with 1µM CT99021 led to significant reduction of HDAC2 activity. Exposure of monocytes to 100µM 
H2O2 for 1 hour also led to inhibition of HDAC2 activity. Histograms represent mean±S.E.M. of four 
independent experiments. *p<0.05 vs unstimulated cells. 
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Figure 4.15. Inactivation of GSK3β leads to increase p-Ser394-HDAC2 levels in primary monocytes. 
Treatment of primary monocytes from healthy subjects with CT99021 (1µM) mediated inhibition of 
GSK3β induced phosphorylation on the Ser394 residue of HDAC2 which peaked following 30 minutes 
of exposure. Western blots were used for band densitometry and the histograms represent 
mean±S.E.M. (n= 4). *p<0.05 vs unstimulated cells. 
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4.3. Discussion 
4.3.1. Mechanism of H2O2 induced GSK3β inactivation 
4.3.1.1. Exposure of monocytes to H2O2 leads to activation of PI3K and ERK1/2 MAPK and 
inactivation of GSK3β in a time-dependent manner 
Monocytes isolated from healthy subjects were treated with H2O2 as a source of reactive 
oxygen species. At the concentration where it did not affect cell viability (100µM), 
treatment with H2O2 resulted in activation of PI3K which was measured by the 
phosphorylation levels of the Ser473 residue of its direct downstream target, Akt (Cross, 
Alessi et al. 1995). Activation of Akt was evident in the first 5 to 10 minutes of exposure to 
H2O2 and levels of phospho-Ser473 Akt were then brought back to normal. Activation of PI3K 
and subsequent phosphorylation of Akt has been previously shown in human monocytic cell 
lines agreeing with my results (Marwick, Caramori et al. 2009; Mercado, To et al. 2011). By 
contrast, phosphorylation of p44/42 (ERK1/2) MAPK on Thr202/Tyr204, a marker of its 
activation, was evident after 5 minutes of exposure, peaked at 15 minutes and remained 
higher than basal levels up to 30 minutes of treatment with H2O2. ERK1/2 activation was 
dependent on MAP/ERK kinase (MEK) activity in my system as inhibition of the kinase 
blocked H2O2 induced phosphorylation on ERK1/2. This finding is in line with previous 
studies showing that oxidative stress leads to phosphorylation of ERK1/2 by MEK in 
response to activation of RTKs and the downstream effector Raf (Meves, Stock et al. 2001; 
Aslan and Ozben 2003; Ramos 2008). Phosphorylation of GSK3β on its Ser9 residue, a 
marker of its inactivation was significantly increased following 30 to 60 minutes of exposure. 
Another phosphorylation site of GSK3β that regulates its kinase activity is the Tyr216 
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residue. Phosphorylation of this residue was increased the first 5-15 minutes of exposure to 
H2O2 but levels were decreased at 30 and 60 minutes following treatment. Since H2O2 
exposure leads to activation of MEK1 in response to Raf activation in several cell systems 
(Son, Cheong et al. 2011) and activated MEK1 is known to phosphorylate GSK3β on Tyr216 
in airway smooth muscle cells (Takahashi-Yanaga, Shiraishi et al. 2004), this could be a 
possible mechanism leading to increased Tyr216 phosphorylation on GSK3β in my system.  
Further investigation is required to identify the exact signalling cascade and kinase 
responsible for H2O2-induced phosphorylation of the Tyr216 residue on GSK3β. However, 
since the levels of p-Tyr216-GSK3β were restored to basal levels after 30 and 60 minutes of 
exposure this confirms that GSK3β activity is inhibited in response to exogenous reactive 
oxygen at those time points. The use of the kinase dead mutants, as described in previous 
chapter, may resolve whether prior activation of GSK3β linked to Tyr216 phosphorylation 
plays a role in the inflammatory or anti-inflammatory response.  
4.3.1.2. H2O2 induced inactivation of GSK3β is mediated by p38 MAPK, ERK1/2 MAPK and 
Akt in primary monocytes 
Inactivation of GSK3β in response to exogenous reactive oxygen species in primary 
monocytes is inhibited by pre-treatment of the cells with the MEK inhibitor, the Akt inhibitor 
and the p38 MAPK inhibitor. These results show that p-Ser9-GSK3β is regulated by these 
protein kinases concluding that they are upstream components of this H2O2-activated 
signalling cascade. As discussed previously, Akt activation follows activation of its upstream 
regulator PI3K. Since, inactivation of the PI3Kδ isoform had no effect on H2O2-induced 
inactivation of GSK3β, it is clear that Akt activation and subsequent phosphorylation of its 
direct target, GSK3β, is not PI3K isoform specific. In addition, inactivation of ERK1/2 MAPK 
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by inhibition of its upstream regulator, MEK, also inhibited GSK3β phosphorylation on Ser9 
in response to H2O2 in my cell system. In addition, my results also showed that p38 MAPK is 
also involved in mediating oxidant stress-induced inactivation of GSK3β. SB239063 exhibits 
equipotent inhibitory activity against α- and β- p38 isoforms (Underwood, Osborn et al. 
2000). The p38α and p38β isoforms are known to be activated in response to reactive 
oxygen species via oxidative modification of the MAP3K intracellular kinases (Son, Cheong et 
al. 2011). One suggested mechanism mediating activation of p38 in response to reactive 
oxygen species is via ASK-1 (apoptosis signal-regulating kinase-1), a member of the MAP3Ks 
which binds to thioredoxin in resting cells. Upon oxidative stress stimulation, thioredoxin 
becomes oxidised and dissociates from ASK-1 leading to activation of the p38 MAPK 
pathway through oligomerisation of ASK-1 (Nagai, Noguchi et al. 2007). The exact nature of 
the signalling intermediates between p38 MAPK and GSK3β however is not known. My 
findings are in line with previous work showing that p38 MAPK regulates GSK3β function in 
the Wnt-beta-catenin signalling cascade and inhibition of p38 blocked Wnt-induced 
phosphorylation of Ser9 on GSK3β in mouse cancer cells (Bikkavilli, Feigin et al. 2008). 
Another possible mechanism that has been suggested by other studies is that p38 MAPK is 
involved in regulating Akt activation in response to intracellular reactive oxygen species 
leading to regulation of GSK3β activity (Wang, Liu et al. 2011). Further work is required to 
elucidate the mechanism by which p38 MAPK regulated GSK3β function in my system.  
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4.3.2. Evaluation of the CT99021 specificity against a range of kinases 
My results so far have demonstrated that loss of GSK3β due to the presence of reactive 
oxygen species leads to corticosteroid insensitivity in healthy monocytes. This was shown by 
using both siRNA targeting the GSK3β gene and by treatment of monocytes with the 
CT99021 compound to inhibit its kinase activity. Because my experiments were conducted 
in primary monocytes, I could not use GSK3β knock down approaches to investigate the 
mechanism that induces steroid insensitivity due to the limitations of availability of primary 
monocytes. Therefore, I ought to investigate whether CT99021 has any off target effects or 
is selective for GSK3β in my cell system. I screened the effects of the CT99021 compound 
over the activation of a range of kinases.  My results showed that CT99021 had no off target 
effects at the time points tested and it only led to increased levels of total beta-catenin 
protein levels. In resting cells, beta-catenin is degraded by active GSK3β and the observed 
increase in its total levels confirms that the target of CT99021 inhibits GSK3β specifically and 
thus inhibits beta-catenin degradation at the concentration and time points tested. 
However, to further confirm that the CT99021 compound has no off-target in my model of 
LPS-stimulated monocytes, another kinase array should be performed to evaluate whether 
LPS-induced activation of any of the kinases tested may be affected by treatment with the 
CT99021 compound. 
As a positive control for the kinase array I used the same technique to measure the levels of 
phosphorylated kinases in response to treatment with H2O2. This exposure led to significant 
activation of a number of kinases. The ERK1/2 MAPK was activated confirming my results 
from Western blotting, possibly due to activation of the upstream kinase Raf MAP3K in 
response to reactive oxygen species. The signal transducer and activator of transcription 3 
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(Stat3) was also activated in response to treatment of monocytes with H2O2. Stat3 also has 
been demonstrated to be sensitive to changes in the redox state several cell types (Simon, 
Rai et al. 1998; Cao, Tal et al. 2007). The mechanism of ROS induced activation of Stat3 is 
not known but activation of receptor tyrosine kinases, such as EGFR has been suggested in 
previous studies (Park, Schaefer et al. 2000). Additionally, H2O2 exposure led to increased 
total protein levels of beta-catenin. This event confirms that H2O2 inactivates GSK3β 
suppressing its action upon beta-catenin, which would normally lead to degradation of the 
latter.  
4.3.3. Mechanism of GSK3β regulated corticosteroid insensitivity in monocytes 
Previous studies have documented that reactive oxygen species directly regulate 
corticosteroid responsiveness via activation of the p38 MAPK and ERK1/2 kinases and 
subsequent modulation of GR activity and ligand-binding affinity in corticosteroid insensitive 
diseases such as severe asthma (Irusen, Matthews et al. 2002; Bhavsar, Hew et al. 2008). A 
recent study identified that stress activated p38 MAPK induces ligand-independent 
phosphorylation on GR which regulates its co-factor binding and GRE binding (Galliher-
Beckley, Williams et al. 2011). Since these pathways were shown to mediate inactivation of 
GSK3β in my system I ought to investigate how GSK3β inhibition affects GR expression. In 
the human monocytic cell line MonoMac6, reduction of total GSK3β protein levels via siRNA 
gene silencing, correlated with a reduction of total GR protein levels. I then investigated 
how inactivation of GSK3β modulates GRα nuclear translocation. My results clearly showed 
that despite reduced GRα expression, inhibition of GSK3β by CT99021 had no effect on GRα 
nuclear translocation upon ligand binding. Therefore I concluded that GSK3β may be 
involved in regulating GRα protein expression by controlling post-translational modifications 
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and degradation processes that the receptor is subjected to. However, my results agree 
with previous studies suggesting that reduction of GR protein in COPD is not responsible for 
the impaired corticosteroid mediated gene transrepression, since even decreased protein 
levels of the receptor are sufficient for corticosteroid to exert their anti-inflammatory 
actions upon binding to the receptor in the cytoplasm and translocating into the nucleus 
(Marwick, Caramori et al. 2009).  
 
Recent studies have identified that GSK3β can lead to in vitro phosphorylation of Ser404 on 
GR in several cell lines (including human osteosarcoma MG-63, liver hepatocellular Hep-G2 
and lung adenocarcinoma epithelial A549 cells) which regulates its ability to bind to co-
regulators such as NF-B (Galliher-Beckley, Williams et al. 2008). Hence I investigated the 
effect that inactivation of GSK3β may have on GR binding to NF-B/p65 in response to 
dexamethasone and LPS. My results demonstrated that the GR-p65 association is not 
regulated by GSK3β in my system. My observation is in line with previous studies showing 
that cigarette smoke induced corticosteroid insensitivity is not mediated by altered GR-p65 
association in A549 epithelial cells (Ito, Yamamura et al. 2006). However, I cannot exclude 
the possibility that the reduction of total GR levels due to inhibition of GSK3β has no effect 
on GR-GRE binding and commercial availability of and anti-p-Ser134-GR or p-Ser404-GR 
antibody would allow me to investigate whether GSK3β is involved in mediating the p38 
MAPK effect on GR. ChIP analysis of GR binding to inflammatory mediator promoters along 
with analysis of co-factor recruitment by mass spectroscopy would provide useful 
information. 
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MAPKs are known to activate NF-B in airway epithelial cells and macrophages exposed to 
cigarette smoke (Koch, Giembycz et al. 2004; Birrell, Wong et al. 2008; Cheng, Luo et al. 
2009), therefore I investigated whether GSK3β is involved in mediating ROS-induced 
regulation of NF-B/p65 DNA binding capacity in peripheral blood monocytes. My data 
illustrated that NF-B/p65 ability to bind to its consensus DNA sequences in the nucleus is 
not affected by inhibition of GSK3β activity. However, further investigation is required to 
show whether GSK3β inhibition has any effect on post-translational modifications on p65 
which do not interfere with its ability to bind to the promoters of inflammatory genes, but 
regulate the recruitment of co-repressor/activators and may therefore interrupt p65-
induced transactivation. In addition, treatment of cells with dexamethasone did not 
suppress LPS-induced NF-B/p65 capacity to bind to DNA. This has been previously shown 
(Ito, Yamamura et al. 2006) and has led to the hypothesis that NF-B-dependent 
inflammatory gene transcription is regulated by GR-mediated recruitment of co-repressors, 
such as HDAC2, which control p65-regulated histone acetylation on the site of gene 
transcription (Barnes 2009).  
Hence, I investigated the possibility that GSK3β modulates GR function via alterations on the 
function its co-repressor HDAC2. I demonstrated that inhibition of GSK3β had no effect on 
mRNA and protein expression of HDAC2. However, my results showed that GSK3β 
inactivation leads to increased Ser394 phosphorylation on HDAC2 which correlates with an 
approximate 30% reduction in HDAC2 enzymatic activity. A similar reduction in HDAC2 
activity was also observed in my system by H2O2 agreeing with what has been previously 
described (Tsai and Seto 2002; Ito, Yamamura et al. 2006; Meja, Rajendrasozhan et al. 2008; 
Mercado, To et al. 2011). It is unclear how regulation of Ser394 phosphorylation affects the 
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enzyme’s activity. Previous studies have proposed that the phosphorylation status of the 
Ser394 residue on HDAC2 is important for the enzyme’s conformational changes and 
regulates its binding capacity to other co-regulators (Tsai and Seto 2002). The mechanism by 
which GSK3β affects HDAC2 phosphorylation and activity has not been elucidated yet. A 
possible indirect mechanism may involve the actions of casein kinase 2 (CK2). CK2 is known 
to phosphorylate HDAC2 on Ser394 and is directly inactivated via phosphorylation by GSK3β 
(Sun, Chen et al. 2002; Tsai and Seto 2002); when the latter is inactive due to reactive 
oxygen species exposure, CK2 remains active and could then bind to and phosphorylate 
HDAC2.  
Previous studies have suggested that cigarette smoke induced loss of HDAC2 leads to hyper-
acetylation of GR which in turn disrupts its binding to NF-B (Ito, Yamamura et al. 2006). 
This does not seem to be the case in my corticosteroid insensitive system since binding to 
p65 was not affected by GSK3β inhibition. My mechanism suggests that reduction of HDAC2 
activity leads to inhibition of GR function and this may be a result of increased levels of 
acetylated histones which lead to increased transactivation. Further investigation is required 
to examine the exact mechanism by which reactive oxygen species-induced inhibition of 
GSK3β leads to reduction of HDAC2 activity. 
Inactive GSK3β is crucial for corticosteroid responsiveness in monocytes as shown in the 
previous chapter. The results shown in this chapter demonstrated that inactivation of GSK3β 
takes place in response to intracellular reactive oxygen species, as mimicked by treatment 
with exogenous H2O2, in an Akt, ERK1/2 and p38 MAPK dependent manner. Next, I sought to 
investigate the downstream mechanism that leads to corticosteroid insensitivity. 
Inactivation of GSK3β leads to decreased levels of total GR protein but did not affect GR 
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nuclear translocation or its capacity to bind to its co-regulator NF-B. The DNA binding 
capacity of the NF-B transcription was also unaffected by the activity of GSK3β. 
Interestingly, I found that inhibition of GSK3β reduced the enzymatic activity of the critical 
co-repressor of GR, HDAC2.  This reduction in activity correlated with an induction of the 
phosphorylation status of its Ser394 residue. The mechanism by which this phosphorylation 
regulates the function of the enzyme is not known. My results show that it is a rapid event 
suggesting that may be priming the enzyme for further post-translational modifications that 
may alter its deacetylase activity or its binding capacity to co-regulators in human 
monocytes. Further investigation of the exact role of this phosphorylation event on 
controlling HDAC2 function under oxidant stress induced inactivation of GSKβ is required.  
In this chapter I identified a mechanism involved in regulating GR function in response to 
oxidant stress in human monocytes. This is mediated via H2O2-induced inactivation of GSK3β 
which results in a reduction of HDAC2 activity and thus promotes NF-B-mediated 
transactivation of pro-inflammatory genes. This oxidant-induced effect on GSK3β function is 
regulated by activation of the upstream Akt and ERK1/2 MAPK kinase. Based on these 
findings, I accept my hypothesis. So far, I have investigated the effect of GSK3β inhibition on 
controlling dexamethasone-induced suppression of GM-CSF, CXCL8 and TNF-α release. In 
order to investigate how inactivation of GSK3β also affects the mRNA expression of other 
corticosteroid-regulated genes, I used microarrays and RT-qPCR as discussed in the 
following chapter.  
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5.1. Introduction 
In the previous chapters I discussed how oxidant stress-mediated inhibition of GSK3β 
induces corticosteroid insensitivity in primary monocytes and MonoMac6 cells. The 
functional effect of GSK3β inhibition was measured by its inhibitory action on LPS-induced 
pro-inflammatory cytokines’ and chemokines’ release (GM-CSF, CXCL8 and TNF-α). In order 
to confirm that the pro-inflammatory effect of GSK3β is regulated on mRNA level of 
inflammatory mediators, I measured the effects of CT99021 on dexamethasone-induced 
inhibition of LPS-stimulated gene expression. I used RT-PCR to measure the effects of GSK3β 
inhibition on corticosteroid-mediated transrepression of IL-8 and CSF2 mRNA expression. 
Hence, I aimed to investigate what are effects of GSK3β inhibition on global gene expression 
and which pathways are consequently differentially regulated due to aberrant GSK3β 
activity. In this chapter, I focus on the effects of CT99021 on LPS-induced and 
LPS/dexamethasone-induced mRNA expression in MonoMac6 cells. My hypothesis is that 
GSK3β activity regulates a wide range of corticosteroid-sensitive inflammatory genes’ 
expression. In order to test this hypothesis I set the following aims: 
 Perform microarrays to investigate the effects of CT99021 on LPS/dex-regulated 
global gene expression  
 Identify the key pathways that these genes encode for and assess their role in 
regulating inflammation 
 Perform qPCR for some genes to confirm the data obtained from the microarrays 
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5.2. Methods 
5.2.1. Culture treatment of MonoMac6 cells and sample preparation 
MonoMac6 cells were treated with CT99021 (1µM) for 30 minutes before being stimulated 
with 10-8M of dexamethasone (30 minutes) and LPS (10ng/ml) for 16 hours before RNA 
(0.5µg) was extracted using the RNeasy Mini Kit. 
 
5.2.2. Agilent microarrays   
The mRNA expression profile was determined using the Agilent SurePrint G3 Human  
microarrays v2 following the manufacturer’s instructions. Following normalisation against 
internal controls, probes with low expression (signal value of < 4.5) were removed. 
 
5.2.3. Data analysis 
Raw array data was imported into Partek Genomics Suite (Partek St. Louise, MI) for initial 
analysis. Principal Component analysis (PCA) was used for array clustering and identification 
of possible outliers. Since no outliers were identified (Figure 5.1) all data sets (n=4) were 
included in the differential expression analysis. Differential gene regulation was determined 
by taking the output from a shrinkage t test (Opgen-Rhein and Strimmer 2007) and then 
computing the p values and q values (false discovery rate (FDR) with “fdrtool” (Strimmer 
2008). The cut-off used for significance is an FDR of less than 0.05, which is a 5% FDR to 
identify the gene that showed the highest change in expression in cells treated with LPS 
alone versus LPS with CT99021. When comparing the effect(s) of CT99021 on 
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dexamethasone function I used a p value of <0.05 as a cut-off for significance. In both cases, 
differences >1.2 fold on mRNA expression were taken into consideration for my analysis. 
Gene sets significantly enriched in Partek were transferred to the Database for Annotation, 
Visualisation and Integrated Discovery (DAVID) version 6.7 (http://david.abcc.ncifcrf.gov/). 
Pathway analysis was performed by KEGG (Kyoto Encyclopaedia of Genes and Genomes) 
within DAVID.  
 
Figure 5.1. Principal Component Analysis of microarray data. Clustering of arrays using PCA showed 
a clear separation of both groups of arrays by the principle component. The repeated treatments 
(n=4) were all clustered and no outliers were identified.  
Control 
LPS-stimulated 
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5.3. Results 
5.3.1. CT99021 regulates the Wnt signalling pathway via up-regulation of 
FRAT1 and FRAT2 gene expression 
I investigated the effect of CT99021 on LPS-induced gene expression. Data analysis using 
Partek identified 17 genes whose expression was differentially regulated (FDR <0.05) by 
CT99021. Among these genes, FRAT1 and FRAT2 were down-regulated by 1.2 and 1.6 fold 
respectively. In order to identify the pathways that these genes regulate I analysed my data 
using the KEGG database (www.genome.ad.jp/kegg). The results showed that CT99021 
affected the Wnt/β-catenin signalling pathway (p=0.05) (Figure 5.2) in LPS-stimulated 
MonoMac6 cells, confirming the specificity of CT99021 action. 
 
5.3.2. Effect of CT99021 on regulation of inflammatory gene expression and 
the pathways regulated 
I next investigated the effect of CT99021 on LPS/dexamethasone-treated MonoMac6 cells. I 
identified 164 known genes that were differentially expressed due to GSK3β inhibition 
(p<0.05) (refer to Appendix I for list of genes). I used KEGG analysis within DAVID to identify 
the key pathways that these genes regulate. As shown in figure 5.3, 14 out of the 164 genes 
encode for inflammatory chemokines, cytokines and cytokine/chemokine receptors 
involved in the cytokine-cytokine receptor interaction pathway (p=2.8×10-6, LPS/dex vs 
LPS/dex/CT99021). Out of the 164 genes, 10 encode for proteins involved in the chemokine 
signalling pathway as shown in figure 5.4 (p=1,5×10-4, LPS/dex vs LPS/dex/CT99021). Among 
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these genes, PRKACG, which encodes for the c-AMP dependent protein kinase, PKA, was 
down-regulated (2.1 fold change, p=0.0008, LPS/dex vs LPS/dex/CT99021) in response to 
CT99021 treatment. The gene encoding for the cell division cycle 42 (cdc42) was up-
regulated (1.6 fold change, p=9.5×10-5M, LPS/dex vs LPS/dex/CT99021) in response to 
CT99021. In addition, CT99021 treatment resulted in an up-regulation (LPS/dex vs 
LPS/dex/CT99021) of mRNA expression of the genes encoding for IL-24 (2.4 fold change, 
p=0.009,), IL-19 (2.5 fold change, p=0.001), IL-10 (1.6 fold change, p=0.001), GM-CSF 
(encoded by CSF2) (2.1 fold change, p=0.01) and G-CSF (encoded by CSF3) (1.9 fold change, 
p=0.02). By affecting expression of these genes, CT99021 regulated the activation of the 
JAK/STAT pathway (p=0.05, LPS/dex vs LPS/dex/CT99021), presumably as a secondary effect 
(Figure 5.5).  
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Figure 5.2. Diagrammatic illustration of the effect on CT99021 on regulating expression of the 
genes involved in regulating the Wnt/β-catenin pathway. FRAT1 and FRAT2 expression was 
significantly down-regulated (p<0.05) in response to CT99021 in LPS-stimulated MonoMac6 cells. 
Both genes encode for FRAT1 and FRAT2 (shown as GBP on the diagram), which regulates GSK3β 
activity and β-catenin degradation in the Wnt signalling pathway. Modified from KEGG 
(www.genome.ad.jp/kegg). 
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Figure 5.3. Effect of CT99021 on dexamethasone-dependent suppression of LPS-induced 
inflammatory gene expression. CT99021 treatment led to up-regulation of 14 genes that encode for 
chemokines, cytokines and chemokine receptors as illustrated by the red star on the diagram 
(p=2.8×10-6). Modified from KEGG (www.genome.ad.jp/kegg). 
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Figure 5.4. Effect of CT99021 on expression of genes involved in regulating the chemokine 
signalling pathway. 10 genes were identified to be differentially expressed in response to CT99021 
in MonoMac6 cells treated with LPS and dexamethasone. CT99021 affected genes encoding for 
chemokines and chemokine receptors resulting in regulation of the chemokine signalling pathway 
(p=1,5×10-4). Among these genes, PRKACG, which encodes for PKA, showed a 2.1 fold reduction 
(p=0.0008) and CDC42 showed a 1.6 fold increase in mRNA expression in response to CT99021 
treatment (p=9.5×10-5M). Modified from KEGG (www.genome.ad.jp/kegg). 
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Figure 5.5. Effect of CT99021 on expression of genes that regulate the JAK/STAT signalling 
pathway. Among the genes whose expression was altered by addition of CT99021 on 
LPS/dexamethasone-treated MonoMac6 cells, those encoding for IL-10, IL-24, IL-19, GM-CSF and G-
CSF were up-regulated. These cytokines are involved in activating the JAK/STAT pathway, which was 
significantly (p=0.05) affected by treatment with CT99021/LPS/dexamethasone compared to 
LPS/dexamethasone alone. Modified from KEGG (www.genome.ad.jp/kegg). 
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5.3.3. Confirmation of the effect of CT99021 on dexamethasone-induced 
inhibition of IL-8 and CSF2 gene expression in LPS-stimulated MonoMac6 cells 
LPS-induced IL-8 mRNA expression was significantly inhibited by 10-8M of dexamethasone 
(3.5 fold change, p=0.02). In cells pre-treated with CT99021 (10-6M) for 30 minutes, 
dexamethasone’s inhibitory effect was reduced by 1.6 fold. CT99021 had no significant 
effect on IL-8 expression in response to LPS stimulation (Figure 5.6). LPS-stimulated mRNA 
expression of CSF2, encoding GM-CSF, was reduced by dexamethasone (10-8M) by 2.2 fold 
(p=0.05). In the presence of CT99021 (10-6M), dexamethasone’s inhibitory effect was 
reduced by 1.7 fold. CT99021 treatment led to increased expression of CSF2 mRNA but this 
effect did not reach statistical significance (Figure 5.7). Although CT99021 had no significant 
effect on LPS/dex-induced IL-8 or CSF2 expression (Figure 5.6 and 5.7), a trend for reversal 
of dexamethasone’s inhibitory function on gene expression was observed for both genes. 
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Figure 5.6. Effect of CT99021 on dexamethasone function on LPS-induced IL-8 mRNA expression. 
MonoMac6 cells were pre-treated with CT99021 for 30 minutes before addition of dexamethasone 
(30 minutes) and LPS stimulation for 16 hours. (Δ)Ct values of IL-8 mRNA expression were 
normalised to the (Δ)Ct values of 18S mRNA expression levels. Histograms represent mean±S.E.M. of 
four independent experiments. *p<0.05. 
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Figure 5.7. Effect of CT99021 on dexamethasone function on LPS-induced CSF2 mRNA expression. 
MonoMac6 cells were pre-treated with CT99021 for 30 minutes followed by treatment with 
dexamethasone (30 minutes) and LPS stimulation for 16 hours. (Δ)Ct values of CSF2 mRNA 
expression were normalised to the (Δ)Ct values of 18S mRNA expression levels. Histograms 
represent mean±S.E.M. of four independent experiments. *p<0.05. 
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5.4. Discussion 
As shown in the previous chapters, I identified that inhibition of GSK3β does not interfere 
with the LPS-induced inflammatory response but reverses dexamethasone-induced 
suppression of inflammatory cytokine release. In order to confirm that these effects are 
exerted at the mRNA level of these inflammatory mediators and to determine whether the 
effects of CT99021 on dexamethasone function were widespread, I assessed the effect of 
CT99021 on global gene expression and the investigated the pathways that are differentially 
regulated upon GSK3β inhibition in MonoMac6 cells. To confirm the data from the 
microarrays, I also performed RT-qPCR and measured the gene expression of IL-8 and CSF2 
as markers of LPS-induced inflammatory gene transactivation.  
 
5.4.1. Inhibition of GSK3β activity affects the activation of the Wnt signalling 
pathway via up-regulation of FRAT expression 
I investigated the effects of CT99021 on LPS-induced gene expression. Using Partek I 
investigated how many genes are differentially up-regulated by FDR<0.05 and showed a fold 
change of >1.5. Among the 17 genes identified, two genes encoding for FRAT1 and FRAT2 
proteins were up-regulated in response to GSK3β inhibition. The rest of the genes identified 
were either unknown or do not regulate any known pathways as analysed by KEGG within 
DAVID. FRAT1 and FRAT2 are negative regulators of GSK3β activity by competing with Axin 
for binding to GSK3β and forming the destruction complex that inhibits β-catenin stability 
(Li, Yuan et al 1999). The mechanisms by which CT99021 down-regulates FRAT mRNA 
expression are not known. A homeostatic feedback mechanism may be activated in the cells 
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that down-regulates FRAT levels to compensate for loss of GSK3β activity upon CT99021 
treatment. Nevertheless, my results confirmed that CT99021 is targeting the correct 
pathways in my system, agreeing with my previous data and hypothesis.  
 
5.4.2. Effect of CT99021 on regulation of inflammatory pathways  
Since in my model of corticosteroid insensitivity GSK3β inhibition reduced dexamethasone-
mediated suppression of LPS-stimulated release of CXCL8, GM-CSF and TNF-α, I sought to 
investigate whether this effect of CT99021 was cytokine specific or it affected other 
inflammatory pathways. Because CT99021 induced a >1.5 fold reduction of dexamethasone 
function in my system, I used Partek to identify the genes that were differentially expressed 
(p<0.05) by more than 1.5 fold in response to CT99021 compared to cells treated with LPS 
and dexamethasone without the drug. Using these parameters, I identified 164 genes whose 
mRNA expression was differentially regulated by CT99021. I used the KEGG database within 
DAVID to identify the pathways that these genes regulate. In support of my hypothesis, 
CT99021 led to up-regulation of the expression of genes that encode for chemokines 
(CXCL6, CXCL3, CXCL2 and CXCL1) and cytokines (GM-CSF, G-CSF) which are involved in 
regulating cytokine-cytokine receptor interactions. These regulate the chemokine signalling 
pathways in neutrophils, lymphocytes and macrophages, suggesting that GSK3β activity is 
important for regulating these inflammatory pathways and supporting my hypothesis that 
aberrant GSK3β activity is involved in driving corticosteroid insensitivity in chronic 
inflammation in COPD. Differential expression of IL-10, IL-24, IL-19, CSF2 (GM-CSF) and CSF3 
(G-CSF) controlled by CT99021, affected the activation of the JAK/STAT signalling pathway. 
Activation of the JAK/STAT pathway in response to IFN-γ has been linked with corticosteroid 
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insensitivity in severe asthma and inhibition of this pathway has been suggested to be a 
novel approach to target steroid-resistant inflammatory lung disease (Clarke, Clifford et al. 
2010). In addition, IFN-α-induced activation of the JAK/STAT pathway has been shown to 
interfere with GR function (Hu, Pace et al. 2009).  
Another gene whose expression was down-regulated (2.1 fold change) by inhibition of 
GSK3β compared to cells treated with dexamethasone and LPS only, was RKACG that 
encodes for the mammalian PKA. PKA is serine/threonine kinase, known to regulate GSK3β 
activity via direct phosphorylation of its Ser9 residue, (Fang, Yu et al. 2000; Suzuki, Ozono et 
al. 2008). PKA has been also shown to phosphorylate FRAT1 (Ser188) and disrupt its activity 
towards regulation of GSK3β function (Hagen, Cross et al. 2006). Importantly, activation of 
PKA has been implicated in having a functional effect on corticosteroid action, since it was 
recently shown to reverse IFN-α-induced reduction of GR activity (Pace, Hu et al. 2011). In 
addition, PKA activation has been implicated in targeting the phosphorylation status of 
serine residues on HDAC5 and HDAC8 thereby regulating their enzymatic activity and 
capacity to bind to their co-repressors (Lee, Rezai-Zadeh et al. 2004; Ha, Kim et al. 2010). 
PKA is also known to phosphorylate p65 on Ser276 and up-regulate its transcriptional 
activity (Yoon, Korade et al. 2008; Arun, Brown et al. 2009; Gao, Hibi et al. 2010) which may 
play a role in mediating GSK3β-induced corticosteroid unresponsiveness. My findings 
suggest that PKA mRNA expression is down-regulated in response to CT99021, but 
assumptions cannot be made on how this affects its protein expression or activity. Since PKA 
targets and inactivates GSK3β, downregulation of PKA mRNA expression may be another 
feedback mechanism aiming to restore GSK3β activity in response to CT99021. Further 
investigation is required to identify the exact role of PKA in regulating corticosteroid 
The effect of CT99021 on global gene expression 
 
206 | P a g e  
 
function and the role of GSK3β in mediating this effect. In addition, I identified an increased 
expression of CDC42 mRNA in response to CT99021. The protein encoded, cdc42, is known 
to regulate cell polarity via phosphorylation of GSK3β (Harwood and Braga 2003). Increased 
mRNA expression of CDC42 may be also a result of a feedback mechanism turned on to 
restore GSK3β activity. My findings confirm the on-target effects of CT99021 and also 
support my hypothesis that GSK3β inhibition is important for regulating inflammatory 
responses in the presence of corticosteroids. It is particularly important to note that the 
pathways affected and discussed above, are signalling pathways that involve proteins whose 
mRNA expression was differentially regulated in response to the CT99021 compound in my 
system. As a result, no assumptions or conclusions can be withdrawn regarding the 
activation of these pathways since the activity of their components is regulated either at a 
post-translational level (via modifications such as phosphorylation, nitration and 
acetylation) or via ligand-receptor and other protein-protein interactions. 
Using PCR to measure the effect of CT99021 on corticosteroid function I confirmed that 
dexamethasone-induced IL-8 transrepression is negatively regulated by inhibition of GSK3β. 
A similar reduction on dexamethasone’s repressive function on LPS-induced CSF2 expression 
was also seen in the presence of CT99021, but none of them reach statistical significance. 
The effect of CT99021 on dexamethasone function was clearer at the level of CXCL8 and 
GM-CSF release following 16 hours of treatment, as discussed in chapter III. This may be due 
to the fact that the mRNA expression was measured also at 16 hours and the effect might 
have been lost by that time point. In addition, CT99021 showed a pro-inflammatory effect 
on LPS-induced CSF2 mRNA expression that although it did not reach statistical significance 
it did not agree with the release data. For that reason, further investigation is required to 
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measure the effects of CT99021 on dexamethasone-induced gene transrepression looking at 
the time course of LPS stimulation.  
I performed gene microarrays to investigate the global genomic effects of GSK3β inhibition 
on corticosteroid function. My results showed that several key inflammatory pathways are 
differentially regulated by GSK3β in monocytes. As a result, I accept the hypothesis that 
GSK3β activity regulates corticosteroid-sensitive inflammatory cytokines and chemokines. 
Further investigation of the list of genes affected by CT99021 and their role in driving 
inflammatory responses/pathways is a future direction required for better understanding of 
GSK3β-regulated corticosteroid insensitivity in COPD. Since these experiments were 
conducted at specific time points, I cannot conclude whether the effects of CT99021 on the 
expression of the genes and the regulation of the pathways described is a primary or a 
secondary effect. For that reason, a full time course is required to investigate whether these 
pathways are directly or indirectly regulated by GSK3β. Investigation of the genes whose 
expression is affected by CT99021 on a dexamethasone full concentration response curve 
will provide a better understanding and validate my hypothesis. Additionally, promoter 
analysis of the genes affected upon GSK3β regulation of activity will allow us to investigate 
whether these effects are mediated by activation of specific transcription factors. The data 
generated by the microarrays are very important for future analysis and potential 
hypothesis generation. 
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6.1. Rationale of the study 
Corticosteroid insensitivity in patients with COPD has been shown to involve the activation 
of kinase pathways and redox sensitive proteins such as the PI3K/Akt and MAPKs in 
response to elevated levels of reactive oxygen species that derive from cigarette smoking 
and other environmental pollutants (Adcock and Barnes 2008; Adcock, Marwick et al. 2010). 
GSK3β has been implicated to play both pro- and anti-inflammatory roles in several cell and 
animal models (Cortes-Vieyra, Bravo-Patino et al. 2012). It is also known that GSK3β activity 
is regulated by the PI3K/Akt and the ERK1/2 MAPK signalling pathways (Grimes and Jope 
2001). However, no evidence exists demonstrating whether GSK3β is also modulated by 
reactive oxidant species in immune cells and how such modulation affects the anti-
inflammatory effects of corticosteroids. In this thesis, I sought to investigate how reactive 
oxygen species regulate GSK3β activity and evaluate whether modulation of its kinase 
activity interferes with corticosteroid function in COPD. I aimed to identify the key 
regulators of oxidant stress-induced regulation of GSK3β activity and the downstream 
effectors of the kinase that control corticosteroid function and the inflammatory response.  
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6.2. Summary of the study findings  
In summary my results demonstrate that oxidative stress induces Ser9 phosphorylation of 
GSK3 and this inactivation of GSK3β impairs corticosteroid responsiveness. P-GSK3-Ser9 is 
elevated in COPD as compared to both healthy smokers and non-smokers. Therefore, the 
elevation in p-GSK3-Ser9 may contribute to the relative reduction in corticosteroid 
responsiveness in COPD. The oxidant-mediated induction of p-GSK3-Ser9 involved p38 
MAPK, ERK1/2 MAPK and PI3K/Akt signalling which are also associated with both COPD 
and/or reduced corticosteroid function under oxidative stress. Therefore, I postulate that 
GSK3 may be a downstream effector of the oxidant-dependent induction of p38 MAPK, 
ERK1/2 MAPK and PI3K/Akt signalling pathways. Activation of this signalling cascade affects 
GR function by reducing the activity of its critical co-repressor, HDAC2, leading to increased 
histone acetylation and pro-inflammatory cytokine release that is resistant to corticosteroid 
function (Figure 6.1)  
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Figure 6.1. Mechanism of GSK3β-regulated corticosteroid function in the presence of reactive 
oxygen species in monocytes. (a) In the absence of reactive oxygen species, GRα exerts its anti-
inflammatory action by recruiting HDAC2 in the site of NF-B driven pro-inflammatory gene 
expression in response to LPS. (b) When monocytes are exposed to reactive oxygen species, the 
redox sensitive proteins Akt, p38 and ERK1/2 MAPKs are activated and lead to phosphorylation and 
subsequent inactivation of GSK3β. Inactivation of the kinase induces reduction of HDAC2 activity 
resulting in decrease of corticosteroid function and increased expression of pro-inflammatory 
cytokines. 
? 
a. 
b. 
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6.3. Discussion 
This work shows that p-GSK3-Ser9 levels, a marker of GSK3 inactivation, are elevated in 
smokers and further elevated in patients with COPD. p-GSK3-Ser9 is elevated in response 
to H2O2 in vitro in a time- and concentration-dependent manner in peripheral blood 
monocytes. This oxidant-mediated induction of p-GSK3-Ser9 was abolished by selective 
inhibition of ERK1/2, Akt and p38 MAPK, suggesting that GSK3 may be an important 
common redox sensing effector molecule for a number of signalling pathways. These 
signalling pathways are fundamental in many inflammatory functions including activation of 
NF-B, pro-inflammatory cytokine expression and inflammatory cell recruitment in COPD 
(Thannickal and Fanburg 2000; Yu, Li et al. 2005; Bhavsar, Hew et al. 2008; Birrell, Wong et 
al. 2008; Matsuzawa and Ichijo 2008; Renda, Baraldo et al. 2008; Chung 2011). In addition to 
their roles in inflammation, p38 MAPK and PI3K/Akt signalling have also been implicated in 
the oxidant-mediated corticosteroid responsiveness (Irusen, Matthews et al. 2002; Marwick, 
Caramori et al. 2010; Marwick and Chung 2010). Certainly, selective inhibition of these 
pathways improved corticosteroid function in both cells from patients with oxidant 
associated diseases and in relatively corticosteroid unresponsive in vivo oxidant models such 
as cigarette smoke exposed mice (Marwick, Caramori et al. 2009; Marwick, Caramori et al. 
2010). Previous studies have shown that PI3K is the isoform responsible for the oxidant-
induced activation of Akt in monocytes (Marwick, Caramori et al. 2010). However, selective 
inhibition of PI3K did not affect the oxidant induction on GSK3-s9. Therefore, other PI3K 
isoforms or cross-talk from other signalling pathways activated by oxidants, are likely to be 
responsible for the oxidant-dependent induction of p-GSK3-s9 through Akt. My data 
showed that the ERK1/2 and p38 MAPKs are also involved in phosphorylating GSK3β. 
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Although, there is evidence supporting that ERK1/2 MAPK directly phosphorylates GSK3β 
(Dozza, Smith et al. 2004), there is not much known about how p38 MAPK affects the kinase 
activity. Further experiments are required to investigate the involvement of other kinases, 
such as ASK1 in regulating p38 MAPK-induced phosphorylation of GSK3β. The results also 
showed that H2O2 induced a quick phosphorylation of the Tyr216 residue of GSK3β, known 
to positively regulate its kinase activity (Cohen and Frame 2001). This may be due to 
activation of upstream redox sensitive kinases, such as MEK1 (Takahashi-Yanaga, Shiraishi et 
al. 2004). Measurement of GSK3β kinase activity at several time points of H2O2 exposure 
would provide information on how phosphorylation on Tyr216 affects its substrate binding.  
 
Using pharmacological inhibition, siRNA knock down and kinase dead overexpression, my 
data shows that abolition of GSK3 signalling reduces the ability of dexamethasone to 
repress pro-inflammatory cytokine release. Conversely, overexpression of a mutant GSK3 
with a Ser9 to alanine mutation restored corticosteroid function in oxidant stress exposed 
cells. The mechanisms by which oxidative stress imposes a relative corticosteroid 
unresponsiveness on cells have not been fully resolved but the oxidant-mediated kinase 
signalling is likely to contribute to several of the mechanisms (Ito, Chung et al. 2006; Adcock 
and Barnes 2008; Adcock, Marwick et al. 2010). Phosphorylation of Ser211 phosphorylation 
on GRα by p38 MAPK promotes GR transcriptional activity (Garza, Khan et al. 2010) whilst 
JNK-mediated phosphorylation of Ser246 inhibits GR transcriptional activity (Rogatsky, 
Logan et al. 1998). The impact of GR phosphorylation on its ability to facilitate 
transcriptional repression is less clear. A reduction in GR transcriptional activity may 
promote inflammation due to a reduction in anti-inflammatory mediators such as SLPI and 
annexin 1 (Perretti and D'Acquisto 2009) as well as MPK-1, which is a negative regulator of 
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p38 MAPK (Clark 2003; Clark and Lasa 2003). Increased p38 MAPK is likely to lead to 
increased NF-B activation and specific NF-B-pro-inflammatory transcriptional targeting 
(Saccani, Pantano et al. 2002). Inhibition of GSK3 did not alter GR phosphorylation, 
corticosteroid-induced GR translocation or its ability to bind to p65 or NF-B DNA binding 
activity. However siRNA knock down did reduce the expression of GR. This result agrees 
with previous data indicating that since GR expression in monocytes and macrophages is 
high, a reduction in the GR expression levels may not translate into a reduction in 
corticosteroid function (Marwick, Caramori et al. 2009). ChIP analysis of GR-GRE binding and 
identification of possible post-translational modifications on GR by mass spectrometry 
under conditions of oxidative stress-induced GSK3β inhibition would allow better 
investigation of the effects of GSK3β on GR function and its binding capacity to its co-
repressors.  
 
The expression and activity of the important GR co-repressor HDAC2 maybe also impeded 
by oxidant and PI3K/Akt-mediated modifications including hyperphosphorylation and 
nitration (Galasinski, Resing et al. 2002; Ito, Hanazawa et al. 2004; Marwick, Kirkham et al. 
2004; Yang, Chida et al. 2006), depriving GR of a key tool to control gene expression 
thereby reducing corticosteroid function. Inhibition of GSK3β induced a significant reduction 
in HDAC2 activity. This reduction in activity was not associated with a change in expression 
but an increase in HDAC2 phosphorylation at Ser394. CK2 phosphorylates HDAC2 at Ser394 
and is a direct target of GSK3 with negatively regulates ifs function (Sun, Chen et al. 2002; 
Tsai and Seto 2002). Therefore, inactivation of GSK3 may increase CK2 phosphorylation of 
HDAC2. However, the precise functions of individual HDAC2 phosphorylation sites are 
unclear and various phosphorylations may promote as well as inhibit its enzymatic function 
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(Tsai and Seto 2002). Cigarette smoke exposure in mice reduces HDAC2 activity and is 
associated with HDAC2 hyperphosphorylation (Marwick, Kirkham et al. 2004; Marwick, 
Stevenson et al. 2010), whilst certain phosphorylations may be important for 
conformational changes to allow co-repressor associations (Tsai and Seto 2002). Therefore, 
it is not clear how the inhibition of GSK3 leading to the induction of Ser394 
phosphorylation may alter its activity. Further investigations are required to fully 
understand the regulation of HDAC2 by phosphorylation. Identification of the exact role of 
CK2 in mediating GSK3β signalling in my model as well as investigation of additional post-
translational modification sites on HDAC2 that may explain the loss of its enzymatic activity 
or disruption of its binding to co-repressors are key approaches need to be taken next. In 
addition, in order to validate that the decreased histone deacetylation levels are mediating 
the reduction of corticosteroid function in response to GSK3β inhibition, promoter analysis 
and measurement of histone acetylation on the site of NF-B-regulated inflammatory gene 
expression is required.  
The microarray data showed that CT99021 treatment affected a number of corticosteroid-
regulated genes in response to LPS stimulation in monocytes. Among these, PKA that was 
significantly upregulated has been shown to regulate post-translational modifications on 
p65, HDAC5 and HDAC8.  Further experiments would be required to validate that GSK3β 
regulates PKA activity and investigate the possible effects it may exert on p65-induced 
transactivation as well as site-specific histone acetylation. Investigation of the oxidative 
stress effects on PKA activity and its levels of expression/activity in monocytes derived from 
COPD patients would allow clarification of the complex mechanisms that regulate 
corticosteroid function under oxidative stress in COPD.  
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The effect of CT99021 on IL8 and CSF2 mRNA expression was not as clear as at the cytokine 
level. This was probably due to the time point chosen to investigate global gene expression 
in response to CT99021 which was the same as the one used to measure cytokine release 
and hence the effects might have been lost at the mRNA level. Due to time and expense 
limitation I was unable to investigate the effects of CT99021 at different time points of LPS 
stimulation. Further microarray and RT-qPCR experiments also assessing the effects of 
CT99021 on a full concentration response curve of dexamethasone would confirm the role 
of GSK3β on corticosteroid function at the mRNA expression level and distinguish the 
primary effects of CT99021 from secondary effects on the inflammatory response. 
Nevertheless, the microarray analysis confirmed that CT99021 targeted GSK3β-regulated 
pathways and that it upregulated several corticosteroid-transrepressed inflammatory genes 
at the time point used. This observation agrees with my hypothesis and further investigation 
of the genes found to be differentially regulated will allow better understanding on the 
mechanisms involved and assist new hypothesis generation. 
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6.4. Future directions  
The following is a summary of future perspectives based on this thesis: 
 Perform promoter analysis and measure the level of histone acetylation at the site of 
NF-B transactivation upon GSK3β inhibition. 
 Investigate whether the pro-inflammatory response observed in the presence of the 
DNA plasmid constructs is NF-B driven. Investigate whether these effects are 
plasmid specific and generate new constructs with different antibiotic resistance 
genes to validate the results. 
 Identify which downstream target of p38 MAPK phosphorylates GSK3β, examining 
the role of ASK1. 
 Investigate the role of CK2 on mediating GSK3β-induced regulation of HDAC2 
phosphorylation. 
 Identify other post-translational modifications on HDAC2 and assess their functional 
effect on its enzymatic activity and ability to bind to co-repressors. 
 Examine whether GR is subjected to post-translational modifications upon GSK3β 
inhibition and evaluate the effect that may have on GR function and GR-GRE binding 
capacity. 
 Measure the effects of CT99021 on corticosteroid-mediated gene transrepression 
using a full time course. 
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 Examine the levels of expression and activity of PKA in primary immune cells from 
COPD patients compared to smokers with normal lung function and non-smokers. 
 Investigate the role of PKA in regulating corticosteroid function under conditions of 
oxidative stress. Examine whether it affects p65 phosphorylation and its 
transactivation capacity. 
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8. Appendix I  
Table 1. List of genes differentially expressed in response to CT99021 in LPS/dexamethasone treated MonoMac6 cells 
Probeset ID Gene symbol p-value(Dex vs. No Dex)
Fold-Change (Dex vs. 
No Dex)
Fold-Change(Dex vs. No Dex) 
(Description)
NM_207404 ZNF662 0,00674204 -1,81182 Drug down vs No Drug
NM_133374 ZNF618 0,00861205 -1,60323 Drug down vs No Drug
NM_153263 ZNF549 0,00186306 -1,64032 Drug down vs No Drug
NM_001001661 ZNF425 0,000451584 -1,57979 Drug down vs No Drug
NM_152625 ZNF366 0,0278916 -1,89155 Drug down vs No Drug
NM_020917 ZFP14 0,0330453 -1,63206 Drug down vs No Drug
NM_005709 USH1C 0,00745013 1,71353 Drug up vs No Drug
NM_025115 TTI2 0,0417509 1,51162 Drug up vs No Drug
NM_003327 TNFRSF4 0,0257022 1,78875 Drug up vs No Drug
NM_018342 TMEM144 0,00580931 -1,52125 Drug down vs No Drug
NM_003256 TIMP4 0,0207209 -1,65983 Drug down vs No Drug
NM_030953 TIGD6 0,048398 -2,09714 Drug down vs No Drug
NM_003248 THBS4 0,007955 -1,63938 Drug down vs No Drug
NM_003216 TEF 0,0191891 2,42807 Drug up vs No Drug
NM_001083965 TDRKH 0,00559371 -2,08654 Drug down vs No Drug
NM_023917 TAS2R9 0,0466577 1,78513 Drug up vs No Drug
NM_176882 TAS2R40 3,19E-05 -2,85758 Drug down vs No Drug
NM_003176 SYCP1 0,0111772 1,86326 Drug up vs No Drug
NM_001123225 SYCE3 0,0110578 -1,52811 Drug down vs No Drug  
*Drug: Cells treated with LPS, dexamethasone and CT99021; No drug: Cells treated with LPS and dexamethasone alone 
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Probeset ID Gene symbol p-value(Dex vs. No Dex)
Fold-Change (Dex vs. 
No Dex)
Fold-Change(Dex vs. No Dex) 
(Description)
NM_001001850 STX19 0,0346969 -1,95302 Drug down vs No Drug
NM_004809 STOML1 0,0123609 -1,52037 Drug down vs No Drug
NM_003125 SPRR1B 0,016791 -1,59192 Drug down vs No Drug
NM_003121 SPIB 0,0247839 -1,52538 Drug down vs No Drug
NM_006038 SPATA2 0,00363046 -1,92177 Drug down vs No Drug
NM_006049 SNAPC5 0,00203734 -1,5094 Drug down vs No Drug
NM_001135585 SLC2A5 0,0322715 1,52877 Drug up vs No Drug
NM_031947 SLC25A2 0,0448554 1,51821 Drug up vs No Drug
NM_003060 SLC22A5 0,0254458 -1,55396 Drug down vs No Drug
NM_003037 SLAMF1 0,00161688 1,52169 Drug up vs No Drug
NM_005413 SIX3 0,00780501 2,21816 Drug up vs No Drug
NM_152386 SGPP2 0,000135768 1,6197 Drug up vs No Drug
NM_001199824 SGK110 0,00216577 1,54412 Drug up vs No Drug
NM_006919 SERPINB3 0,0338799 1,69111 Drug up vs No Drug
NM_002575 SERPINB2 0,000802337 2,94252 Drug up vs No Drug
NM_004263 SEMA4F 0,0147106 -1,53138 Drug down vs No Drug
NM_006379 SEMA3C 0,0144995 1,51587 Drug up vs No Drug
NM_021920 SCT 0,0415144 -1,52065 Drug down vs No Drug
NM_000335 SCN5A 0,0204442 -2,46405 Drug down vs No Drug
NM_174934 SCN4B 0,0107068 -1,77321 Drug down vs No Drug  
*Drug: Cells treated with LPS, dexamethasone and CT99021; No drug: Cells treated with LPS and dexamethasone alone 
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Probeset ID Gene symbol p-value(Dex vs. No Dex)
Fold-Change (Dex vs. 
No Dex)
Fold-Change(Dex vs. No Dex) 
(Description)
NM_006695 RUNDC3A 0,0057861 2,97615 Drug up vs No Drug
NM_178841 RNF166 0,041919 -1,55844 Drug down vs No Drug
NM_001012264 RNASE13 0,00409734 1,75587 Drug up vs No Drug
NM_015672 RIMBP3 0,0417028 -2,03322 Drug down vs No Drug
NM_007211 RASSF8 0,00725939 1,58176 Drug up vs No Drug
NM_017805 RASIP1 0,0318475 -1,75596 Drug down vs No Drug
NM_002878 RAD51D 0,0191789 -1,54742 Drug down vs No Drug
NM_001099218 RAD51AP2 0,000336395 -2,03043 Drug down vs No Drug
NM_002847 PTPRN2 0,000140823 -1,61784 Drug down vs No Drug
NM_000963 PTGS2 0,000782428 1,74818 Drug up vs No Drug
NM_003738 PTCH2 0,00964862 2,04534 Drug up vs No Drug
NM_002732 PRKACG 0,000881015 -2,11513 Drug down vs No Drug
NM_174981 POTEC 0,0196713 -1,5688 Drug down vs No Drug
NM_015352 POFUT1 0,00960895 -1,7013 Drug down vs No Drug
NM_145167 PIGM 0,0237348 -1,52478 Drug down vs No Drug
NM_002611 PDK2 0,0112896 -1,61288 Drug down vs No Drug
NM_001243533 PDIK1L 0,0444497 -1,58106 Drug down vs No Drug
NM_002599 PDE2A 0,0100159 1,72669 Drug up vs No Drug
NM_001102566 PCP4L1 0,00248305 -1,69081 Drug down vs No Drug
NM_005485 PARP3 0,0363548 -1,7499 Drug down vs No Drug  
*Drug: Cells treated with LPS, dexamethasone and CT99021; No drug: Cells treated with LPS and dexamethasone alone 
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Probeset ID Gene symbol p-value(Dex vs. No Dex)
Fold-Change (Dex vs. 
No Dex)
Fold-Change(Dex vs. No Dex) 
(Description)
NM_001104554 PAQR5 0,0218125 1,66853 Drug up vs No Drug
NM_007365 PADI2 0,0219132 -1,83302 Drug down vs No Drug
NM_148962 OXER1 0,000301143 -1,64548 Drug down vs No Drug
NM_001005325 OR6M1 0,0118228 1,70693 Drug up vs No Drug
NM_030876 OR5V1 0,0126892 -1,64221 Drug down vs No Drug
NM_020201 NT5M 0,0113004 -1,50646 Drug down vs No Drug
NM_033004 NLRP1 0,0498332 -1,59322 Drug down vs No Drug
NM_145912 NFAM1 0,00671062 -1,69317 Drug down vs No Drug
NM_024800 NEK11 0,0181113 1,67096 Drug up vs No Drug
NM_002476 MYL4 0,00596909 4,4746 Drug up vs No Drug
NM_001040114 MYH11 0,00934473 -1,80152 Drug down vs No Drug
NM_058173 MUCL1 0,0470281 2,18126 Drug up vs No Drug
NM_002447 MST1R 0,0200945 -1,61087 Drug down vs No Drug
NM_024021 MS4A4A 0,00263466 -1,52943 Drug down vs No Drug
NM_178832 MORN4 0,0368906 -1,65815 Drug down vs No Drug
NM_002421 MMP1 0,0157117 3,14064 Drug up vs No Drug
NM_024608 MIR631 0,023765 -1,59621 Drug down vs No Drug
NM_145341 MIR4680 0,00783356 -1,58471 Drug down vs No Drug
NM_003480 MFAP5 0,0319986 2,0808 Drug up vs No Drug
NM_014611 MDN1 0,0396479 -1,80643 Drug down vs No Drug  
*Drug: Cells treated with LPS, dexamethasone and CT99021; No drug: Cells treated with LPS and dexamethasone alone 
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Probeset ID Gene symbol p-value(Dex vs. No Dex)
Fold-Change (Dex vs. 
No Dex)
Fold-Change(Dex vs. No Dex) 
(Description)
NM_001025101 MBP 0,0236304 1,58333 Drug up vs No Drug
NM_178496 MB21D2 0,0220217 1,69083 Drug up vs No Drug
NM_002345 LUM 0,0133283 1,53336 Drug up vs No Drug
NM_001002811 LOC728802 0,00228593 1,72304 Drug up vs No Drug
NM_030583 LOC100506558 0,0145837 -1,89669 Drug down vs No Drug
NM_006669 LILRB1 0,0137974 -1,6534 Drug down vs No Drug
NM_006498 LGALS2 0,00490906 -1,87273 Drug down vs No Drug
NM_002272 KRT4 0,0253803 -1,50727 Drug down vs No Drug
NM_198582 KLHL30 0,0458122 -1,62912 Drug down vs No Drug
NM_012282 KCNE1L 0,00574719 -1,6094 Drug down vs No Drug
NM_002207 ITGA9 0,00355439 -1,93926 Drug down vs No Drug
NM_003637 ITGA10 0,00993771 -1,67588 Drug down vs No Drug
NM_019618 IL36G 0,0181708 1,93362 Drug up vs No Drug
NM_001185156 IL24 0,00972094 2,41576 Drug up vs No Drug
NM_153758 IL19 0,00107334 2,49705 Drug up vs No Drug
NM_172217 IL16 0,000213555 -1,88452 Drug down vs No Drug
NM_000572 IL10 0,0146015 1,64022 Drug up vs No Drug
NM_000871 HTR6 0,00421498 1,75274 Drug up vs No Drug
NM_213621 HTR3A 0,0266721 1,56595 Drug up vs No Drug
NM_000867 HTR2B 0,00540293 -1,61329 Drug down vs No Drug  
*Drug: Cells treated with LPS, dexamethasone and CT99021; No drug: Cells treated with LPS and dexamethasone alone 
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Probeset ID Gene symbol p-value(Dex vs. No Dex)
Fold-Change (Dex vs. 
No Dex)
Fold-Change(Dex vs. No Dex) 
(Description)
NM_001510 GRID2 0,00492313 1,67623 Drug up vs No Drug
NM_014710 GPRASP1 0,0209568 -1,53296 Drug down vs No Drug
NM_006794 GPR75 0,0192838 -1,5348 Drug down vs No Drug
NM_130759 GIMAP1 0,00129264 -1,63262 Drug down vs No Drug
NM_001024071 GCH1 0,00373262 1,6165 Drug up vs No Drug
NM_003857 GALR2 0,0159618 -1,68192 Drug down vs No Drug
NM_005458 GABBR2 0,0374034 -1,66574 Drug down vs No Drug
NM_001470 GABBR1 0,0174927 1,52901 Drug up vs No Drug
NM_001136007 FXYD3 0,00318742 2,03785 Drug up vs No Drug
NM_032296 FLYWCH1 0,0113072 -2,48651 Drug down vs No Drug
NM_001204478 FAM18B2-CDRT4 0,0486641 -2,19393 Drug down vs No Drug
NM_173678 FAM115C 0,0134738 1,65462 Drug up vs No Drug
NM_003950 F2RL3 0,000474657 2,13011 Drug up vs No Drug
NM_000127 EXT1 0,0111586 1,90344 Drug up vs No Drug
NM_138961 ESAM 0,0428241 1,55782 Drug up vs No Drug
NM_001432 EREG 0,0164562 1,56136 Drug up vs No Drug
NM_024930 ELOVL7 0,00283784 1,54068 Drug up vs No Drug
NM_013302 EEF2K 0,0295201 -1,53032 Drug down vs No Drug
NM_001955 EDN1 0,000131268 1,73597 Drug up vs No Drug
NM_005128 DOPEY2 0,013278 -1,73194 Drug down vs No Drug  
*Drug: Cells treated with LPS, dexamethasone and CT99021; No drug: Cells treated with LPS and dexamethasone alone 
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Probeset ID Gene symbol p-value(Dex vs. No Dex)
Fold-Change (Dex vs. 
No Dex)
Fold-Change(Dex vs. No Dex) 
(Description)
NM_203486 DLL3 0,00124517 -1,50295 Drug down vs No Drug
NM_001040702 DEFB104B 0,0094182 2,3797 Drug up vs No Drug
NM_000765 CYP3A7-CYP3AP1 0,0343862 1,54625 Drug up vs No Drug
NM_002993 CXCL6 0,0148288 1,94894 Drug up vs No Drug
NM_002090 CXCL3 0,00191039 1,70123 Drug up vs No Drug
NM_002089 CXCL2 0,00734121 1,58348 Drug up vs No Drug
NM_001511 CXCL1 0,0206388 1,66333 Drug up vs No Drug
NM_001337 CX3CR1 0,0154665 -3,05066 Drug down vs No Drug
NM_003476 CSRP3 0,0170099 -1,6419 Drug down vs No Drug
NM_000759 CSF3 0,0261798 1,95245 Drug up vs No Drug
NM_000758 CSF2 0,0143936 2,12293 Drug up vs No Drug
NM_032607 CREB3L3 0,0462598 -1,73753 Drug down vs No Drug
NM_080538 COLQ 0,00582421 -1,79629 Drug down vs No Drug
NM_000246 CIITA 0,00797994 -1,50978 Drug down vs No Drug
NM_015147 CEP68 0,00693231 -1,81551 Drug down vs No Drug
NM_001408 CELSR2 0,0403657 -1,95496 Drug down vs No Drug
NM_044472 CDC42 9,52E-05 1,6379 Drug up vs No Drug
NM_001123396 CCR2 0,00206779 -1,64586 Drug down vs No Drug
NM_004591 CCL20 0,0112292 2,27151 Drug up vs No Drug
NM_006274 CCL19 0,0188326 -1,61181 Drug down vs No Drug  
*Drug: Cells treated with LPS, dexamethasone and CT99021; No drug: Cells treated with LPS and dexamethasone alone 
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Probeset ID Gene symbol p-value(Dex vs. No Dex)
Fold-Change (Dex vs. 
No Dex)
Fold-Change(Dex vs. No Dex) 
(Description)
NM_053054 CATSPER1 0,000215174 -1,74186 Drug down vs No Drug
NM_020893 C9orf174 0,00976329 -2,35508 Drug down vs No Drug
NM_001010906 C8orf80 0,0493365 1,52573 Drug up vs No Drug
NM_000562 C8A 0,0347646 1,63713 Drug up vs No Drug
NM_130848 C5orf20 0,0360374 -1,92769 Drug down vs No Drug
NM_181707 C17orf64 0,0485919 -3,9047 Drug down vs No Drug
NM_001162997 C17orf110 0,000106118 -2,19974 Drug down vs No Drug
NM_001162995 C17orf109 0,0148367 -1,58644 Drug down vs No Drug
NM_001076680 C17orf108 0,00848463 -1,87782 Drug down vs No Drug
NM_001170633 C12orf56 0,0202579 1,71039 Drug up vs No Drug
NM_001195 BFSP1 0,000333364 -1,6844 Drug down vs No Drug
NM_183050 BCKDHB 0,03777 -2,01405 Drug down vs No Drug
NM_001031739 ASB9 0,0199567 1,93174 Drug up vs No Drug
NM_212556 ASB18 0,0325503 1,84413 Drug up vs No Drug
NM_001172 ARG2 0,00287393 1,9394 Drug up vs No Drug
NM_145298 APOBEC3F 0,0365497 -1,6646 Drug down vs No Drug
NM_005883 APC2 0,0216917 2,30503 Drug up vs No Drug
NM_000037 ANK1 0,0314673 -1,7782 Drug down vs No Drug
NM_001113402 AMN1 0,0112763 1,67303 Drug up vs No Drug
NM_153206 AMICA1 0,0181398 -1,55836 Drug down vs No Drug  
*Drug: Cells treated with LPS, dexamethasone and CT99021; No drug: Cells treated with LPS and dexamethasone alone 
 
 
 245 | P a g e  
 
Probeset ID Gene symbol p-value(Dex vs. No Dex)
Fold-Change (Dex vs. 
No Dex)
Fold-Change(Dex vs. No Dex) 
(Description)
NM_032717 AGPAT9 0,00945166 1,62907 Drug up vs No Drug
NM_080431 ACTRT2 0,0266595 1,56526 Drug up vs No Drug
NM_030812 ACTL8 0,0107936 1,55786 Drug up vs No Drug
NM_033110 A2LD1 0,0307094 -1,50452 Drug down vs No Drug  
*Drug: Cells treated with LPS, dexamethasone and CT99021; No drug: Cells treated with LPS and dexamethasone alone 
 
